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ASSESSING AND MODIFYING BONE QUALITY 
IN CHRONIC KIDNEY DISEASE 
 
 
 Chronic kidney disease (CKD) results in an increased fracture risk, 
partially due to elevations in parathyroid hormone (PTH) that lead to substantial 
bone loss. On its own, bone loss does not explain bone fragility in CKD, 
suggesting that changes in skeletal tissue (bone quality) may also be present. 
Understanding the factors that lead to fracture in these patients will have a 
substantial impact on patient care and could lead to a better understanding of 
how to reduce their fracture risk. Due to their suppression of PTH, calcitriol and 
its analogues are the current standard of care for bone disease in CKD. Yet, 
surprisingly little is known of their effects on bone. Agents effective in treating 
osteoporosis are not recommended in advanced CKD due to the lack of data 
regarding their efficacy and safety in these patients. The goals of the current 
study were to determine (1) the impact of CKD on bone quality, (2) the ability of 
calcitriol to improve skeletal parameters, and (3) the efficacy of various 
pharmacological interventions (calcium, bisphosphonates, anti-sclerostin 
antibody, and raloxifene) on bone mass, quality, and mechanical properties in 
CKD bone disease. Using a slowly progressive rat model of CKD, renal and 
mineral metabolism, bone morphology, bone quality, and bone mechanics (at 
several length scales) were assessed. Primarily due to elevated PTH, 
mechanical testing and tissue-level assessments revealed compromised bone 
quantity (high cortical porosity and low trabecular volume) and quality (high 
vii 
 
collagen cross-linking and low matrix bound water). Despite clinically relevant 
reductions in PTH, calcitriol treatment had no positive impact on skeletal 
properties. Most agents were only effective when PTH levels were normal. 
Raloxifene, however, led to greater whole bone and material toughness (the 
ability of bone to tolerate existing damage) despite modest PTH suppression. 
While the examination of bone quality in CKD is still in its infancy, these results 
indicate that enhancing bone quality with raloxifene may be an effective means to 
compensate for bone loss in CKD. 
 
 
Matthew R. Allen, Ph.D., Chair 
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CHAPTER 1 
INTRODUCTION 
 Chronic kidney disease (CKD) is a major healthcare concern with 
widespread and detrimental impacts on both morbidity and mortality1. Nearly 1 in 
8 individuals in the United States has some degree of kidney failure2. With the 
increasing prevalence of obesity, type 2 diabetes, and hypertension in the United 
States, these rates are projected to consistently increase because these factors 
are the most common causes of kidney failure3. 
 CKD represents a fairly heterogeneous description of chronic renal 
damage from numerous causes. Nevertheless, once the kidneys have been 
irreparably damaged, the later stages of disease lead to similar outcomes 
regardless of the cause4. Even though only a small portion of patients will reach 
end stage disease and need dialysis or transplantation, CKD remains the most 
expensive chronic disease in the United States and has a significant impact on 
the lifespan and quality of life of those afflicted5. 
 Unfortunately, there are currently no treatments to completely halt or 
reverse the progression of renal failure6. The primary goal of treatment is to slow 
the progression of disease by addressing the specific etiological factors (e.g., 
hypertension, diabetes, etc.) responsible for the damage7. When not addressed, 
CKD leads to abnormalities in endocrine function and mineral metabolism, which 
ultimately result in pathological dysfunction of cardiovascular, endocrine, and 
skeletal processes, a constellation now collectively known as CKD-mineral and 
bone disorder (CKD-MBD). Hence, the increasing rates of CKD and the absence 
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of a cure ensure that the prevalence of these manifestations will only increase in 
the coming years. 
 
The pathogenesis of CKD-MBD leads to complex metabolic phenotypes. 
 Disturbances in bone and mineral metabolism are the hallmark of CKD-
MBD8-9. Along with hyperphosphatemia, secondary hyperparathyroidism, and 
vascular calcification, patients exhibit an increased risk of fractures10-19. Given 
the complexities of normal mineral metabolism20, CKD-MBD encapsulates the 
compensatory mechanisms (and their failure) that preserve calcium and 
phosphate homeostasis in the face of declining glomerular filtration21 (Figure 1). 
These physiological and pathological adaptations play a significant role in 
fracture risk and mortality.  
 As kidney function begins to decline, there is an increased demand on the 
remaining nephrons to maintain mineral homeostasis and normal excretory 
functions22-23. Changes in phosphate excretion drive the metabolic derangements 
that characterize CKD-MBD. In response to increased phosphate load, 
osteocytes secrete fibroblast growth factor 23 (FGF23), which acts on tubular 
epithelial cells in the kidney to decrease phosphate reabsorption. In concert with 
FGF23, parathyroid hormone (PTH) levels also increase to compensate for these 
rises in phosphate (though simultaneous declines in vitamin D synthesis are also 
involved). While recent evidence indicates that FGF23 normally suppresses PTH  
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Figure 1. The adaptations of mineral metabolism that result from CKD. 
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activity24-25, secondary hyperparathyroidism ensues nonetheless. Initially, these 
responses effectively maintain normal serum phosphate levels. Eventually 
though, this process fails, and serum phosphate begins to increase. 
 In skeletal tissue, concomitant increases in osteoclast differentiation and 
activity occur, which is what primarily leads to the bone deficits present in CKD-
MBD26. Though several metabolic derangements may have some impact on 
osteoclast activity, high levels of PTH are most prominent27. Specifically, these 
levels are known to act through the PTH receptors present on osteoblasts and 
osteocytes to upregulate osteoclast formation and activation28. Though these 
changes in PTH are ultimately secondary to metabolic changes occurring during 
CKD, these patients begin to exhibit many of the same bone cell changes 
present in primary hyperparathyroidism29. While the circumstances specific to 
CKD are beginning to be elucidated, the metabolic complexity of CKD has led to 
great challenges in understanding and treating skeletal manifestations, resulting 
in an inability to substantially reduce fracture risk in this population.  
 
Metabolic changes in CKD lead to significant skeletal alterations and, ultimately, 
fracture. 
 Patients with chronic kidney disease have more than double the risk of 
having a fracture compared to the general population14-15. Of even greater 
concern, mortality rates in CKD patients with hip fractures more than double 
those of non-CKD patients with hip fractures18,30. The presence of secondary 
hyperparathyroidism causes changes in bone metabolism that lead to the 
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preferential breakdown of cortical bone. Specifically, chronic elevations in PTH 
can lead to subperiosteal and intracortical erosion, resulting in drastic increases 
in cortical porosity31 (Figure 2). The impact on cancellous bone is more variable. 
In cases of mild hyperparathyroidism, cancellous bone is usually unchanged or 
even increased32. But, imaging studies indicate that hyperparathyroidism can 
also detrimentally impact trabecular bone in CKD33. Nevertheless, cortical bone 
is thought to be prominently impacted and drive much of the increase in fracture 
risk. Specifically, CKD patients with a history of fracture have lower volumetric 
BMD and thinner cortices than those without fractures. These data may help 
explain why BMD estimates in the distal radius are the strongest predictors of 
fracture in these patients31,34. 
 
Fracture risk is affected by both bone mass and bone quality. 
 While bone mineral density (BMD) is a useful surrogate of fracture risk in 
the general population, its ability to predict fractures in CKD has been 
inconsistent, especially in patients on dialysis35-42. Even with recent indications 
that BMD does predict fracture in patients with CKD34,43-45, bone mass is but one 
factor involved in fracture development. BMD does not assess the structural 
organization or material composition of bone (routinely referred to as bone 
quality)46. 
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Figure 2. Tibiae (left) and radii (right) of an individual without CKD (top) and an 
individual with advanced CKD and severe cortical porosity (bottom)31. 
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While environmental factors (activity, falls, etc.) play an important role in 
fracture, its occurrence is largely a reflection of the maximum load that can be 
borne by a bone (ultimate load) and the amount of energy it can dissipate 
(energy to failure). These structural properties are determined by the amount of 
skeletal tissue present, its three-dimensional orientation, and its material 
properties (Figure 3). Material properties are a product of tissue mineralization, 
the structure and composition of the organic matrix, tissue hydration, and the 
presence of existing microdamage. While standard engineering calculations 
derived from whole bone mechanical tests provide estimates of material 
properties47, these derivations assume material homogeneity and are difficult to 
interpret in light of significant variations in composition. 
 While some direct bone quality data are available from patient biopsies48, 
bone quality has not been extensively studied in CKD-MBD. A detailed 
assessment of material properties could provide insight into the tissue-level 
mechanisms responsible for fractures associated with CKD as well as reveal 
novel avenues of treatment. Unfortunately, assessing these multiscale 
mechanisms is either difficult or impossible in humans. Therefore, a thorough 
assessment of the hierarchical contributions to mechanical properties and their 
failure in light of kidney disease requires the use of animal models. 
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Figure 3. The hierarchical nature of the mechanical properties of bone. 
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Animal models present an opportunity to examine interventions against skeletal 
deterioration from CKD. 
 Because of the widespread impact of CKD on human health, numerous 
animal models have been developed to address the systemic repercussions of 
kidney disease. The most common approach is to induce end stage renal 
disease by surgical nephrectomies (with numerous variations), electrocautery, or 
the administration of adenine. These models represent an acute injury that leads 
to chronic renal failure. Given that the vast majority of patients with CKD have 
either hypertensive nephropathy or diabetic nephropathy7, sudden trauma does 
not accurately represent the progression of disease in the majority of cases. 
While adenine does provide a slower progression (three to four weeks), animals 
exhibit severe weight loss not seen in other models49. The consequences of this 
weight loss on pertinent disease parameters are unclear. Despite the drawbacks 
of acute onset, these models still have important potential for examining the 
impact of CKD on mature skeletal tissue. Unfortunately, most of these data 
derive from experiments in which CKD is induced in skeletally immature animals 
with actively growing bones50-51. Not only do these animals exhibit rapid bone 
modeling not present in adult rodents, but there also is no way to distinguish the 
direct impact of kidney disease on bone from its impact on altered skeletal 
development. 
 Alternative models use genetic manipulation to induce kidney failure, 
primarily in the form of polycystic kidney disease52. For example, the jck mouse 
has a primary ciliary defect that leads to cystic kidney disease by four weeks of 
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age. Similarly, pcy mice exhibit ciliary disease leading to cysts by three weeks. 
The greatest challenge with most genetic models is the rapid onset of disease 
during early growth and development. As above, this makes it exceedingly 
difficult to determine if skeletal manifestations are a direct result of the disease or 
rather an indirect byproduct of disturbed skeletal development. While these are 
important models for pediatric CKD, their application to end stage disease in 
adults is limited.  
 The model utilized in the current studies (the Cy/+ rat) avoids many of the 
limitations intrinsic to other models. Unlike surgical models, these animals display 
a gradual onset of disease. And unlike most genetic models, they exhibit a slow 
enough progression that bone disease does not begin to occur until after skeletal 
maturity. The Cy/+ rat is characterized by autosomal dominant polycystic kidney 
disease (PKD)53. These animals have a mutation (R823W) in Anks6, a gene that 
codes for the protein SamCystin. Currently, the function of this protein is 
unknown, and the specific role of this mutation in the development of PKD is 
unclear. Aside from its expression in the kidney, little is known about its role in 
the cell54. But, unlike most other PKD-related proteins, SamCystin does not 
localize to the primary cilia of kidney cells55. While only recently has this gene 
been related to a known human disease (nephronophthisis)56, its slow and 
gradual onset provides a helpful phenotypic animal model of human CKD53. It 
parallels the human condition through the gradual development of abnormal 
mineral homeostasis and vascular calcification of the great vessels, all of which 
typify CKD-MBD. Animals exhibit significant detriments in bone structural and 
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mechanical properties, with substantial cortical porosity arising in advanced 
disease (Figure 4). This cortical effect closely mimics the human condition57. The 
gradual progression of disease in the Cy/+ rat and the onset of mineral 
derangements after skeletal maturity make it the most promising rodent model 
available for examining the effects of chronic kidney disease on adult bone. 
 
Clinical treatments focus on lowering PTH, but their effects on fracture risk and 
bone quality are unclear. 
 High levels of PTH have been implicated in cortical bone alterations and 
fracture risk in CKD patients57, making PTH regulation a major goal of 
treatment58-59. For patients with early stage CKD, when PTH levels are still 
normal, most guidelines employ treatment recommendations for adults with 
osteoporosis60-61. Unfortunately, a lack of clinical data regarding patients with 
later stage disease has led to great difficulty in treating skeletal abnormalities in 
this population. 
Current approaches have focused on minimizing phosphate intake and 
lowering PTH levels. Calcitriol and its various analogues (paricalcitol, 
doxercaliferol, etc.) effectively suppress PTH, though higher doses can lead to 
hypercalcemia60,62-64. Calcimimetics have also been shown to effectively 
decrease PTH59. Unfortunately, few studies have examined the skeletal effects of 
these therapies. Recent evidence indicates that cinacalcet does decrease 
fracture risk in advanced CKD patients65. Unfortunately, its failure to lower 
mortality rates and cardiovascular outcomes66-67 and the cost 
12 
 
 
 
Figure 4. Tibiae of a normal rat without CKD (left) and a Cy/+ rat (right) with 
advanced CKD and severe cortical porosity. 
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effectiveness of less expensive vitamin D analogues68 indicate that calcitriol and 
its analogues will remain the standard of care in this population. 
 Despite its prevalence in CKD patients, though, the impact of calcitriol on 
bone quality and fracture risk is currently unknown. While most osteoporosis 
clinical studies in non-CKD patients demonstrate that calcitriol reduces fracture 
risk through improvements in BMD69-70, the extension of these benefits to 
patients with advanced kidney disease, where cortical bone is so adversely 
affected, is unclear68. In numerous rodent models of osteoporosis, vitamin D 
analogues have been shown to increase bone mass, improve whole bone 
mechanical properties, and decrease rates of bone remodeling71-75. However, 
whether these benefits extend to CKD in the presence of hyperparathyroidism is 
not clear. In addition, because these studies were limited to whole bone 
mechanical testing, how these analogues directly impact material properties 
remains to be seen. 
 
The lack of data regarding traditional pharmacological agents has limited their 
application in late stage CKD patients. 
 The majority of patients with osteoporosis are treated with anti-resorptive 
agents that aim to prevent bone loss76. Though there are rare adverse events 
with these medications in patients with osteoporosis77, they have largely been 
successful. As a result, the rate of fracture in patients with osteoporosis has been 
substantially reduced78. Unfortunately, the complex metabolic background of 
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patients with CKD has led to numerous concerns about the use of these 
osteoporosis agents in late stage CKD60. 
 Bisphosphonate clinical trials that inadvertently included individuals with 
CKD showed similar benefits in CKD patients as those patients without kidney 
disease79-80. Unfortunately, these data did not include late stage CKD patients, 
where skeletal changes are more severe. Currently, CKD treatment guidelines do 
not recommend bisphosphonates due to concerns over their renal clearance and 
the impact of low bone turnover rates in these patients60. Because of the 
historical impact of aluminum toxicity on fracture risk in CKD patients81 and the 
more concrete associations between low turnover bone disease and arterial 
calcifications82-85, all forms of low bone turnover in CKD have become a 
significant concern86. These concerns have been exacerbated by the presence of 
low bone turnover in late stage CKD patients taking bisphosphonates87. 
Bisphosphonates clearly cause declines in bone turnover (this is precisely their 
mechanism of efficacy in osteoporosis). The link that has yet to be made is 
whether low bone turnover induced by bisphosphonate use is associated with 
fracture risk or vascular calcifications. Unfortunately, these concerns are 
ultimately theoretical as there are no data linking low bone turnover induced by 
bisphosphonates and an increased risk of fracture (or other negative effects) in 
CKD patients. The lack of data display a need for further preclinical studies using 
bisphosphonates to examine their safety and efficacy in CKD. 
While bisphosphonate use in CKD is surrounded by a cloud of confusion, 
other osteoporosis treatments are even less clear61 (Table 1). The recently 
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developed anabolic PTH analogue (teriparatide) has had a positive impact in 
patients with osteoporosis88-89. Unfortunately, as with bisphosphonates, there are 
theoretical concerns over administering PTH in the setting of secondary 
hyperparathyroidism, and again, the data are extremely limited. Teriparatide may 
have utility in patients with low turnover bone disease. Unfortunately, the lack of 
data significantly limits the conclusions that may be drawn in the setting of CKD. 
More promising for CKD has been the recent development of a humanized 
anti-sclerostin antibody for the treatment of osteoporosis. Romosozumab has 
been employed successfully in women with postmenopausal osteoporosis90 and 
is currently being examined in a randomized clinical trial. Given that sclerostin 
levels are elevated in the blood of patients with CKD91 and the bones of patients 
and animals with CKD92, the anabolic agent anti-sclerostin antibody may be 
efficacious in all forms of renal osteodystrophy independent of PTH and bone 
turnover. Because PTH suppresses sclerostin secretion from osteocytes93, 
hyperparathyroidism may be partially explained by elevations in sclerostin levels. 
Hence, the early suppression of sclerostin using an anti-sclerostin antibody holds 
promise for controlling some of the earliest changes in CKD bone disease. 
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Table 1. Summary of approved agents for patients with CKD61. 
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Raloxifene improves bone quality. 
 Raloxifene is a selective estrogen receptor modulator with mild anti-bone 
remodeling properties. Clinical trials have shown it to effectively reduce fracture 
risk in patients with osteoporosis despite modest improvements in BMD95-96. 
Preclinical studies have revealed that raloxifene improves mechanical properties 
in part through its effects on material properties97-99. This is in contrast to the 
more commonly used bisphosphonates. Bisphosphonates work primarily by 
increasing bone mass and improving bone strength (the ability of bone to resist 
damage)100. Raloxifene, on the other hand, works primarily by improving bone 
toughness (the ability of bone to tolerate damage before fracture occurs). In fact, 
this occurs in the absence of significant changes in bone mass97-98. In other 
words, raloxifene appears to improve bone quality. Specifically, both ex vivo and 
in vivo experiments demonstrate that increased bone matrix hydration is 
responsible for these improvements101-102. Recent studies have even indicated 
that these changes in hydration can be detected using clinical magnetic 
resonance methods102, making raloxifene an appealing agent for examining the 
treatment of bone quality in patients with CKD. 
 Given its unique ability to positively affect bone quality, raloxifene could 
provide an important impact on fracture resistance in CKD. Furthermore, 
secondary analyses of a human clinical trial revealed beneficial renal outcomes 
in patients using raloxifene103. These results, which have been supported by 
animal models104-105 and a clinical study in dialysis patients106, led to the 
recommendation for further studies in patients with late stage kidney disease60-61. 
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CHAPTER 2 
CORTICAL BONE MECHANICAL PROPERTIES IN AN ANIMAL MODEL OF 
PROGRESSIVE CHRONIC KIDNEY DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter has been previously published: 
PLoS One (2014) 9:e99262 
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Rationale 
 Based on previous studies in animals with CKD, whole bone mechanical 
testing indicates that structural mechanical properties are compromised by 
chronic kidney disease. Estimated material properties from these tests suggest 
that bone quality is also impacted. However, the specific tissue-level changes 
that are responsible have not been well defined. Hence, the purpose of this study 
was to directly examine these changes using mechanical, morphological, and 
compositional assessments at various length scales. 
 
Introduction 
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is 
characterized by hyperphosphatemia, secondary hyperparathyroidism, and an 
increased risk of fractures8-9,60. Unlike osteoporosis, CKD-MBD appears to have 
a preferential impact on cortical bone, leading to reduced bone mass and 
increased porosity31,33,38. These effects likely underlie the increased fracture risk 
observed in patients with CKD14-15,18. 
Whole bone (structural) mechanical properties are dependent upon a 
number of variables46,107. While bone mass is a major determinant, both the 
distribution of bone and its material properties (inherent physical and chemical 
properties) also play crucial roles. Most biomechanical studies in rodent models 
of CKD have focused on structural mechanical properties, employing three-point 
bending or dynamic mechanical analysis (DMA)51,92,108-112. These studies indicate 
that the bending and viscoelastic properties of bone are compromised in animals 
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with CKD. Specifically, DMA indicates that diseased animals have lower storage 
modulus (a measure of stiffness) and tan delta (a measure of energy 
dissipation)51,110, while three point bending studies indicate that ultimate load, 
stiffness, and energy to failure are lower in CKD animals108. 
While there is an increasing awareness of the importance of bone quality 
in CKD48, few studies have explicitly examined material properties in animal 
models50-51,110. Material properties can be estimated from whole bone mechanical 
tests using standard engineering equations that account for whole bone structure 
and geometry. Because these estimates assume that skeletal tissue is 
homogeneous, isotropic, and linearly elastic, direct measures of material 
properties in bone would provide additional insight into how the disease is 
affecting fracture resistance. Therefore, the goal of the present study was to 
examine material-level changes in cortical bone at several length scales using a 
rat model with the progressive development of CKD. Specifically, we 
hypothesized that CKD adversely impacts cortical bone material properties as 
determined by material-level mechanical testing and assessments of bone 
composition and collagen morphology. 
 
Materials and Methods 
Animal Model 
The current study utilized a slowly progressive animal model of CKD, the 
Cy/+ rat. Cy/+ rats are characterized by autosomal dominant polycystic kidney 
disease53. These animals have a mutation (R823W) in Anks6, a gene that codes 
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for the protein SamCystin. Currently, the function of this protein is unknown, and 
the specific role of this mutation in the development of polycystic kidney disease 
is unclear. Aside from its expression in the kidney, however, little is known about 
its role in the cell52. Unlike most other PKD-related proteins, though, SamCystin 
does not localize to the primary cilia of kidney cells55. While there is no known 
human disease associated with this gene, the spontaneous onset of disease 
provides a helpful phenotypic model of human CKD52. Unlike the more common 
surgical models49, Cy/+ rats display a gradual onset of disease and, unlike most 
genetic models54,113, they exhibit a slow enough progression that bone disease 
does not begin to occur until after skeletal maturity. 
Skeletal tissue from animals in a previous study was utilized108. All 
animals were fed a casein diet (Purina AIN-76A; 0.7% Pi) to increase 
phosphorus availability in order to produce a more consistent kidney disease 
phenotype. Fresh frozen tibiae from 30-week-old male Cy/+ rats and their age-
matched non-affected littermates were assessed mechanically, compositionally, 
and morphologically at several length scales. Fresh frozen femora were used for 
collagen cross-linking analyses. Blood was collected at the end of the experiment 
for biochemical analyses (previously reported in 108). All procedures were 
conducted under the approval of Indiana University School of Medicine 
Institutional Animal Care and Use Committee protocol # 10479. 
Reference Point Indentation 
Tibiae were thawed to room temperature and soaked overnight in 
phosphate-buffered saline. The anteromedial surface of the proximal diaphysis of 
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the tibia was assessed using reference point indentation (RPI) (Biodent Hfc, 
Active Life Scientific, Santa Barbara, CA). The reference probe, which housed a 
BP2 test probe, was lowered vertically, normal to the surface, until it rested on 
the surface of the bone. In order to stabilize the unit, a reference force of ~13 N 
was applied before each measurement was initiated. Each test included a series 
of 10 cycles at 2 Hz to a force of 10 N. Bones were maintained in a hydrated 
state throughout the test. Five locations per sample, each ~2 mm apart, were 
indented. Raw data from the RPI analysis software (version 2.0) were imported 
into a customized MATLAB code (Mathworks) designed to provide cycle-by-cycle 
data for each test114, from which first cycle unloading slope, indentation distance 
increase, first cycle energy dissipation, creep indentation distance, first cycle 
indentation distance, total indentation distance, and total energy dissipation were 
calculated for each test. All five tests from each animal were averaged to 
produce a single value for each variable. 
Tissue Composition 
Raman spectroscopy was performed using a LabRAM HR 800 Raman 
Spectrometer (HORIBA JobinYvon, Edison, NJ) connected to a BX41 
microscope (Olympus, Tokyo, Japan). A 660 nm laser was focused on the bone 
surface using a 50X objective to a spot size of ~10 µm. Five locations were 
imaged ~1 mm apart on the anteromedial mid-diaphysis with five 20 second 
acquisitions at each location as previously published115. A five point linear 
baseline correction was applied in LabSpec 5 (HORIBA JobinYvon). Using 
OriginPro 8.6 (OriginLab, Northampton, MA), a single Gaussian peak was fit to 
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the PO43-ν1 peak, and the areas under the PO43-ν1, CO32-ν1, and Amide I peaks 
were calculated at each location. Type B carbonate substitution was found by the 
band area ratio of CO32-ν1/PO43-ν1. The degree of matrix mineralization was 
determined by the band area ratios of PO43-ν1/Amide I. Mineral maturity 
(crystallinity) was determined by the inverse of the full width at half maximum 
(FWHM) of the PO43-ν1 peak. 
AFM Indentation 
The anteromedial portion of the mid-diaphysis used above was polished 
with a 3 µm polycrystalline water-based diamond suspension in order to create a 
flat region for testing. Nanoindentation was performed using a BioScope Catalyst 
atomic force microscope (Bruker, Santa Barbara, CA), operating in peak force 
tapping mode using previously published methods116. Indentations were 
performed using a polycrystalline diamond probe (NaDia ND-DYC series; 
Advanced Diamond Technologies, Inc.) with a measured spring constant of 
29.25 N/m. Four locations per sample were indented and, at each location (20 
µm×20 µm grid), 49 indentations were performed. Samples were loaded to 200 
nN with force-separation curves acquired from each indentation. Within each 
location, indentations were spaced about 2 µm apart in order to avoid 
interactions from neighboring indentations. In total, 196 indentations were 
performed for each sample. The indentation elastic modulus was calculated from 
5% to 95% of the withdrawal curve using the classic Hertz model of contact 
between a rigid sphere and an elastic half space because the indentation depth 
is much smaller than the radius of curvature of the probe116. The indentation 
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elastic modulus was determined from the following equation: E = 3F(1-
v∧2)/(4r∧(1/2) δ∧(3/2)) where E is the indentation elastic modulus, F is the 
indentation force, v is the Poisson's ratio of the sample (assumed to be 0.35), r is 
the tip radius (nominal radius of 50 nm, with the same probe used for all 
samples), and δ is the indentation depth. All of the individual indentations were 
averaged to produce a single value for each animal, though individual tests were 
used for distribution comparisons among the groups. 
Collagen Morphology 
Following AFM indentation, the polished surface was partially decalcified 
by soaking the bones in 0.5 M EDTA for 25 minutes followed by five minutes of 
sonication in a water bath. This process was repeated five times for each 
sample. For imaging, RTESPA probes were used (Bruker; radius nominally 8 nm, 
spring constant = 40 N/m). The scan size was set at 3.5 µm with 512×512 pixels 
and a scan rate of 0.5 lines/s. For measurements of collagen morphology, four 
locations were imaged per sample, and 10 to 15 fibrils were measured at each 
location. 40 to 50 fibrils per sample were averaged to produce a single value for 
each animal, though the individual tests were used for distribution comparisons. 
Using SPIP 5.1.10 (Image Metrology, H∅rsholm, Denmark), D-periodic spacing 
was calculated using2D Fast Fourier Transformations (2D FFTs) as previously 
described115. 
Collagen Cross-Linking 
Segments of bone (~3 mm in length) from the proximal femoral diaphysis 
were fully demineralized in 20% EDTA (0.68 M, pH 7.4). Approximately 10 mg of 
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demineralized bone were hydrolyzedin6 N HCl (~10 µL per 1 mg) at 110°C for 20 
to 24 hours. After evaporating the acid using a SpeedVAC centrifuge with cold 
trap, each hydrolysate was resuspended in ultrapure water, split into two equal 
portions, and dried. Half the residue was resuspended in ultrapure water with an 
internal standard (5×10−6 g/L pyridoxine). The solution was filtered and diluted 
with 0.05% heptafluorobutyric acid in 10% acetonitrile, and 50 µL of each 
hydrolysate were assayed by a high performance liquid chromatography (HPLC) 
system (Beckman-Coulter System Gold 168) with a silica-based column (Waters 
Spherisorb). Standards with varying concentrations of pyridinoline (Pyd) 
(Quidel),deoxypyridinoline (Dpd) (Quidel), pentosidine (PE) (International 
Maillard Reaction Society), and a constant amount of pyridoxine were also 
assayed. Using a Waters 2475 fluorescence detector (excitation/emission 
of295/400 nm for Pyd and Dpd and 328/378 nm for PE), chromatograms were 
recorded to determine the amount of each crosslink. These amounts were then 
normalized by collagen content, which was determined from the other half of 
each hydrolysate by another HPLC assay117. Briefly, with α-amino-butyric acid 
(α-ABA) included as an internal standard, the amino acids were subjected to 
derivatization with phenyl isothiocyanate (PITC). Along with standards of varying 
concentrations of hydroxyproline (Sigma) and proline (Sigma) and a constant 
amount of α-ABA, the derivatized samples were resuspended in a buffer solution 
of 5% acetonitrile in 5 mM disodium phosphate. Upon injecting 50 µLof this 
sample, chromatograms were generated with a UV detector (Beckman-Coulter 
System Gold 168). The calculated mass of hydroxyproline was then multiplied by 
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7.5 (assuming 13–14% of type I collagen by mass) and divided by the molecular 
weight of collagen (30,000 Da)118, thereby giving crosslink concentration as 
mol/mol of collagen. 
Statistical Analysis 
All analyses were performed using SPSS software. Comparisons between 
groups were made with Student's t-tests (assumptions validated by Shapiro-Wilk 
and Levene tests). When non-normal distributions or unequal variances were 
present, comparisons were made using Wilcoxon ranked-sum tests and unequal 
variance t-tests, respectively. Distributions included all measures from each 
individual, and comparisons were made using Kolmogorov-Smirnov tests.A 
priori α-levels were set at 0.05 to determine significance. 
 
Results 
Animal Model 
Details about the phenotype of these animals have been previous 
published108. Briefly, measures of kidney function, including BUN (+116%) and 
the albumin-to-creatinine ratio (+301%), were significantly higher in Cy/+ animals 
compared to the normal controls. Similar to what is observed in humans with 
CKD, there were no differences between groups for phosphorus or calcium 
levels, but both serum PTH (+240%) and FGF23 (+195%) were drastically higher 
(Figure 5). Cy/+ animals had higher numbers of osteoclasts and higher levels of 
bone remodeling. Using three-point bending, they exhibited lower ultimate load 
(−28%), stiffness (−17%), and energy to fracture (−46%). Estimates of material 
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properties indicate that they had lower ultimate stress (−20%) and toughness 
(−47%)108 (Figure 6). 
Reference Point Indentation 
Indentation distance increase (IDI) provides an assessment of the change 
in depth between the first cycle and the final cycle. Cy/+ animals had significantly 
higher IDI (+18%), indicating that the tissue is more prone to damage under the 
same applied load (Figure 7). The amount of energy dissipated during the first 
cycle was also significantly higher in animals with CKD (+8%). While the first 
cycle creep indentation distance (+18%) was higher in Cy/+ animals, there was 
no difference in microstructural stiffness (first cycle unloading slope) between the 
two groups. No differences were noted in first cycle indentation distance, total 
indentation distance, or total energy dissipation (Table 2). 
AFM-based indentation 
There was no difference in the indentation elastic modulus between the 
groups (Figure 8). However, when all indentations within each group were 
considered as a population, the distribution of elastic modulus values did differ 
between the two groups. Animals with CKD had a greater proportion of both high 
and low values of elastic modulus than their normal counterparts (Figure 8). 
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Figure 5. Biochemical assessment of kidney function and mineral metabolism. 
These previously published data108 show abnormalities in kidney function and 
mineral metabolism resulting from hyperparathyroidism in the animals utilized in 
the current work. Data are presented as a percentage of non-affected normal 
animals with (*) representing statistical significance. 
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Figure 6. Structural mechanical properties and estimated material properties. 
These previously published data108 show compromised whole bone mechanical 
properties from femoral 3-point bending and apparent material-level mechanical 
properties derived from standard beam bending equations in the animals utilized 
in the current work. Data are presented as a percentage of non-affected normal 
animals with (*) representing statistical significance. 
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Figure 7. Microindentation reveals that CKD skeletal tissue is less able to resist 
damage. 
Using reference point indentation (RPI), the indentation distance increase (IDI) 
was found to be significantly higher in CKD animals compared to normal. These 
data indicate that the mechanical integrity of the bone is less able to resist 
microscale damage formation and propagation. Data are presented as mean and 
standard deviation. *p<0.05 versus normal controls. 
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Table 2. Mechanical properties from microindentation and nanoindentation. 
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Figure 8. Nanoindenation reveals that CKD skeletal tissue has increased 
heterogeneity in the elastic modulus compared to normal bone. There was no 
significant difference in the average elastic modulus (A), but the distribution of 
elastic modulus values was significantly broader (B), with a greater proportion of 
both high and low values in CKD relative to normal (p<0.0001). 
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Tissue Composition 
Raman spectroscopy revealed no differences between animals with CKD 
and their normal counterparts with regard to overall composition of the mineral 
and organic matrices (Table 3). Specifically, there were no differences between 
the groups in the phosphate-to-amide I ratio (the mineral-to-matrix ratio), mineral 
crystallinity, or the carbonate-to-phosphate ratio (a reflection of type B carbonate 
substitution). 
Collagen Morphology and Cross-Linking 
There were no mean differences in D-periodicity between the two groups 
(Table 3). There were also no differences in the distribution of D-periodicity when 
all fibrils were considered. In addition, both enzymatic and non-enzymatic cross-
links as assessed by HPLC were similar between groups (Table 3). 
 
Discussion 
The mechanical integrity of skeletal tissue is determined by the amount of tissue 
present, its distribution, and its quality. Compromises in any of these factors can 
lead to an increased fracture risk. The notable loss of cortical bone mass 
associated with CKD is assumed to be primarily responsible for the increased 
fracture risk seen in patients31. The current study advances our understanding of 
bone fragility in CKD by showing that microscale and nanoscale mechanical 
properties are altered independently of changes in bone mass and porosity. 
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Table 3. Tissue composition and collagen morphology. 
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Our lab has previously documented reductions in both structural and 
estimated material properties in Cy/+ rats, animals with progressive CKD108,119. 
But, whole bone testing only provides indirect estimates of material properties, 
which is why we directly assessed microscale mechanical properties using 
reference point indentation (RPI). RPI data from the present study indicate that 
animals with CKD had higher IDI, higher first cycle creep indentation distance, 
and first cycle energy dissipation. Taken together, these results indicate that the 
tissue in animals with CKD is less resistant to indentation and more prone to 
damage. Indentation distance increase was nearly 20% higher in CKD animals 
compared to their normal counterparts. Similar differences in IDI have been 
previously reported in diabetic rats120. These data have two important 
implications. First, they show that CKD negatively affects skeletal tissue 
independently of bone mass, which means that estimates of bone mass alone 
likely underestimate the overall mechanical effects of CKD. These differences in 
bone quality may explain the conflicting data available on BMD and fracture risk 
in CKD patients35-42. Second, our data provide a basis for considering in 
vivo applications of RPI in the clinical setting of CKD. RPI has been used to 
successfully differentiate patients with and without hip fractures121 as well as 
those with and without atypical femoral fractures122. A related indentation device 
has also been shown to discriminate patients with diabetes from their normal 
counterparts123. Assessment of tissue-level mechanical properties, combined 
with standard imaging modalities to measure bone mass, cortical geometry 
(especially porosity), and trabecular architecture, may prove to be an ideal 
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combination by which to assess the overall mechanical integrity of bones in 
patients with CKD. 
The current study also employed a hierarchical approach by examining 
nanoscale mechanical properties with atomic force microscopy. AFM indentation 
provides a direct assessment of the nanoscale stiffness produced by the collagen 
and mineral composite. Consistent with measurements of microscale stiffness 
(first cycle unloading slope), these results show that the average indentation 
elastic modulus was not significantly different between the two groups. Yet, the 
distribution of elastic modulus values was different. Animals with CKD displayed 
a greater degree of heterogeneity in nanoscale elasticity. Because increased 
material heterogeneity is often considered advantageous124, these results may 
reflect an adaptive response to declining integrity at larger length scales. 
Alternatively, extreme variations in nanoscale properties may lead to localized 
stress concentrations that result in damage accumulation from lower forces125. 
Although heterogeneity is likely necessary for normal mechanical integrity, 
extreme heterogeneity may be problematic from a mechanical standpoint126. 
Future studies should attempt to better understand the role of material 
heterogeneity in CKD in order to specify the contribution of microscale and 
nanoscale properties to whole bone mechanical properties. 
While whole bone, microscale, and nanoscale mechanical differences are 
present in animals with CKD, tissue composition, collagen morphology, and 
collagen cross-linking fail to account for the differences. These data conflict with 
studies showing higher mineral-to-matrix ratios, lower mineral crystallinity, 
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increased advanced glycation end products (AGEs), and decreased gene 
expression of lysyl oxidase in alternative models of CKD51,110,127. One potential 
explanation for these disparate results is that these previous studies utilized 
younger animals that developed advanced CKD during skeletal growth. Teasing 
apart the interaction between growth and disease is difficult, which is why the 
present study employed the use of a model in which kidney disease occurs after 
skeletal maturity. 
Previous studies have demonstrated that non-enzymatic cross-links 
(pentosidine, specifically) are increased in the circulation of patients with CKD128-
131. These findings coincide with the accumulation of AGEs in soft tissues 
detected by fluorescence methods132. Because high levels in the circulation are 
associated with the deposition of AGEs in other tissues, this may be true of 
skeletal tissue as well. To date, this has only been confirmed in one small clinical 
study in patients on dialysis133. Currently, there are few data in animal models, 
and clinical trials examining predialysis patients are lacking. Using a low turnover 
5/6 nephrectomy model, two studies have reported increased pentosidine using 
Raman spectroscopy51,110. While Raman spectroscopy has been utilized to 
detect AGEs in ocular tissue134, its ability to detect changes in bone is unknown 
as HPLC is the standard method used to measure AGEs in skeletal tissue133, 135-
138. Here, having employed HPLC, the hypothesized increases in AGE content 
were not observed. While increases may occur with more advanced disease in 
these animals, the relationship between circulating pentosidine and its 
accumulation in bone collagen in CKD remains unresolved. 
38 
 
At present, clinical data on bone quality in CKD are minimal. Aside from 
the aforementioned dialysis study133, CKD patients with high bone turnover had 
reduced stiffness and a decreased mineral-to-matrix ratio as assessed on iliac 
crest biopsies139. As these data are from cancellous bone, though, direct 
comparison with the current work on cortical bone is difficult. Connecting these 
dots by examining cortical bone properties in patients (which is possible with iliac 
crest biopsies) and cancellous properties in rats will be an essential step in 
moving forward. 
Limitations to the current study should also be recognized. First, because 
tissue from a previous study was used, the sample sizes used here were small. 
Hence, any applications to other animal models or patients should occur with a 
measure of caution. Second, the mechanical assessments were localized to the 
periosteal surface, which may not be fully representative of the entire cortex. As 
such, the assessed parameters may differ at other cortical sites. Finally, this 
study assessed material properties in 30-week-old animals. As the disease 
progresses, differences in composition and morphology may arise. Nevertheless, 
the advantage of using 30-week-old animals is that these animals are skeletally 
mature but do not yet exhibit the rampant increase in cortical porosity present at 
35 weeks119. 
In conclusion, these data show that both microscale and nanoscale 
cortical bone material properties are altered in an animal model of CKD. The 
specific skeletal tissue alterations responsible for these mechanical differences 
remain unclear. Nevertheless, in addition to bone loss and cortical porosity, 
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defects in material-level mechanical properties may also contribute to the 
increased fracture risk associated with CKD. 
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CHAPTER 3 
CHANGES IN SKELETAL COLLAGEN CROSSLINKS AND MATRIX 
HYDRATION IN HIGH AND LOW TURNOVER CHRONIC KIDNEY DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter has been previously published: 
Osteoporosis International (2015) 26:977-985 
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Rationale 
 Given the difficulties explaining why microscale and nanoscale mechanical 
properties were impacted by CKD without obvious changes in tissue composition 
or morphology, samples from older rats were examined for changes in collagen 
cross-linking and bone matrix hydration. This was performed in order to assess 
the tissue properties of animals with more advanced disease to test the 
hypothesis that severe changes arise that are not apparent in the younger less 
disease-ridden animals. 
 
Introduction 
There are clear and consistent data showing that chronic kidney disease 
(CKD) is associated with an increased fracture risk compared to individuals 
without CKD14,140-143. More concerning is that individuals with CKD who 
experience a fracture are at greater risk of mortality compared to people without 
CKD who fracture18,144. There are numerous challenges to reducing fracture risk 
in CKD patients because of the complexity in the underlying bone disease. CKD 
is associated with significant metabolic derangements, including secondary 
hyperparathyroidism, yet some patients have low levels of parathyroid (PTH) for 
unclear reasons140,145-146. At the skeletal level, CKD appears to have a 
preferential impact on cortical bone, leading to increased porosity, and likely 
playing a major role in fracture57,119,147-149. Preclinical studies have documented 
CKD-associated reductions in biomechanical properties of whole bones, as well  
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as at the micro- and nanoscale levels of the hierarchical organization of bone108-
109,112,119,150. Properties of the tissue, such as mineral content, have not shown 
clear differences between normal and diseased bone, leaving a cloud of 
uncertainty as to what properties of the tissue are responsible for this 
compromised mechanical phenotype associated with CKD150. 
Increased attention to “bone quality” (those aspects other than BMD that 
account for a bone’s resistance to fracture) has led to a greater understanding of 
various skeletal properties46,139,150. Collagen plays a vital role in bone with 
changes in collagen cross-links showing clear influence on bone mechanical 
properties151-155. CKD-induced collagen changes have been noted in serum and 
several soft tissues but data in bone are limited110,127,133. A less often discussed 
bone quality variable, bone hydration, also affects bone mechanical properties156-
158, but only recently has it become clear that in vivo modulation of hydration can 
play a role in a bone’s fracture resistance capacity101,159-160. 
While there is an increasing awareness of the importance of bone quality 
in CKD48,139, few studies have explicitly examined material properties in animal 
models108,110,112,119,150. The goal of the present study was to examine two specific 
properties, collagen cross-links, and matrix hydration (bound and pore water) in a 
rat model with progressive development of CKD that can be manipulated to have 
either high- or low-turnover disease53,119. We hypothesized that CKD adversely 
affects both collagen cross-links and matrix hydration, and that these parameters 
would be most affected in high-turnover disease, and there would be 
relationships between these properties and bone mechanical outcomes. 
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Materials and methods 
Animal model 
The current study utilized a slowly progressive animal model of CKD, the 
Cy/+ rat, which has been described in detail several times53,108,150,112,161,162. 
Tissues analyzed in the current study were from select groups of animals that 
were part of a larger study119. Specifically, the animals were in one of three 
groups: Cy/+ animals that were untreated and thus had high-turnover bone 
disease, Cy/+ given calcium supplementation in their drinking water to suppress 
PTH starting at 25 weeks of age (low-turnover disease), or normal littermate 
controls (n  =  8–10/gp). All animals were euthanized at 35 weeks of age and the 
femora (used to study both outcome measures) were saved and wrapped in 
saline-soaked gauze at −20 °C. Prior to the assays reported in this paper, the 
femora were tested in three-point bending119. Blood was also collected at the end 
of the experiment for biochemical analyses. Dynamic histomorphometry 
(detailing turnover rates), three-point bending, and biochemical assays have all 
been previously reported119. All procedures were conducted under the approval 
of Indiana University School of Medicine Institutional Animal Care and Use 
Committee protocol no. 10479. 
Collagen cross-linking 
Segments of the femoral diaphysis (~3 mm in length) were processed for 
collagen cross-links as previously described150. Briefly, following demineralized in 
20 % EDTA (0.68 M, pH 7.4), demineralized bone was hydrolyzed. Each 
hydrolysate was resuspended in ultrapure water, split into two equal portions, 
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and dried. Half of the residue was resuspended in ultrapure water with an internal 
standard (5  ×  10−6 g/L pyridoxine) and assayed by a high-performance liquid 
chromatography (HPLC) system (Beckman-Coulter System Gold 168). 
Standards with varying concentrations of pyridinoline (Pyd) (Quidel), 
deoxypyridinoline (Dpd) (Quidel), pentosidine (PE) (International Maillard 
Reaction Society), and a constant amount of pyridoxine were also assayed. 
Using a Waters 2475 fluorescence detector (excitation/emission of 295/400 nm 
for Pyd and Dpd and 328/378 nm for PE), chromatograms were recorded to 
determine the amount of each cross-link. These amounts were then normalized 
by collagen content (hydroxyproline), which was determined from the other half 
of each hydrolysate by another HPLC assay. The calculated mass of 
hydroxyproline was then multiplied by 7.5 (assuming 13–14 % of type I collagen 
by mass) and divided by the molecular weight of collagen (30,000 Da), thereby 
giving cross-link concentration as mole per mole of collagen. For each 
chromatogram, the area of the peak is calculated and divided by an internal 
standard. These values are then plotted onto a standard curve that plots the 
known masses of the standards to their given areas, providing an estimate of the 
mass of the given molecule in the unknowns (hydroxyproline, pyridinoline, 
deoxypyridinoline, and pentosidine). 
1H nuclear magnetic resonance spectroscopy 
A ~5-mm cross-section of the femur mid-shaft was placed into a low 
proton, loop-gap-style radio-frequency (RF) coil163 along with a reference 
microsphere of water (T2  ~  2 s). The nuclear magnetic resonance spectroscopy 
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(NMR) analysis to separate proton signals within the bone was then performed in 
a 4.7-T horizontal-bore magnet (Varian Medical Systems, Santa Clara, CA) using 
90°/180° RF pulses of ~9/18-µs duration and collecting Carr-Purcell-Meiboom-
Gill (CPMG) measurements with 10,000 echoes at 100-µs spacing. To generate 
the spectrum of transverse relaxation time constants (T 2), the echo magnitudes 
were fitted with multiple exponential decay functions164. Upon normalizing the 
integrated areas of bound water (T 2  =  100–800 µs) and pore water (T 2  =  800–
600 ms) to the area of the reference (T 2  =  600 ms–10 s)165, the volume of bound 
water and the volume of pore water were divided by the specimen volume 
(calculated from Archimedes’ principle) to give bound water (bw) and pore water 
(pw) volume fractions. 
Material-level biomechanical properties 
Whole bone material properties, determined using three-point bending of 
the femora, have been previously reported119. Material-level properties were 
estimated using standard beam theory equations156. Bone diameters were 
measured at the mid-diaphysis using digital calipers, while cross-sectional 
moment of inertia was measured using micro-computed tomography. 
Statistical analysis 
All analyses were performed using SAS software. Comparisons among 
the groups were made using Student’s t-tests as the focus of this work was to 
independently assess high/lower turnover conditions versus control. Pearson 
product moment correlation tests were used to assess the relationship between 
variables across all treatments with the exception of hydration for which 
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Spearman correlations were used, as the data were not normally distributed. A 
priori α levels were set at 0.05 to determine significance. 
 
Results 
High-turnover CKD model 
Details about the phenotype of these animals with secondary 
hyperparathyroidism have been previous published119. Briefly, measures of 
kidney function and PTH were both significantly higher compared to normal 
(+200 and 2800 %, respectively), indicative of active disease. Trabecular bone 
turnover, measured by dynamic histomorphometry, was more than fourfold 
higher in compared normal; cortical porosity was more than doubled. Structural 
biomechanical properties, ultimate load, and stiffness, were both significantly 
lower than controls with no difference in energy to fracture, a biomechanical 
property that is not independent of bone structure119. 
All measured forms of collagen cross-links were significantly different 
compared to normal. The two mature enzymatic cross-links, Pyd and Dpd, were 
both significantly lower (−21 %; p  =  0.004 and 0.02) compared to control (Figure 
9a). There was no significant difference in the Pyd/Dpd ratio. PE, an advanced 
glycation product, was 71 % (p  =  0.001) higher compared to normal (Figure 9b). 
Pore water volume fraction within the femoral cortex was higher 
(+46 %; p  =  0.024), while matrix bound water volume fraction was significantly 
lower (−10 %; p  =  0.04) compared to normal animals (Figure 9c). 
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Figure 9. High-turnover CKD associated changes in skeletal collagen cross-
linking and tissue hydration. (A) Enzymatic collagen cross-links (pyridinoline, Pyd 
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and deoxypyridinoline, Dpd) were significantly lower in CKD compared to normal 
littermates. (B) Pentosidine, an advanced glycation end product, was found in 
significantly higher concentrations in CKD bone compared to normal. (C) Pore 
water fraction was significantly higher and bound water fraction significantly lower 
in CKD animals compared to normal. *p  <  0.05 compared to normal animals 
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Ultimate stress was significantly lower than normal animals (−22 %; p  =  0.001) 
with no difference in modulus and a trend toward lower toughness 
(−21 %; p  =  0.11) (Table 4). 
Low-turnover CKD model 
Details about the phenotype of these animals, where PTH is suppressed 
with the administration of calcium in the drinking water, have been previously 
published119. Briefly, measures of kidney function were significantly higher 
(+150 %), while PTH was significantly lower (−75 %)  
compared to normal. Trabecular bone turnover, cortical porosity, and structural 
properties were not different from controls. 
Levels of Pyd in the bone matrix were not different from controls, while 
Dpd levels were significantly higher (+24 %;p  =  0.002) compared to normal 
(Figure 10a). There was no significant difference in the Pyd/Dpd ratio. PE was 
72 % higher (p  =  0.001) compared to normal (Figure 10b). The NMR-derived 
pore water within the femoral cortex was lower (−60 %; p  =  0.001), and bound 
water was significantly higher (7 %; p  =  0.04) compared to normal animals 
(Figure 10c). 
Toughness was significantly lower than normal animals (−27 %; p  =  0.005) 
(Table 4). Ultimate stress and modulus were similar to normal animals. 
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Table 4. Femoral diaphysis morphology and calculated material-level  
 
biomechanical properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
 
Figure 10. Low-turnover CKD associated changes in skeletal collagen cross-
linking and tissue hydration. (A) The enzymatic collagen cross-link 
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(deoxypyridinoline, Dpd) was significantly higher than normal in low-turnover 
disease; pyridinoline, Pyd, was unaffected. (B) Pentosidine, an advanced 
glycation end product, was found in significantly higher concentrations in CKD 
bone compared to normal. (C) Pore water fraction was significantly lower and 
bound water fraction significantly higher in CKD animals compared to normal. 
*p  <  0.05 compared to normal animals 
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Correlations 
To examine relationships between outcome measures, correlations were 
assessed across the entire data set (controls, low-turnover CKD, and high-
turnover CKD). Kidney function (assessed by BUN) was significantly correlated 
to PE (R  =  0.68) (Figure 11a). PTH was significantly correlated to several 
outcomes including pore water (R  =  0.81), bound water (R  =  −0.70), Pyd (−0.58), 
Dpd (R  =  −0.72), and PE (R  =  0.46). PE levels were negatively correlated to 
ultimate stress and toughness (R  =  −0.44 and −0.57, respectively) (Figure 11b). 
 
Discussion 
It is becoming clear that the increased risk of skeletal fracture associated 
with chronic kidney disease is multifactorial and occurs due to changes in both 
bone quantity and quality48,57,139,166. We have previously documented in an 
animal of progressive kidney disease that compromised biomechanical 
properties can be quantified at the whole bone level as well as at the micro- and 
nanoscales150. These data illustrate that loss of bone mass, as has been 
repeatedly documented in both clinical and preclinical studies, is just one piece of 
the CKD fracture risk puzzle. Given the nanoscale changes in bone mechanical 
properties, our laboratory has focused on measuring properties of the tissue 
matrix that contribute to this level of mechanical integrity150. The results of the 
current work, in a preclinical animal model of progressive CKD, point to 
modification of both collagen cross-linking and bone hydration in  
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Figure 11. Correlations between skeletal pentosidine levels and kidney function 
(a) and mechanical properties (b). As both high- and low-turnover CKD models 
55 
 
were shown to have higher pentosidine levels compared to normal, we explored 
the relationship between kidney function and pentosidine. This relationship was 
statistically significant (r  =  0.68, p   <  0.001). Given the known role of pentosidine 
in modulation of mechanical properties, we also explored the relationship 
between pentosidine and bone toughness (b). This relationship was statistically 
significant (r  =  −0.57, p  =  0.002) 
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late-stage CKD. The changes in cross-links confirm previous preclinical work in a 
different CKD model of high-turnover bone110, while the hydration data results 
represent novel data and a potential variable that could be used for noninvasive 
clinical assessment of bone quality159,167. Collagen cross-links in bone are either 
enzymatically mediated (via lysyl oxidase) or nonenzymatically mediated (in the 
form of advanced glycation end products (AGEs) such as pentosidine)151. The 
predominant mature enzymatic cross-links pyridinoline and deoxypyridinoline 
(also known as hydroxylyslpyridinoline and lyslpyridinoline, respectively) have 
been shown to be associated with changes in bone mechanical properties151. 
Previous work by our lab in the same animal model as the current study showed 
no difference in Pyd or Dpd in CKD animals at 30 weeks150. We have 
documented that this animal model has rapid disease progression, in high-
turnover states, between 30 and 35 weeks of age108,119, leading us to 
hypothesize that major changes in collagen cross-links might manifest with 
progression to advanced disease. Although this turned out to be the case, the 
story is more complicated as the enzymatic cross-link changes were dependent 
of rate turnover; high-turnover groups had reduced enzymatic cross-links while 
low-turnover animals had higher than normal levels of Dpd. 
The simplistic relationship between bone turnover and collagen cross-links 
is an inverse one. High bone turnover leads to lower levels of mature enzymatic 
cross-links because the mean tissue age is lower; while low-turnover bone 
typically has high levels. Yet this relationship model assumes that the process of 
collagen cross-links formation/maturation is not disrupted. Levels of lysyl 
57 
 
oxidase, the key enzyme involved in enzymatic cross-linking, are tissue-specific. 
Kidney levels of lysyl oxidase have been shown to be higher in CKD, and this is 
associated with increased fibrosis in renal tissue168. Serum measures of 
pyridinoline have been shown to be increased in patients with end-stage renal 
disease, and these levels were higher in patients with high turnover compared to 
those with low turnover169. Yet these serum measures do not provide insight into 
skeletal levels, as the latter are determined both the rate of formation/breakdown 
(i.e., bone turnover) and the rate of cross-link maturation (i.e., divalent to trivalent 
bonded). Skeletal levels of mature cross-links have been found to be lower in 
patients with high-turnover end-stage renal disease133, while animal models of 
low turnover have shown reductions in bone lysyl oxidase levels127. Reduction in 
lysyl oxidase would reduce enzymatic cross-links—although neither the clinical 
nor preclinical study measured both enzyme and cross-links. Unfortunately, 
levels of lysyl oxidase were not assessed in the current work and thus definitive 
mechanisms underlying changes in mature cross-links cannot be ascertained. 
Clinical studies have demonstrated that nonenzymatic cross-links 
(pentosidine, specifically) are increased in the circulation and soft tissue of 
patients with CKD170. Increased oxidative stress in CKD leads to increased 
production of AGE, and AGEs worsen oxidative stress, creating a vicious cycle 
that is independent of blood glucose levels171. Skeletal levels of AGEs have been 
shown to be elevated in a small clinical study in patients on dialysis133. Although 
we have recently shown that at 30 weeks of age there is no difference in skeletal 
AGEs in our progressive CKD model, the current results show that at 35 weeks 
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there is a striking difference (>70 % higher than normal). This suggests that, like 
the enzymatic cross-links, major changes occur between 30 and 35 weeks in this 
animal model. More interesting is that the levels of AGEs in the bone are 
independent of bone remodeling rate—both high- and low-turnover models had 
similarly higher AGE levels compared to controls (Figs. 1b and 2b). AGEs are 
typically linked to mean tissue age—since they accumulate in tissues over time 
when mean tissue age is higher AGEs are higher. It therefore follows that, in 
normal situations, bone with higher turnover rates will have lower AGEs 
compared to bone with lower turnover rates. This does not seem to hold true in 
the setting of CKD suggesting there is some intrinsic aspect of the disease that 
results in more AGE accumulation in bone independent of tissue age, perhaps 
due to ongoing AGE production in CKD171 and reduced clearance by the 
kidney172. We hypothesize that elevations in oxidative stress may be underlying 
the accumulation of AGEs in this model. Thus, the severity of kidney disease 
may be more important than the level of bone turnover for determination of 
skeletal AGEs. The importance of the severity of kidney function is supported by 
a modest positive correlation between serum BUN and skeletal pentosidine 
(R  =  0.679) in the current study (Fig. 11a). 
The influence of hydration on bone mechanical properties has long been 
appreciated as it pertains to ex vivo mechanical testing156-157. More recently, data 
have emerged showing modulation of hydration can occur in vivo101, suggesting 
that it could play a role in disease-related bone mechanical phenotypes. The 
results of the current study show that in high-turnover disease, pore water is 
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significantly higher, while in low-turnover disease, pore water is lower, than 
normal animals. Changes in pore water track closely to changes in cortical 
porosity, which is high in high-turnover animals and low in low-turnover animals 
at 35 weeks of age119. The changes in bound water, which have been shown to 
have predominant mechanical effect on bone101, were unexpected and the 
mechanisms through which bound water is modulated in vivo remain unclear. 
Bound water tends to be inversely related to mineralization and at least at 
30 weeks of age mineralization characteristics (determined by Raman 
spectroscopy) are not different from controls150. It is possible that mineral has 
changed by week 35 in these animals, yet unfortunately, tissue is not available 
for such analyses. Also, as intracortical porosity increases, there is more pore 
water but less matrix interactions with water molecules. This is confirmed in the 
current work by the positive correlation between pore water and porosity 
(R  =  0.69). 
Both AGE levels and bone hydration have been documented as having 
significant effects on bone mechanical properties. Increasing AGE levels either in 
vitro, or in vivo, are inversely related to bone toughness—the ability of the bone 
tissue to absorb energy before fracture152,173. Reductions in bone toughness 
reflect a bone that fractures more easily and in a more brittle fashion174. 
Conversely to AGEs, modulating bone hydration (specifically bound water) has 
been shown to have a positive relationship to bone toughness101,175. Estimation 
of material-level mechanical properties in the current study shows that both high- 
and low-turnover disease lower bone toughness relative to normal animals, with 
60 
 
only the lower turnover animals reaching statistical significance (Table 4). 
Interestingly, these two conditions had contrasting effects on pore and bound 
water, as well as enzymatically mediated cross-links. The only common feature 
of the two conditions was a significant increase in levels of AGEs (pentosidine). 
Skeletal pentosidine was negatively correlated to bone toughness (r  =  −0.57; 
Fig. 11b). While we cannot definitively conclude that the higher AGE levels are 
fully responsible for the biomechanical phenotype, the results of this work 
suggest it is an outcome that should be a primary focus in future studies. 
In conclusion, using an animal model of progressive chronic kidney 
disease, we have shown that both collagen cross-linking and skeletal hydration 
are affected in late-stage renal disease. Although both of these variables are 
known to play roles in bone mechanical properties, the data suggest that 
accumulation on nonenzymatic collagen cross-links may be a key change that is 
responsible for altering mechanical properties associated with late-stage disease 
progression. 
 
 
 
 
 
 
 
 
61 
 
CHAPTER 4 
CLINICALLY RELEVANT SUPPRESSION OF HYPERPARATHRYROIDISM 
WITH CALCITRIOL DOES NOT IMPROVE SKELETAL PROPERTIES IN AN 
ANIMAL MODEL OF CHRONIC KIDNEY DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter is being prepared for publication. 
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Rationale 
 Data from the previous studies indicate that in addition to significant bone 
loss, chronic kidney disease also has a direct effect on bone quality. Current 
treatment approaches primarily target the suppression of PTH with the goal of 
minimizing bone loss by slowing the activity of osteoclasts. While these agents 
(calcitriol and its analogues) improve BMD and reduce fractures in the general 
population, the extension of these benefits to patients with advanced kidney 
disease is unclear. Here, the impact of calcitriol on the skeleton is examined in 
the setting of 50% reduction in PTH levels, which is considered clinically 
efficacious in humans. 
 
Introduction 
Chronic kidney disease—mineral and bone disorder (CKD-MBD) 
represents a conglomeration of various metabolic and skeletal changes, such as 
hyperphosphatemia, secondary hyperparathyroidism, and an increased fracture 
risk8-9,60. Currently, the primary goal of therapy is the suppression of elevated 
levels of parathyroid hormone (PTH)62. Using calcitriol (and its analogues) and 
calcimimetics, clinicians target reductions of greater than 30% for serum PTH167-
177. Unfortunately, the impact of these levels of suppression on vascular and 
skeletal outcomes is not clear due to a paucity of data64-67. 
While most osteoporosis clinical studies in non-CKD patients demonstrate 
that calcitriol reduces fracture risk through improvements in BMD69-70, the 
extension of these benefits to patients with advanced kidney disease, where 
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cortical bone is so adversely affected, is unclear62. Previous studies in animal 
models of CKD have shown that suppression of PTH levels at or below normal 
levels with calcium has positive skeletal effects, essentially normalizing skeletal 
properties108,119,178-179. Unfortunately, this effectiveness comes at the cost of 
increased vascular calcification. These data are consistent with concerns raised 
about the use of calcium supplementation and calcium-based phosphate binders 
in late stage CKD patients180-185. 
 In light of these data, a more thorough examination of the effects of 
calcitriol therapy on specific skeletal outcomes is necessary. Specifically, since 
current recommendations for PTH suppression still lead to PTH levels well above 
the normal range60, how these levels of suppression affect bone parameters in 
CKD is not completely clear. Therefore, the current study sought to investigate 
how the clinically relevant suppression of PTH levels (~50%) in CKD would 
impact skeletal properties using an animal model of progressive chronic kidney 
disease. 
 
Methods 
Animal Model 
Cy/+ rats are characterized by autosomal dominant polycystic kidney disease 
(PKD)53. Details of the model have been previously reported108,119,178. This model 
is characterized by the slow and gradual onset of CKD53. It parallels the human 
condition through the gradual development of abnormal mineral homeostasis and 
vascular calcification. Blood urea nitrogen (BUN) and creatinine are elevated by 
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20 weeks of age. Progressive hyperphospatemia, hyperparathyroidism, and 
skeletal abnormalities are present by 30 weeks. 
Experimental Design 
At 24 weeks, male Cy/+ rats were placed on a casein diet (Purina AIN-
76A; 0.7% Pi, 0.6% Ca)  to increase phosphorus availability. This diet has been 
shown to produce a more consistent kidney disease phenotype53. Starting at 25 
weeks of age, Cy/+ rats were treated with vehicle (n=9) or calcitriol (n=11) (10 
ng/kg 3x weekly; intraperitoneal) for 5 weeks. This treatment duration was 
chosen as it approximates an average bone remodeling cycle in skeletally 
mature rats (roughly six months in humans) and has been shown to be sufficient 
to detect treatment-induced skeletal changes in this model108,119. Calcitriol doses 
were chosen to achieve approximately 50% suppression of PTH levels in the 
Cy/+ rats. Non-affected male littermates served as controls (n=8). All rats were 
injected with calcein (10 mg/kg; subcutaneous) 14 and 4 days prior to sacrifice to 
label surfaces with active bone formation. 
At 30 weeks of age, animals were anesthetized with isoflurane and 
underwent cardiac puncture for blood draw. The lumbar spine, tibiae, and femora 
were removed and stored at -20OC for analysis. All procedures were approved by 
and carried out according to the rules and regulations of the Indiana University 
School of Medicine’s Institutional Animal Care and Use Committee. 
Biochemistry 
Blood plasma at 30 weeks was analyzed for BUN, calcium, and 
phosphorus using colorimetric assays (Point Scientific, Canton, MI, or Sigma 
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kits). Intact PTH was determined by ELISA (Alpco, Salem, NH). FGF23 was 
assessed with a two-site assay (Immunotopics, San Clemente, CA)11,53,112. 
MicroCT 
Using microCT (Skyscan 1172), trabecular architecture was determined 
from the metaphysis of the proximal tibia and the full length of the L4 vertebra. 
Cortical bone geometry was determined from the femoral midshaft. Cortical 
thickness was assessed at 75% of the height of the vertebra (from cranial to 
caudal) because this represents a region free of zygapophyseal attachment. All 
bones were wrapped in parafilm to prevent drying and scanned at a resolution of 
12 µm in accordance with standard guidelines186. 
Histomorphometry 
Static and dynamic histomorphometric measures were obtained from the 
proximal metaphysis of the tibia as well as the caudal metaphysis of the L3 
vertebra. Histological processing followed previously used protocols from this 
lab187-189. Tissues were embedded in methyl methacrylate for undecalcified 
sections. Mid-transverse sections (4 µm) of cancellous bone from the proximal 
tibia and the caudal portion of the L3 vertebra were cut and left unstained for 
dynamic histomorphometry or stained with with tartrate-resistant acid 
phosphatase (TRAP) for osteoclast measurements (tibia only). For cancellous 
bone, a region of interest approximately 0.8 mm from the growth plate that was 
analyzed. Unstained sections were assessed for total bone surface, single-
labeled surface, and double-labeled surface to calculate mineral apposition rate 
(MAR), percent mineralizing surface (MS/BS), and bone formation rate 
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(BFR/BS). TRAP-stained sections were assessed for bone surface, osteoclast 
number, and osteoclast surface to calculate the number of osteoclasts per unit 
bone surface (N.Oc/BS) and percent osteoclast surface (Oc.S/BS). All 
histomorphometric nomenclature follows standard usage190. 
Whole Bone Mechanics 
Structural mechanical properties of the left femur were determined by four-
point bending. The anterior surface was placed on two lower supports located +/- 
9 mm from the mid-diaphysis (18 mm span length) with an upper span length of 6 
mm. Specimens were loaded to failure at a rate of 2 mm/min. Structural 
mechanical properties were obtained directly from the force-displacement curves, 
while apparent material properties were derived from the force-displacement 
curves, cross-sectional moments of inertia (Iml), and the distances from the 
centroid to the tensile surface using standard beam-bending equations for four-
point bending47. 
Structural mechanical properties of the L4 vertebra were determined by 
uniaxial compression. Vertebra height was assessed from microCT images. Prior 
to mechanical testing, the vertebral arch and endplates were removed to create 
parallel surfaces for compression testing. Specimens were loaded at a rate of 0.5 
mm/min. Structural mechanical properties were obtained directly from the force-
displacement curves, while apparent material properties were derived from the 
force-displacement curves, pre-test sample heights, and the average bone area 
of five microCT slices (10%, 30%, 50%, 70%, and 90% slices of the pre-test 
sample height) using equations for uniaxial compression191-192. 
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Tissue Composition 
The anteromedial portion of the tibial mid-diaphysis was polished with a 
0.05 µm alumina suspension in order to create a flat region for spectroscopy and 
indentation testing. Composition was assessed using a LabRAM HR 800 Raman 
Spectrometer (HORIBA JobinYvon, Edison, NJ). A 660 nm laser was focused on 
the bone surface using a 50X objective to a spot size of ~10 µm. Three locations 
were imaged ~3 mm apart with five 20 second acquisitions at each location as 
previously published115. A five-point linear baseline correction was applied in 
LabSpec 5 (HORIBA JobinYvon). Using OriginPro 8.6 (OriginLab, Northampton, 
MA), a single Gaussian peak was fit to the PO43-ν1 peak, and the areas under 
the PO43-ν1, CO32-ν1, and Amide I peaks were calculated at each location. Type 
B carbonate substitution was found by the band area ratio of CO32-ν1/PO43-ν1. 
The degree of matrix mineralization was determined by the band area ratio of 
PO43-ν1/Amide I. Mineral maturity (crystallinity) was determined by the inverse of 
the full width at half maximum (FWHM) of the PO43-ν1 peak. 
Nanoindentation 
After Raman spectroscopy, nanoindentation was performed on the same 
tibial samples using a Hysitron TI950 TriboIndenter. Samples were partially 
submerged in ultrapure water with the surface remaining uncovered for optical 
imaging of the surface to determine indentation locations but then fully 
submerged during testing. Locations were imaged using in situ scanning probe 
imaging. Then, 6 indentations were performed on a 10 µm x 20 µm grid, avoiding 
interactions from neighboring indentations. A previously calibrated fluid cell 
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Berkovich diamond probe was used for the indentations. Machine calibrations 
were performed at the beginning of each day of testing. Tests were conducted in 
load control with a 10s loading period, a 10s hold at 3000 µN, and a 10 s 
unloading period. From the resulting load-displacement profiles, the indentation 
elastic modulus and hardness were calculated according to the following 
equations: 
𝐸! =    𝜋2 𝐴(ℎ!)    ∙   𝑆 
𝐻 =    𝑃!"#𝐴(ℎ!) 
where Er is the reduced indentation elastic modulus of the sample, A is contact 
area, hc is the contact displacement, S is the stiffness of the sample determined 
from 40-95% of the unloading slope, H is the hardness of the sample, and Pmax  
is the peak force. All of the individual indentations (n=6 per location) were 
averaged to produce a single value for each location, and each of these locations 
was averaged to produce a single value for each sample. 
Statistics 
Comparisons among groups were assessed by one-way ANOVA with 
Fisher’s LSD post-hoc tests. A priori α-levels were set at 0.05 to determine 
significance. 
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Results 
Mineral Metabolism 
Animals with CKD had higher serum levels of BUN compared to normal 
littermates. Serum calcium was normal, while phosphorus, FGF23, and PTH 
levels were all significantly higher than their normal counterparts (Table 5). 
Animals treated with calcitriol had BUN, calcium, and phosphorus values similar 
to their untreated CKD counterparts. PTH levels in calcitriol animals were 
significantly lower than untreated CKD animals (-61%) but still higher than normal 
controls (+381%). Likewise, FGF23 values in calcitriol-treated animals were 
lower than the vehicle-treated animals (-25%) but higher than normal controls 
(+176%). 
MicroCT 
Vehicle-treated CKD animals had lower trabecular bone volume than normal 
animals at the proximal tibia. A similar pattern was observed in the vertebra. In 
both cases, animals treated with calcitriol displayed no differences compared to 
their CKD-vehicle counterparts (Figure 12 and Table 6). All other trabecular 
parameters were similar between calcitriol animals and the untreated CKD 
animals. 
Cortical bone of the femoral midshaft and lumbar vertebra was also 
negatively affected by CKD. CKD animals had lower cortical area, cortical 
thickness, and bending moments of inertia compared to normal controls (Table 
6). Animals treated with calcitriol displayed cortical values similar to CKD-vehicle 
animals. Calcitriol did not correct CKD-induced changes in cortical area,  
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Biochemistry Normal CKD (Vehicle) CKD (Calcitriol) 
BUN (mg/dL) 14.62 ± 1.95 48.32 ± 8.20 * 43.01 ± 7.07 * 
Calcium (mg/dL) 9.979 ± 0.987 11.610 ± 2.323 10.240 ± 1.872 
Phosphorus 
(mg/dL) 
4.527 ± 0.579 6.682 ± 2.408 * 7.776 ± 1.170 * 
PTH (pg/mL) 181.97 ± 105.05 2194.39 ± 
1811.01 * 
875.12 ± 432.51 
*# 
FGF23 (pg/mL) 698.36 ± 93.03 2556.83 ± 
1401.96 
1924.78 ± 748.81 
*# 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 5. Biochemistry 
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Figure 12. Cancellous bone structure in the proximal tibia and lumbar vertebra as 
determined by microCT. *, p<0.05 compared to NL 
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Proximal Tibia Normal CKD (Vehicle) CKD (Calcitriol) 
BV/TV (%) 17.04 ± 3.34 11.26 ± 1.51 * 10.70 ± 1.77 * 
Tb.Th (mm) 0.106 ± 0.010 0.108 ± 0.004 0.101 ± 0.005 * 
Tb.N (1/mm) 1.611 ± 0.253 1.052 ± 0.150 * 1.057 ± 0.163 * 
Tb.Sp (mm) 0.369 ± 0.044 0.604 ± 0.114 * 0.523 ± 0.084 * 
Femoral 
Diaphysis 
   
Ct.Th (mm) 0.876 ± 0.037 0.748 ± 0.056 * 0.769 ± 0.045 * 
Ct.Ar (mm2) 8.767 ± 0.631 7.324 ± 0.358 * 7.647 ± 0.378 * 
Iap (mm4) 15.00 ± 2.59 12.40 ± 0.58 * 13.19 ± 0.89 * 
Iml (mm4) 10.23 ± 1.56 7.50 ± 0.59 * 8.30 ± 0.99 * 
Ct.Po (%) 0.681 ± 0.348 0.750 ± 0.357 0.769 ± 0.377 
Lumbar Vertebra    
BV/TV (%) 41.88 ± 2.92 30.01 ± 3.98 * 29.83 ± 2.88 * 
Tb.Th (mm) 0.119 ± 0.004 0.110 ± 0.007 * 0.105 ± 0.008 * 
Tb.N (1/mm) 3.581 ± 0.258 2.726 ± 0.324 * 2.823 ± 0.220 * 
Tb.Sp (mm) 0.213 ± 0.021 0.280 ± 0.031 * 0.275 ±0.018 * 
Ct.Th (mm) 0.236 ± 0.033 0.170 ± 0.012 * 0.191 ± 0.035 * 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 6. MicroCT 
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thickness, porosity, or polar moment of inertia of the femur or cortical thickness of 
the vertebra (Table 6). 
Histology 
Vehicle-treated CKD animals had higher trabecular bone formation rates 
in the tibia and vertebra as well as higher osteoclast number and percent 
osteoclast surface than their normal counterparts (Figure 13 and Table 7). 
Calcitriol animals displayed similar values to CKD-vehicle animals with regard to 
mineral apposition rate, osteoclast number, and percent osteoclast surface. 
While animals with calcitriol had a slightly higher proportion of mineralizing 
surfaces than CKD-vehicle animals (in the tibia only), bone formation rates at 
both sites were similar between these groups.  
Whole Bone Mechanics 
Animals with CKD had lower femoral ultimate force, stiffness, and energy 
to fracture compared to normal animals (Figure 14 and Table 8). Estimated 
material properties revealed a significantly lower modulus of toughness in CKD 
animals (Figure 14) with no differences in the ultimate stress or elastic modulus 
(Table 8). Animals treated with calcitriol displayed no treatment effects compared 
to vehicle-treated CKD. They were similar with regard to ultimate force, stiffness, 
and energy to fracture (Figure 14). Calcitriol treatment also had no effect on 
estimated material properties (Table 8). 
Vertebral compression tests, which assess both trabecular and cortical 
bone, revealed that CKD animals had lower ultimate force and energy to ultimate 
force but no differences in stiffness compared to normal animals (Figure 14). 
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Figure 13. Bone formation rates in the proximal tibia and caudal lumbar vertebra 
as determined by dynamic histomorphometry. *, p<0.05 compared to NL 
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Tibia Normal CKD (Vehicle) CKD (Calcitriol) 
MAR (µm/day) 1.305 ± 0.185 2.470 ± 0.569 * 2.285 ± 0.343 * 
MS/BS (%) 26.56 ± 5.14 33.32 ± 4.11 35.86 ± 3.26*# 
BFR 
(µm3/µm2/year) 
126.65 ± 31.02 299.62 ± 74.35 * 298.51 ± 47.41 * 
Oc.S/BS (%) 7.157 ± 1.250 15.739 ± 3.332 * 13.538 ± 2.790 * 
N.Oc/BS (1/mm) 1.966 ± 0.412 4.125 ± 0.785 * 3.604 ± 0.590 * 
Vertebra    
MAR (µm/day) 1.057 ± 0.339 1.983 ± 0.876 * 1.87 ± 0.52 * 
MS/BS (%) 13.62 ± 3.98 27.81 ± 5.73 * 31.39 ± 4.58 * 
BFR 
(µm3/µm2/year) 
52.14 ± 21.76 211.94 ± 128.49 * 220.61 ± 94.32 * 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 7. Histomorphometry 
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Figure 14. Whole bone mechanical properties of the femur as determined by 
four-point bending: (a) ultimate load, (b) stiffness, and (c) energy to fracture. *, 
p<0.05 compared to NL 
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Femur Normal CKD (Vehicle) CKD (Calcitriol) 
Ultimate Force (N) 272.08 ± 17.75 204.81 ± 23.20 * 214.00 ± 20.04 * 
Stiffness (N/mm) 531.67 ± 47.41 412.96 ± 56.28 * 446.99 ± 58.57 * 
Energy to Fracture 
(mJ) 
119.16 ± 15.33 91.65 ± 14.13 * 101.305 ± 17.98 * 
Ultimate Stress 
(MPa) 
153.81 ± 15.68 143.94 ± 17.93 136.49 ± 9.60 
Elastic Modulus 
(MPa) 
4.649 ± 0.633 5.144 ± 0.971 4.830 ± 0.696 
Toughness (MPa) 4.336 ± 0.382 3.652 ± 0.545 * 3.815 ± 0.518 * 
Vertebra    
Ultimate Force (N) 256.89 ± 60.01 187.06 ± 48.03 * 171.31 ± 38.19 * 
Stiffness (N/mm) 952.09 ± 314.20 866.74 ± 260.33 845.67 ± 144.32 
Energy (mJ) 46.27 ± 10.60 28.05 ± 8.93 * 25.38 ± 10.88 * 
Ultimate Stress 
(MPa) 
42.49 ± 10.00 38.74 ± 9.16 35.33 ± 10.88 
Elastic Modulus 
(MPa) 
954.37 ± 334.35 1174.00 ± 447.08 1131.84 ± 170.17 
Toughness (MPa) 1.310 ± 0.470 0.924 ± 0.347 0.819 ± 0.386  
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 8. Whole Bone Mechanics 
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 Estimated material properties were similar among all three groups. As 
above, vertebrae from calcitriol animals were no different than their untreated 
CKD counterparts. 
Bone Quality 
Animals with CKD were found to have no differences in indentation 
properties determined using nanoindentation compared to normal controls. 
Calcitriol animals showed no effect on these properties either (Table 9). Tissue 
composition assessed by Raman spectroscopy revealed no differences in any of 
the compositional parameters among the groups. 
 
Discussion 
The goal of this study was to assess the impact of clinically relevant levels 
of PTH suppression on CKD-induced bone disease. Using calcitriol, the current 
standard of care in patients with secondary hyperparathyroidism, PTH levels 
were suppressed by 60% in animals with CKD. Despite this reduction, no skeletal 
benefits were observed. This is likely due in part to the failure of calcitriol to 
suppress bone formation rates and osteoclast formation, which remained 
significantly higher than normal in both long bone and vertebral cancellous bone. 
While there is value in examining the efficacy of larger doses, these data raise 
important questions regarding how much PTH suppression is needed to produce 
skeletal benefits in the setting of CKD. 
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Raman 
Spectroscopy 
Normal CKD (Vehicle) CKD (Calcitriol) 
Crystallinity 
(1/FWHM PO43-ν1) 
0.0529 ± 0.0003 0.0534 ± 0.0008 0.0534 ± 0.0004 
Carbonate 
Substitution (CO32-
ν1/ PO43-ν1) 
0.247 ± 0.008 0.242 ± 0.013 0.238 ± 0.013 
Relative 
Mineralization (PO43-
ν1/Amide I) 
2.598 ± 0.341 2.403 ± 0.442 2.759 ± 0.299 
Nanoindentation    
Elastic Modulus 
(GPa) 
11.066 ± 2.766 9.666 ± 1.021 9.987 ± 2.610 
Hardness (MPa) 202.62 ± 22.86 192.68 ± 47.35 209.426 ± 43.65 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 9. Bone Quality 
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 Numerous studies have examined the effectiveness of calcitriol and its 
analogues for patients with CKD using biochemical outcomes61,64. These studies 
indicate that patients receiving vitamin D supplementation exhibit effective 
restoration of 1,25[OH]2D3 serum levels and suppression of PTH levels roughly 
25-50% of pre-treatment levels193-194. Few studies have examined the impact of 
these treatments on bone outcomes, however. Calcitriol treatment suppressed 
high bone turnover in pediatric patients and was associated with normal PTH 
values195. Clinical strategies generally do not successfully (nor even seek to) 
attain these levels of suppression. In adult populations, decreases in static 
osteoblast and osteoclast measures were observed in patients taking 
alfacalcidol, but no changes were observed by dynamic measures196. Similar 
results have been observed with calcitriol. Both osteoblast and osteoclast static 
measures were lowered, but there were no changes in dynamic measures197. In 
the current study, dynamic measures were consistent with those studies, but 
osteoclast number and percent surface remained at the level of untreated CKD 
animals. Unfortunately, neither of these previous studies revealed clear 
relationships between bone remodeling and PTH suppression. Despite these 
data, there have been no fracture trials using calcitriol in CKD. More extensive 
bone analyses of calcitriol and its analogues have been conducted in patients 
with osteoporosis69-70. While fracture reduction is clear in that population, similar 
effects in CKD patients have not been examined. 
 Despite the lack of data in humans, there are several studies examining 
the impact of vitamin D analogues in animals. Using adult nephrectomized rats, 
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some studies have shown suppression of PTH, while others have not111,198-200. 
Even in the studies with PTH suppression, only one showed positive bone 
outcomes111. In that study, levels of PTH suppression similar to the current study 
were observed in 5/6 nephrectomized rats. Femoral neck bone mineral density 
and mechanical properties were higher than CKD animals and equivalent to 
normal animals. Interestingly, in their analysis of the femoral diaphysis (a site 
also assessed in the current study), no benefits were observed in bone mineral 
density or mechanical properties. Hence, while variations in these models may 
explain some of the skeletal differences, one possible explanation is that calcitriol 
has a preferential effect at certain skeletal sites. Although the femoral neck is a 
clinically relevant site, why it would be positively affected when the proximal tibia, 
femoral diaphysis, and lumbar vertebra in the current study were not is unclear. 
 Calcitriol is generally thought to increase FGF23 levels201-204. In the 
current study, though, animals treated with calcitriol had lower levels of FGF23. 
Several studies have failed to show a clear relationship between FGF23 levels 
and calcitriol205-206. Because serum 1,25[OH]2D3 levels were not obtained from 
these animals, determining the cause of lower FGF23 levels will require further 
studies in this model. Furthermore, because the anticipated bone effects were 
less than expected, these results may represent a dosage effect. 
 The current study demonstrated that calcitriol treatment, while efficacious 
in terms of PTH suppression in animals with CKD, did little to curb the 
detrimental effects of CKD on the skeleton. This was demonstrated by its lack of 
effect on biochemical and histomorphometric measures. Animals treated with 
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calcitriol also showed no effect with regard to bone structural properties, whole 
bone mechanical properties, or bone quality despite a greater than 50% 
reduction in PTH levels. This indicates that a greater degree of PTH suppression 
may be required for efficacy in skeletal properties to occur in the setting of CKD.  
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CHAPTER 5 
A COMPARISON OF CALCIUM TO ZOLEDRONIC ACID FOR IMPROVEMENT 
OF CORTICAL BONE IN AN ANIMAL MODEL OF CKD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter has been previously published: 
Journal of Bone and Mineral Research (2014) 29:902-910 
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Rationale 
 The role of pharmacological interventions routinely used in the treatment 
of metabolic bone diseases, such as osteoporosis, has been understudied in the 
setting of CKD-MBD. While the current clinical strategy is to lower PTH levels in 
an effort to reduce bone resorption, the previous study indicates clinical levels of 
suppression may not translate into skeletal benefits. To better understand basic 
treatment approaches in CKD, this study compared calcium (to lower PTH and 
bone resorption) and zoledronic acid, one of the most common and effective anti-
resorptive therapies employed in osteoporosis. 
 
Introduction 
Chronic kidney disease–mineral and bone disorder (CKD-MBD) is a 
disorder of abnormal biochemistries, bone fragility, and arterial calcification in 
patients with advanced CKD140. Patients with CKD have increased risk of bone 
fracture compared to the general population17. The increased fracture risk is due 
to a combination of abnormal bone quantity and quality31,207. 
The pathophysiology of bone loss associated with CKD-MBD is different 
than postmenopausal osteoporosis, suggesting that extrapolation of data from 
trials of treatments in postmenopausal or corticosteroid-induced osteoporosis 
may not be appropriate. Secondary analyses of randomized controlled trials of 
bisphosphonates in postmenopausal women subsequently identified to have 
kidney disease demonstrated reduced fracture risk and improved bone mineral 
density without adverse consequences79-80. However, these patients had neither 
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advanced kidney disease nor elevated parathyroid hormone (PTH) levels. These 
differences provided the rationale for global clinical practice guidelines to 
recommend against treating patients with CKD stage 3b-5 with bisphosphonates 
without a bone biopsy60. We have previously used our slowly progressive animal 
model of CKD-MBD to test different doses of the bisphosphonate zoledronic acid 
on bone mass, turnover, and biomechanical properties in animals with 
hyperparathyroidism and moderate renal disease108. In the present study, we 
extend these findings to compare the skeletal (both cortical and cancellous) and 
vascular effects of zoledronic acid with and without calcium in the setting of high 
and low PTH levels in CKD animals with more advanced renal disease. 
 
Subjects and Methods 
Animal model and experimental design 
Male Cy/+ rats, Han:SPRD rats with autosomal dominant polycystic kidney 
disease, and their nonaffected (normal) littermates were used for this study. Male 
heterozygous rats (Cy/  +) develop characteristics of CKD (azotemia) around 10 
weeks of age that progresses to terminal uremia by about 40 weeks. This animal 
model spontaneously develops all three manifestations of CKD-MBD: 
biochemical abnormalities, extraskeletal calcification, and abnormal bone53,112. 
At 25 weeks of age, animals were assigned to treatment groups. In the 
CKD (Cy/  +) animals, this age represents approximately 30% to 40% of the 
kidney function of the normal littermates. This was chosen to simulate late stage 
3b CKD, a stage at which there is elevated PTH, yet normal calcium and 
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phosphorus levels, and a stage at which clinical practice guidelines do not 
recommend treatment with bisphosphonates60. The CKD treatment groups 
(n  =  10 per group) were given: (1) a single subcutaneous (SQ) dose of vehicle as 
control (CTL) and normal deionized drinking water; (2) a single SQ dose of 
zoledronic acid (ZOL) (20  µg/kg body weight) and normal deionized drinking 
water; (3) no injection but administered 3% calcium gluconate (3% Ca) in the 
drinking water; or (4) zoledronic acid plus 3% Ca in the drinking water 
(Ca  +  ZOL). The calcium gluconate group was used to simulate calcium 
administration as a phosphate binder. In addition, we studied age-matched 
normal (NL) littermate animals (n  =  10) to determine if treatments normalized 
bone manifestations or extraskeletal calcification. All animals were fed a casein 
diet (Purina AIN-76A, Purina Animal Nutrition, Shreevport, LA, USA); 0.53% Ca 
and 0.56% P) during the experiment, which has been shown to produce a more 
consistent kidney disease in this model53. Two weeks prior to the end of the 
study, all animals were given an intraperitoneal injection of calcein (1% 
concentration, 0.1  mL/100  g body weight); a second injection was given 10 days 
later. At 35 weeks of age all animals were euthanized by an overdose of sodium 
pentobarbital. All procedures were reviewed and approved by the Indiana 
University School of Medicine Institutional Animal Care and Use Committee. 
Tissue collection and analysis 
At euthanasia at 35 weeks, blood and urine were collected by cardiac and 
bladder puncture, respectively. The heart and aorta arch were excised and 
weighed. Left ventricular mass index (LVMI) was determined by dividing total 
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heart weight by body weight. To quantify aorta and heart calcification, proximal 
segments of the ascending aorta and a segment of the inferior apex of the left 
ventricle of the heart were snap frozen and the degree of calcification was 
determined biochemically as described208. Left tibias were placed in 10% neutral 
buffered formalin for 48 hours and then changed to 70% ethanol for imaging 
followed by histological processing. 
Serum and urine biochemical measurements 
Blood plasma was analyzed for blood urea nitrogen (BUN), calcium, 
phosphorus, and creatinine using colorimetric assays (Point Scientific, Canton, 
MI, USA; or Sigma kits; Sigma, St. Louis, MO, USA). Intact PTH was determined 
by ELISA (Alpco, Salem, NH, USA). FGF23 was assessed with a two-site assay 
(Immunotopics, San Clemente, CA, USA). Urine was analyzed for creatinine, 
calcium, and phosphorus using colorimetric methods112. 
Computed tomography 
Morphological parameters of the proximal tibia were assessed using high-
resolution micro–computed tomography (µCT) (Skyscan 1172). Bones were 
wrapped in parafilm to prevent drying during scanning. Scans were obtained 
using an X-ray source, set at 60  kV and 167  µA over an angular range of 180 
degrees (rotational steps of 0.70 degrees) with a 12-µm pixel size. Projection 
images were reconstructed using standard Skyscan software (NRecon). A 1-mm 
region of interest of the proximal tibia (located ∼0.5  mm distal to the growth plate) 
was analyzed by segmenting the trabecular bone from the cortical shell and 
calculating trabecular bone volume per total volume (BV/TV) in accordance with 
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recommended guidelines186. On the most distal slice of the 1-mm region of 
interest, the cortical shell was manually isolated from the trabecular bone by 
tracing the periosteal and endocortical edges. Porosity of the cortical shell was 
calculated as total bone area within the cortex divided by total area of bone plus 
void space within the cortex. 
Bone histomorphometry 
Tibias were embedded in methylmethacrylate for sectioning as 
described108,209. The proximal tibial metaphysis was thin sectioned (4  µm) and 
mounted unstained using nonfluorescent medium. Sections were analyzed using 
a microscope interfaced with a semiautomatic analysis system (Bioquant OSTEO 
7.20.10; Bioquant Image Analysis Co.). Two of 10 CKD vehicle-treated animals, 
and 2 of 9 CKD calcium-treated animals did not have double labels in the 
proximal tibia section region of interest. In these animals, tibia midshafts were 
sectioned and also found to contain no double label. This suggests these animals 
were not properly administered both labels (likely due to injection directly into 
bladder) and thus these animals were excluded from the histological analysis, 
according to published recommendations210. For trabecular bone analyses, a 
region of interest of approximately 8 mm2 within the secondary spongiosa 
(∼0.5  mm distal to the growth plate) was defined, and then measures of single-
label and double-label perimeter (sL.Pm, dL.Pm), total bone perimeter (B.Pm), 
and interlabel width (Ir.L.Wi) were conducted. From these primary 
measurements, derived parameters were calculated as: mineralizing surface 
(MS/BS  =  [1/2sL.Pm  +  dL.Pm]/B.Pm; %), mineral apposition rate 
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(MAR  =  Ir.L.Wi/days between labels; µm/d), and bone formation rate 
(BFR/BS  =  MAR  ×  MS/BS  ×  3.65; µm3/µm2/year). All parameters were measured 
and calculated in accordance with ASBMR recommended standards211. 
Bone mechanics 
Femurs were tested via three-point bending using standard methods as 
described for the rat108. Femurs were thawed to room temperature, hydrated in 
0.9% saline, and placed on the bottom support of a servohydraulic test system 
(Test Resources). All bones were loaded to failure in an anterior-posterior 
direction using a displacement rate of 2  mm/min with force versus displacement 
data collected at 10  Hz. Structural mechanical properties, ultimate load, stiffness, 
and energy to failure were determined from the load-deformation curves using 
standard definitions. 
Statistics 
All analyses were run using SigmaStat software. The five groups were 
compared using a one-way ANOVA with Fisher's post hoc analyses for within 
group comparisons. Correlations were examined by the Pearson product-
moment algorithm. A priori α-levels were set at 0.05. Data are presented as 
means and standard errors. 
 
Results 
Biochemical outcomes 
At 35 weeks, there was no difference in the plasma BUN in the CKD 
animal treatment groups, but values for all CKD animals were higher than normal 
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animals as expected (CKD BUN 59.6  ±  1.5 versus NL BUN 19.9  ±  0.63  mg/dL). 
The total body weight was not different between any of the five groups. There 
were overall differences in the other blood results (Figure 15). In the CKD rats, 
treatment with calcium, both alone and in combination with zoledronic acid, led to 
an increase in plasma calcium (p  <  0.001) and FGF23 (p  <  0.005) levels and a 
decrease in PTH (p  <  0.001) and phosphorus (p  <  0.05) levels compared to CKD-
CTL. In contrast, treatment with zoledronic acid alone had no significant effect on 
these biochemical measures. The effect of the combination of zoledronic acid 
with calcium was not different than calcium alone for any of these plasma 
biochemistry results. The plasma calcium level was negatively correlated with 
PTH (r  =  −0.53, p  <  0.001) and positively correlated with FGF23 
(r  =  0.44, p  <  0.002). The plasma phosphorus level was more strongly related to 
the PTH (r  =  0.79, p  <  0.001) than FGF23 (r  =  0.33, p  <  0.003). The urine 
calcium/creatinine ratio was significantly increased in both calcium treatment 
groups (Vehicle  =  0.27  ±  0.09; Zol  =  0.27  ±  0.12; Ca  =  0.70  ±  0.22; 
Zol  +  Ca  =  0.50  ±  0.20  mg/mg, p  <  0.0001). The urine phosphorus/creatinine ratio 
was decreased in both calcium treatment groups (Vehicle  =  1.33  ±  0.56; 
Zol  =  1.75  ±  0.44; Ca  =  1.08  ±  0.49; Ca  +  Zol  =  0.79  ±  0.35  mg/mg, 
overall p  =  0.002). The albumin/creatinine ratio was not different among the 
groups. 
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Figure 15. Biochemical changes in response to therapies. CKD animals were 
treated beginning at 25 weeks of age with control vehicle (CTL), calcium in 
drinking water daily for 10 weeks (Ca), zoledronic acid 20  µg/kg given 
subcutaneously once at 25 weeks (ZOL), or the combination of Ca  +  ZOL. The 
results were compared to normal animals (NL) treated with vehicle. Blood was 
drawn at 35 weeks of age. The results demonstrate that treatment with calcium, 
with or without zoledronic acid, led to increased calcium levels (A), increased 
fibroblast growth factor 23 (B), decreased parathyroid hormone levels to those in 
NL (C), and decreased phosphorus levels (D). *different than NL; +different than 
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CKD-CTL; #different than CKD  +  ZOL; all p  <  0.05. Graphs are mean  ±  SEM, 
n  =  8 to 10 per group. CKD  =  chronic kidney disease; CTL  =  control; 
ZOL  =  zoledronic acid; NL  =  normal animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
Cardiovascular outcomes 
At 35 weeks, the CKD animals had increased left ventricular mass index 
(LVMI) compared to normal animals (p  <  0.001) that was unaffected by 
treatments (CKD  +  CTL  =  3.8  ±  0.19, CKD  +  Ca  =  3.9  ±  1.2, CKD  +  ZOL  =  4.0  ±  0.4,  
CKD  +  Ca  +  ZOL  =  4.0  ±  0.4, NL +Vehicle 3.2  ±  0.06, overall p  =  0.035). However, 
treatment with calcium increased aortic arch calcium content, and this adverse 
effect was mitigated by zoledronic acid (Figure 16). The aorta arch calcium 
content was significantly (all p  <  0.01) correlated with LVMI (r  =  0.48), BUN 
(r  =  0.47), calcium (r  =  0.43), and FGF23 (r  =  0.51) but not phosphorus or PTH. In 
contrast to our previous studies in this model208, there was no difference in the 
heart calcification between any of the groups. 
Bone outcomes 
By µCT, there was no difference in the trabecular bone volume between 
CKD and NL animals. ZOL, calcium, and calcium  +  ZOL treatment significantly 
increased percent bone volume (p  <  0.0001) in CKD rats but there was no 
difference among these three treatment groups (Figure 17a). The bone volume 
was strongly correlated with trabecular number (r  =  0.77, p  <  0.001). The 
trabecular bone volume was positively correlated with the calcium (r  =  0.53) and 
FGF23 (r  =  0.42), negatively correlated with PTH (r  =  −0.47; all p  <  0.01), but not 
correlated with phosphorus. Cortical porosity was increased in CKD animals 
compared to normal animals, with significant reduction in animals treated with 
calcium and calcium plus ZOL; the ZOL treatment showed a nonsignificant 
reduction (p  =  0.13; Figure 17b). Corresponding 3D reconstruction of the µCT  
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Figure 16. Aorta arch calcification in response to therapies. CKD animals were 
treated beginning at 25 weeks of age with control vehicle (CTL), calcium in 
drinking water daily for 10 weeks (Ca), zoledronic acid 20  µg/kg given 
subcutaneously once at 25 weeks (ZOL), or the combination of Ca  +  ZOL. The 
results were compared to normal animals (NL) treated with vehicle. The aorta 
calcium content was determined biochemically. The results demonstrated that 
CKD animals given any treatment had increased aorta calcification compared to 
NL animals, and that the treatment with calcium increased calcification further 
among the CKD animals. The coadministration of calcium with zoledronic acid 
led to a reduction of the calcium induced arterial calcification compared to 
calcium alone. *different than NL; +different than CKD-CTL; $different than 
CKD  +  Ca; all p  <  0.05. Graphs are mean  ±  SEM, n  =  8 to 10 per group. 
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CKD  =  chronic kidney disease; CTL  =  control; ZOL  =  zoledronic acid; NL  =  normal 
animals. 
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Figure 17. Trabecular bone volume and cortical porosity in response to therapies. 
CKD animals were treated beginning at 25 weeks of age with control vehicle 
(CTL), calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20  µg/kg 
given subcutaneously once at 25 weeks (ZOL), or the combination of Ca  +  ZOL. 
The results were compared to normal animals (NL) treated with vehicle. At 
euthanasia at 35 weeks, the tibias were assessed by µCT for trabecular bone 
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volume (A) and cortical porosity (B). The results demonstrate that there was no 
difference in trabecular bone volume between CKD and NL animals treated with 
vehicle. However, all of the treatments led to higher bone volume in the CKD 
animals compared to CKD-vehicle. In contrast, the cortical porosity was 
increased in vehicle-treated CKD animals compared to NL animals. Treatment 
with calcium, or calcium plus zoledronic acid, but not ZOL alone, reduced cortical 
porosity to NL levels. The 3D reconstructions (C) provide visualization of these 
trabecular and cortical effects across groups. *different than NL; +different than 
CKD-CTL; all p  <  0.05. Graphs are mean  ±  SEM, n  =  7 to 10 per group. 
CKD  =  chronic kidney disease; CTL  =  control; ZOL  =  zoledronic acid; NL  =  normal 
animals. 
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images are shown in Figure 17c. The magnitude of cortical porosity was strongly 
associated with phosphorus (r  =  0.80) and PTH (r  =  0.70, both p  <  0.001), but not 
associated with FGF23, calcium, or bone volume. 
Dynamic bone histomorphometry demonstrated that the MAR was 
increased in the CKD animals compared to normal, and decreased by all  
treatments in the CKD animals to levels similar to that observed in NL animals 
(Figure 18a). Similar results were observed for mineralizing surface (MS/BS; 
Figure 18b) and BFR (Figure 18c). PTH and phosphorus were positively 
associated with all three histomorphometric indices with the strongest 
relationship with MAR (r  =  0.61 for PTH and r  =  0.42 for phosphorus, 
both p  <  0.01). The calcium level was negatively correlated only with BFR 
(r  =  −0.35, p  =  0.03) and MS/BS (r  =  −0.53, p  <  0.001). 
Ultimate load and stiffness of the femoral diaphysis were both significantly 
lower in untreated CKD animals compared to NL (Table 10 and Figure 19). CKD 
animals treated with ZOL had properties similar to untreated CKD (and lower 
than NL-VEH), while those treated with calcium, or the combination of ZOL and 
calcium had mechanical properties significantly higher than CKD and similar to 
NL. 
Relationship of bone to cardiovascular outcomes 
The aortic arch calcification was correlated with trabecular bone volume 
(r  =  0.43, p  =  0.005) and cortical porosity (r  =  0.34, p  =  0.03), but not with any of 
the three histomorphometry measures. 
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Figure 18. Bone histomorphometry in response to therapies. CKD animals were 
treated beginning at 25 weeks of age with control vehicle (CTL), calcium in 
drinking water daily for 10 weeks (Ca), zoledronic acid 20  µg/kg given 
subcutaneously once at 25 weeks (ZOL), or the combination of Ca  +  ZOL. The 
results were compared to normal animals (NL) treated with vehicle. At 
euthanasia at 35 weeks, the tibias were processed for bone histomorphometry. 
The results for MAR (A), MS/BS (B), and BFR (C). The results demonstrate that 
there was higher MAR, BFR, and MS/BS in the CKD animals treated with vehicle 
compared to NL animals. Treatment with calcium or zoledronic acid reduced all 
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parameters to levels similar in the NL animals with additive reduction in the 
calcium plus zoledronic acid group. *different than NL; +different than CKD-CTL; 
#different than CKD  +  ZOL; all p  <  0.05. Graphs are mean  ±  SEM, n   =  7 to 10 per 
group. CKD  =  chronic kidney disease; CTL  =  control; ZOL  =  zoledronic acid; 
NL  =  normal animals; MAR  =  mineral apposition rate; MS/BS  =  mineralizing 
surface as a percentage of bone surface; BFR  =  bone formation rate. 
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Table 10. Mechanical properties of the femoral diaphysis. 
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Figure 19. Bone biomechanics in response to therapies. CKD animals were 
treated beginning at 25 weeks of age with control vehicle (CTL), calcium in 
drinking water daily for 10 weeks (Ca), zoledronic acid 20  µg/kg given 
subcutaneously once at 25 weeks (ZOL), or the combination of Ca  +  ZOL. The 
results were compared to normal animals (NL) treated with vehicle. At 
euthanasia at 35 weeks, the femurs were tested via three-point bending. The 
results demonstrate that the CKD animals had reduced ultimate load (fracture 
predisposition) than normal animals and this was improved by calcium treatment 
with or without zoledronic acid. *different than NL; +different than CKD-CTL; 
#different than CKD  +  ZOL; all p  <  0.05. Graphs are mean  ±  SEM, n  =  7 to 10 per 
group. CKD  =  chronic kidney disease; CTL  =  control; ZOL  =  zoledronic acid; 
NL  =  normal animals. 
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Discussion 
Multiple studies have documented increased fractures in patients with 
CKD as a result of a combination of abnormal bone volume and bone 
quality38,141. Although secondary analyses support the use of bisphosphonates in 
postmenopausal women with moderate to advanced kidney disease, these 
studies did not enroll individuals with elevated PTH levels79-80. Clinical practice 
guidelines recommend lowering PTH as a primary treatment approach in 
CKD60. There is no evidence that bisphosphonates directly reduce PTH; 
however, their potent bone resorption inhibition could effectively offset the 
osteoclast-medicated effects of high PTH. 
We have previously shown efficacy of zoledronic acid in improving 
trabecular bone volume in animals with earlier stages of CKD and mild 
hyperparathyroidism108. In the present study we tested the hypothesis that 
zoledronic acid would be efficacious in animals with more advanced CKD, severe 
hyperparathyroidism, and even when combined with oral calcium 
supplementation. The latter has been shown to induce low bone turnover in 
patients on dialysis212. Our results demonstrate that individually, zoledronic acid 
and calcium each improved trabecular bone volume and reduced bone formation 
rate and the mineralizing surface to a similar magnitude, but only the calcium 
treatment improved cortical porosity and cortical biomechanical properties. In 
addition, only the calcium treatment induced hypercalcemia and increased 
arterial calcification, although hypercalcemia was not a prerequisite for aortic 
calcification. These results demonstrate that lowering PTH is more effective at 
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improving cortical bone porosity and biomechanical integrity; however, doing so 
with calcium may adversely impact arterial calcification risk. The elevations in 
plasma calcium levels may have a played a role in inducing aorta calcification, 
and it is possible that lower doses of calcium would not results in this adverse 
effect. In our previous study in this animal model we demonstrated that the 
administration of calcium at similar doses to the current study led to aorta 
calcification. This occurred even if the calcium was given together with a 
calcimimetic that resulting in normal plasma calcium levels resulting in increased 
calcium load but normal calcium levels208. These results would imply that it is the 
calcium load, not the level itself that contributes to calcification. However, dose 
finding studies would be required to fully assess the importance of elevated 
calcium levels versus calcium load or decreased bone formation. 
The concern over the use of bisphosphonates in CKD has been the 
potential induction of low-turnover bone disease60. In the present study, 
zoledronic acid did not suppress BFR any more than calcium alone. In humans, 
zoledronic acid has been shown to improve bone mineral density and reduce 
bone fractures in both primary and secondary prevention trials in patients with 
postmenopausal osteoporosis213-215. In contrast, in postmenopausal osteoporosis 
the efficacy of calcium alone on fracture prevention is minimal to uncertain216 and 
its adverse effects have recently come under scrutiny217. We cannot definitively 
determine if the efficacy of calcium on bone in the present study was due to 
calcium itself, or suppression of PTH, but based on the strong correlation of PTH, 
but not calcium, with cortical porosity it is most likely PTH-mediated. Interestingly, 
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the effects of zoledronic acid on improving trabecular bone volume in the present 
study was less than compared to our previous study108 when the drug was given 
at an earlier time point with less severe hyperparathyroidism and over a 5-week 
duration. One possible explanation is that the severe hyperparathyroidism 
induced such a profound increase in bone resorption that the zoledronic acid 
bound to bone was actually resorbed out of bone with the “first pass” effect of the 
osteoclasts, leaving little drug bound for continued effect because the drug was 
only dosed one time. This dosing schedule was used to mimic the dosing to 
osteoporosis patients, in whom a single dose is given once per year—about two 
remodeling cycles in humans. Ten weeks in a rat is also equivalent to about two 
remodeling cycles. If true that a single dose was inefficient to control osteoclasts 
over this duration, this could be overcome by using a less potent 
bisphosphonate, such as alendronate or risedronate, normally administered on a 
more regular basis (daily/weekly). Current clinical practice guidelines recommend 
dose reduction of bisphosphonates in the setting of CKD60. Our data suggests 
that the pharmacokinetics could be altered in the setting of significant secondary 
hyperparathyroidism requiring increased dosing frequency although perhaps a 
lower dose could still be given. Thus, further studies are needed to evaluate 
pharmacokinetics of bisphosphonates in CKD, and further studies should 
determine if the efficacy and adverse effects of zoledronic acid are different when 
given to CKD animals and humans with and without hyperparathyroidism. It 
should also be emphasized that changes in bone volume may not reflect an 
improvement in biomechanical properties/strength. Zoledronic acid did not 
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improve cortical measures of strength, but similar measures to test strength of 
trabecular bone are not available. 
In our CKD animals, the hyperparathyroidism produced profound changes 
in cortical bone porosity and biomechanical properties that were corrected with 
the administration of calcium. Cortical bone is more adversely affected than 
trabecular bone in hyperparathyroidism218-219. However, traditional assessment of 
renal osteodystrophy by bone biopsy in CKD patients has been with trabecular 
bone. Our results suggest that the apparent disconnect between PTH and bone 
turnover assessed by histology in cross-sectional studies220 may be partly due to 
the use of trabecular bone. Supporting this is that in patients with CKD, the distal 
radius DXA, which is nearly entirely cortical bone, is more predictive of fractures 
than other sites166. These data, and our results in the present study, support 
current clinical practice guidelines that emphasize treating hyperparathyroidism 
as first line initial therapy in patients with CKD stages 3-5D60. However, in a 
recent study of nearly 4000 hemodialysis patients, the largest fracture 
assessment study to date in CKD, there was no effect of the calcimimetic 
cinacalcet on fractures despite improved PTH66. However, this study only 
evaluated clinical (reported) fractures and thus may have underestimated true 
fracture prevalence and efficacy of lowering PTH. Thus more studies specifically 
designed to compare the treatment of hyperparathyroidism versus antiresorptive 
agents on fracture prevention in CKD are required. 
Previous studies have demonstrated that bisphosphonates reduce arterial 
calcification in CKD animal models. Tamura and colleagues221 found that 
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etidronate decreased arterial calcification in 5/6th nephrectomy rats also given 
calcitriol. Price and colleagues222 found similar efficacy in the adenine model of 
CKD treated with alendronate or ibandronate. Lomashvili and 
colleagues223 found that pamidronate reduced arterial calcification in 5/6th 
nephrectomy animals treated with high phosphate diet, but also found 
suppression of bone turnover and concluded the drug may be efficacious but not 
safe, although there was no comparison of the degree of bone turnover to normal 
animals. Bisphosphonates work by suppression of remodeling and therefore 
induce lower bone formation rates are expected. In our previous study, the level 
of BFR suppression was no different in CKD animals treated with zoledronic acid 
compared to normal animals treated with zoledronic acid108. In the current study, 
the turnover was equally suppressed with zoledronic acid compared to calcium 
given in the drinking water (to act as a phosphate binder, a treatment used 
worldwide). 
A major concern about inducing suppressed bone turnover is the 
association of such suppression with arterial calcification in patients with CKD 
and in dialysis patients212,224-225. This has been hypothesized to be due to the 
inability of bone to take up excess calcium in the setting of low bone formation 
rates226, predisposing to extra skeletal deposition. In the present study we found 
that despite similar suppression of BFR with zoledronic acid and calcium, only 
the calcium induced arterial calcification and suppression of PTH and zoledronic 
acid appears to ameliorate this effect but had no efficacy by itself. Thus, positive 
calcium balance that occurs in CKD227 may be a critical factor involved in the 
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development of arterial calcification. The calcium treatment also increased 
FGF23, as has been noted in animals228. In other studies of human and animal 
arteries, FGF23 appeared to be protective against arterial calcification, but only 
when klotho was present229. We have previously shown in our animal model that 
klotho expression in the kidney is markedly decreased as early as 20 
weeks230 and thus, assuming similar suppression in arteries, this potential 
positive effect of FGF23 may have been negated with advanced kidney disease. 
The mechanism by which calcium stimulates FGF23 is likely direct on the 
osteocytes, because calcium altered FGF23 secretion in rats who had undergone 
a parathyroidectomy and then were infused with calcium or given a high calcium 
diet228. This increase in FGF23 may have adverse cardiac consequences in 
rodents224,230, and higher FGF23 levels have been found to predict progression of 
left ventricular hypertrophy (LVH) in patients with CKD 3-4230. In the current 
study, we did not observe differences in LVH in animals with the various 
treatments, but the duration of therapy was relatively short. 
In humans with end-stage renal disease (ESRD), there are only small 
studies examining the role of bisphosphonates in the prevention of arterial 
calcification. In small cohort or observational studies from Japan, etidronate 
reduced arterial calcification231-233. In contrast, in a randomized controlled trial of 
50 patients, Toussaint and colleagues234 found that alendronate had no effect on 
arterial calcification. These differences may be explained by the increased 
mineral dissolution properties of etidronate compared to alendronate and other 
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nitrogen-containing bisphosphonates, although a number of other explanations 
such as dosing and disease stage are also plausible. 
In summary, we found similar efficacy of calcium and a single dose of 
zoledronic acid on improving trabecular bone volume in animals with advanced 
CKD and severe hyperparathyroidism. However, only the calcium treatment 
improved cortical porosity and lowered PTH. Unfortunately, calcium also induced 
arterial calcification, whereas zoledronic acid did not, despite similar suppression 
of bone remodeling. These results suggest that suppression of bone remodeling 
with bisphosphonates may not have the same adverse consequences as 
suppression of bone remodeling with calcium. It is important to caution on the 
extrapolation of changes in bone remodeling or bone volume in animal studies to 
human disease. However, the data supports the conduct of a study in CKD 
patients, directly testing whether suppression of PTH with non-calcium-containing 
agents (eg, calcimimetics) is more effective than antiresorptive agents for 
fracture prevention. 
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CHAPTER 6 
ANTI-SCLEROSTIN ANTIBODY TREATMENT IN A RAT MODEL OF 
PROGRESSIVE RENAL OSTEODYSTROPHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter has been previously published: 
Journal of Bone and Mineral Research (2015) 30:539-549 
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Rationale 
 Building upon the previous study, the goal of this study was to further 
examine potential therapies in the treatment of CKD-MBD by assessing the utility 
of anabolic therapy using anti-sclerostin antibody. As before, calcium was used 
to lower PTH. However, in this case, it was employed to create a low turnover 
condition. So, in both high and low bone turnover settings, anabolic (anti-
sclerostin antibody) and anti-resorptive (zoledronic acid) therapies were 
assessed. 
 
Introduction 
 Chronic Kidney Disease affects over 20 million Americans and many of 
these individuals are older and at risk for fragility fractures60. CKD-Mineral Bone 
Disorder is a systemic disease in patients with estimated glomerular filtration 
rates (eGFR) < 60 ml/min (CKD stage 3-5) that manifests as abnormal 
biochemistries, renal osteodystrophy, and extraskeletal calcification140,235. 
 The potential contribution of renal osteodystrophy, versus osteoporosis, in 
the pathogenesis of fragility fractures in patients with impaired kidney function 
has led to confusion on the treatment of bone loss. In human trials, secondary 
analyses of individuals with CKD stage 3-5 have found a beneficial effect of 
bisphosphonates, raloxifene, and denosumab in post-menopausal women 
with reduced fractures and improved bone mineral density without adverse 
consequences79-80,236-237. However, these individuals were enrolled into the 
studies based on normal kidney function and parathyroid hormone levels and 
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only subsequently identified to have CKD in post hoc analyses. With normal PTH 
levels, one can argue that the change in GFR is related to age-based decline in 
kidney function rather than intrinsic disease and therefore not representative of 
CKD-MBD. 
The role of PTH in renal osteodystrophy has been the focus of therapies 
for many years. Low and high levels of PTH have been correlated with low and 
high bone formation rates, and lowering elevated PTH with calcitriol and its 
analogs or cinacalcet is currently the primary therapy for renal osteodystrophy. 
Clinical practice guidelines recommend correction of elevated PTH prior to any 
consideration for other bone/anti-osteoporotic treatment in patients with bone 
loss60. The concern over the use of anti-resorptives has stemmed from reports 
that these agents may ‘over suppress’ PTH and cause adynamic bone disease60, 
which may be associated with bone fractures and extra-skeletal calcification. 
Unfortunately, PTH, despite being a major contributor to the pathogenesis of 
renal osteodystrophy, lacks ideal discriminatory ability for the differentiation of 
low and high turnover and thus misclassification is common238. Therefore, 
treatments that are efficacious in improving or ameliorating bone loss regardless 
of the PTH are needed. 
In addition to elevated PTH, patients with CKD also have elevated FGF23 
and sclerostin levels. PTH stimulates FGF23 secretion from osteocytes via a 
sclerostin mediated pathway239-240 and suppresses sclerostin secretion from 
osteocytes93. Sclerostin levels are increased in CKD compared to normal 
individuals with osteoporosis, and levels are inversely associated with PTH 
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levels94. Sclerostin, the protein product of the gene SOST, binds to LRP5/6 on 
the osteocyte to competitively inhibit the binding of Wnt ligands. Normally, Wnt 
binding to LRP5/6 leads to stabilization of β-catenin (canonical pathway), and 
regulation of normal bone accrual via osteoblast differentiation. In the presence 
of sclerostin, the β-catenin is degraded and mesenchymal stem cell 
differentiation to mature bone cells is inhibited (reviewed in 241). In animal 
models, sclerostin deletion enhances bone accrual242-246 and in early human 
trials247 treatment with an antibody to sclerostin is anabolic. Given that sclerostin 
levels are elevated in blood of patients with CKD91 and bone of patients and 
animals with CKD92 the anabolic agent anti-sclerostin antibody may be 
efficacious in all forms of renal osteodystrophy independent of PTH and bone 
turnover. To test this hypothesis we used a slowly progressive model of CKD-
MBD, manipulating the PTH to low and high levels. We then compared treatment 
with anti-sclerostin Ab, zoledronic acid, or no treatment on biochemical, vascular 
calcification, and bone outcomes. 
 
Materials and Methods 
Animal model and experimental design 
We tested the hypothesis that anti-sclerostin antibody is efficacious in 
preventing bone loss in animals with both high PTH and low PTH, the latter 
induced by calcium in the drinking water. We have previously shown that these 
two extremes of PTH lead to high and low activation frequencies and bone 
formation rates, respectively108,248. Briefly, male Cy/+ rats, Han:SPRD rats with 
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autosomal dominant polycystic kidney disease, and normal age matched 
Han:SPRD rats (NL) were used for this study. Male heterozygous rats (Cy/+) 
develop characteristics of CKD (azotemia) around 10 weeks of age which 
progresses gradually. By 35 weeks, as we have previously reported53,112,119, 
untreated CKD animals at 35 weeks of age have biochemical abnormalities that 
parallel advanced CKD in humans: in the CKD animals versus NL littermates, the 
BUN was 49.3 ± 8.3 vs 22.0 + 4.7 mg/dl, the PTH was 1560 ± 859 vs 132 ± 67 
pg/ml; the phosphorus was 8.4 ± 1.8 vs. 3.6 + 0.6 mg/dl; and the calcium was 
8.99 ± 2.0 vs. 10.3 ± 0.5 mg/dl. 
For the current study, animals were placed on a standard casein diet 
(Purina AIN-76A; 0.53% Ca and 0.56% P) at 24 weeks of age which has been 
shown to produce a more consistent disease in this model53. At 25 weeks of age, 
with an estimated kidney function of 35% of normal, animals were randomly 
assigned to 3% calcium in the drinking water or normal water to suppress or 
maintain the hyperparathyroid state (Figure 20). The additional calcium intake 
based on average water consumption is 1.98 ± 0.57 g/day. At 30 weeks of age 
with estimated kidney function at 20% of normal, animals in both the low and 
high PTH groups were randomly assigned to anti- sclerostin Ab (Scl-Ab; 100 
mg/kg given by tail vein IV q week for 5 total doses; Novartis Institutes for 
BioMedical Research, Novartis Pharma AG), zoledronic acid (ZOL; 20 µg/kg 
body weight given subcutaneously once at week 30, a dose previously shown to 
suppress bone remodeling in this model95), or no treatment (CTL) for 5 weeks. In 
addition, we studied age-matched normal (NL) littermate animals as a positive 
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Figure 20. Schematic of study design: CKD animals were fed a casein based diet 
beginning at 24 weeks, then given drinking water with or without 3% calcium 
beginning at 25 weeks. Drug administration began at 30 weeks of age, and 
sacrifice was at 35 weeks. Data are mean ± SD. * = p < 0.05 for comparison 
between animals given calcium or no calcium, + = p < 0.05 for anti-sclerostin Ab 
versus control. Final n for each group is included in the boxes. 
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control for the anti-sclerostin Ab. Each group had a final n of 9 to 12 animals 
(Figure 20); 1 animal died suddenly in each of three groups: the CKD group 
treated with zoledronic acid, the CKD group treated with calcium and anti-
sclerostin Ab, and the CKD group treated without calcium and anti-sclerostin Ab. 
This is consistent with our previous studies. In addition, two animals had to be 
sacrificed early in the anti-sclerostin treatment groups due to saphenous vein 
inflammation resulting from pharmacokinetic blood sampling. These animals 
were not included in the final analyses. At 35 weeks of age all animals were 
euthanized by an overdose of sodium pentobarbital. All procedures were 
reviewed and approved by the Indiana University School of Medicine Institutional 
Animal Care and Use Committee. 
Tissues collection and analysis 
At sacrifice at 35 weeks, blood was collected by cardiac puncture. Left 
tibiae were placed in 10% neutral buffered formalin for 48 hours and then 
changed to 70% ethanol for imaging followed by histological processing. Right 
femora were wrapped in saline-soaked gauze and frozen for later biomechanical 
analyses and CT evaluation. Left ventricular mass index (LVMI) was determined 
by dividing total heart weight by body weight. To quantify aorta and heart 
calcification, proximal segments of the ascending aorta were snap frozen and the 
degree of calcification determined biochemically as previously described108,119. 
Serum and urine biochemical measurements 
Pharmacokinetics analyses of the Scl-Ab were performed by measuring 
levels of the antisclerostin Ab in serum of eight CKD rats after the first and last 
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dose at 6 and 24 hours post injection using a custom made immunoassay 
(Novartis Pharma AG). Blood plasma was analyzed for BUN, calcium, 
phosphorus, and creatinine using colorimetric assays (Point Scientific, 
Canton, MI, USA, or Sigma kits). Intact PTH was determined by ELISA (Alpco, 
Salem, NH, USA). FGF23 was assessed with a two-site assay (Immunotopics, 
San Clemente, CA, USA). Dickkopf-related protein family-1 (Dkk-1) and 
Sclerostin levels were measured by ELISA (Enzo Life Sciences, Farmingdale 
NY; R&D systems, Minneapolis, MN, respectively). 
Computed tomography (CT) 
Morphological parameters of the proximal tibia and femoral mid-diaphysis 
were assessed using high-resolution microCT (Skyscan 1172) as previously 
described119. Scans were obtained using a 60kV x-ray source (167 µA), an 
angular range of 180 degrees (rotational steps of 0.70 degrees with 2 frame 
averaging) with a 12-µm pixel size and 0.5mm Al filter. Projection images were 
reconstructed using standard Skyscan software (NRecon). A 1mm region of 
interest of the proximal tibia (located ~ 0.5 mm distal to the growth plate) was 
analyzed by manually segmenting the trabecular bone from the cortical shell and 
calculating trabecular bone volume normalized to total volume (BV/TV) in 
accordance with recommended guidelines186. The most distal slice of the region 
of interest was analyzed for cortical porosity. Scans of the femoral diaphysis 
were conducted with similar scan settings to assess geometry (bone area, 
perimeter, cross-sectional moment of inertia) for normalization of mechanical 
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properties. Measures were made in accordance with recommended 
guidelines249. 
Biomechanics 
Femoral diaphysis mechanical properties were assessed in 4-point 
bending studies on an electromechanical test system (Test Resources). Bones 
were thawed, hydrated in saline, and then placed posterior surface down on 
bottom supports (span = 18 mm). The upper supports (span = 6 mm) were 
brought down in contact with the specimen’s anterior surface, and then testing 
was conducted at a displacement rate of 2 mm/min. Force versus displacement 
data was collected at 10 Hz and structural parameters were determined from 
curves using a customized MATLAB program. Material properties were estimated 
using standard equations250. 
Bone Histomorphometry 
Proximal tibiae were embedded in methylmethacrylate for sectioning as 
previously described108,209. The proximal tibial metaphysis was thin sectioned (4 
µm) and mounted unstained using non-fluorescent medium. Sections were 
analyzed using a microscope interfaced with a semiautomatic analysis system 
(Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.). For trabecular bone 
analyses, a region of interest of ~ 8 mm2 within the secondary spongiosa (~ 0.5 
mm distal to the growth plate) was outlined, and then measures of single- and  
double-label perimeter (sL.Pm, dL.Pm), total bone perimeter (B.Pm) and 
interlabel width (Ir.L.Wi) were conducted. From these primary measurements, 
derived parameters were calculated as: mineralizing surface (MS/BS = [1/2sL.Pm 
119 
 
+ dL.Pm]/B.Pm; %), mineral apposition rate (MAR =Ir.l.W/days between labels; 
µm/day), and bone formation rate (BFR/BS = MAR x MS/BS x 3.65; m3/µm2/yr). 
All parameters were measured and calculated in accordance with ASBMR 
recommended standards211.  
Real time RT-PCR analysis of SOST expression 
Total RNA was isolated from tibiae using miRNeasy Mini kit (Qiagen, 
Valencia, CA) after flushing out the bone marrow. The SOST expression in bone 
was determined by real time PCR using 1 ug of total RNA in TaqMan Reverse 
Transcription reagent (Applied Biosystems, Foster City, CA). Target-specific PCR 
primer for SOST was obtained from Applied Biosystems. 
Real-time PCR amplification was performed using TaqMan Gene 
Expression Assays (TaqMan MGP probes, FAM dye-labeled) using Applied 
Biosystems ViiA-7 RealTime PCR system (Applied Biosystems). The cycle 
number at which the amplification plot crosses the threshold was calculated (CT), 
and the ∆∆CT method was used to analyze the relative changes in gene 
expression using β-actin as a housekeeping gene.  
Western blot analysis of β-catenin activation in bone tissue 
To determine the effect of sclerostin antibody treated animals on β-catenin 
signaling in bone tissue, proteins were isolated from tibiae by homogenizing the 
tissue with RIPA buffer using the Bullet Blender (Next Advance, Inc, Averill Park, 
NY) according to manufacturer’s instructions. The β-catenin activation was 
determined by Western blot as we previously described251 using phosphorylated 
β-catenin antibody. Briefly, the blots were incubated with antibody against 
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pSer33/37 β-catenin (1:1000, Cell Signaling Technology, Danvers, MA) overnight 
at 4oC followed by incubating with peroxidase conjugated secondary antibody 
(1:5000 dilution), and immunodetection with the Enhanced Chemiluminescence 
Prime Western blot Detection Reagent (Amersham, Piscataway, NJ). The band 
intensity was analyzed by ChemiDocMP Imaging System (Imaging Lab 4.0, Bio-
Rad, Richmond, CA). 
Statistics 
All analyses were run using SigmaStat software. The two CKD groups 
(high and low PTH) at week 30, prior to drug treatment and the normal animals 
with and without Scl-Ab were compared by t-test. The six CKD groups at 35 
weeks were analyzed by two-way ANOVA after log transformation for non-
normally distributed data. The two groups compared were PTH status (low vs. 
high), and drug effect (Scl-Ab, Zol, CTL) in order to test the efficacy of treatments 
in the setting of low and high PTH. Fisher’s Post hoc tests were done for within 
group comparisons for the different drugs if the overall drug effect was 
significant. When there was a significant interaction between PTH group and 
drug treatment we made statements regarding the relative effect of the drug in 
the setting of high PTH versus low PTH. Correlations were done by Pearson 
Product after log transformation if appropriate. A priori α-levels were set at 0.05. 
Data are presented as means and standard deviation. 
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Results 
Biochemical outcomes 
As detailed in Figure 20, at 25 weeks of age, the CKD animals had 
established secondary hyperparathyroidism. After 5 weeks on oral calcium, the 
PTH was suppressed to 120 ± 100 pg/ml in the calcium treated group compared 
to 759 ± 778 in the high PTH (p < 0.05). At 35 weeks, the calcium treated 
animals (low PTH groups) had a further decline in PTH compared to week 30, 
whereas the non-calcium (high PTH groups) animals had a further rise in PTH 
(overall p < 0.001; Figure 20). There was no difference of drug treatment on PTH 
with the exception of a slightly more elevated PTH in the high PTH group treated 
with anti-sclerostin Ab compared to control (p = 0.03). At 35 weeks, there was no 
difference in the level of BUN among CKD groups, indicating no adverse effect 
on kidney function (data not shown). Figure 21 shows the high PTH (left set of 
bars) compared to low PTH groups (right set of bars) at 35 weeks for calcium, 
phosphorus, FGF23, and Dkk-1. The high vs. low PTH groups were different for 
calcium (p = 0.016), phosphorus (p = 0.034), and FGF23 (p< 0.001), but the drug 
effect was not significant for any of these and there was no interaction between 
PTH group and drug treatment by 2 way ANOVA.  
 As expected, serum levels of Dkk-1 and sclerostin were both elevated in 
CKD compared to NL animals (p = 0.04, p < 0.001). In the CKD animals, Dkk-1 
levels were unaffected by PTH group (p = 0.52), but were affected by drug 
treatment (overall p = 0.004; ZOL different than SclAb and CTL, both p < 0.03; 
Figure 21). There was a weak correlation between Dkk-1 and FGF23  
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Figure 21. Biochemical results: At 35 weeks, the CKD animals had blood 
assessed for calcium (A), phosphorus (B), FGF23 (C), and dkk-1 (D) levels. The 
animals with high PTH (left) were compared to those treated with calcium and 
with low PTH (right) by two way ANOVA examining effect of PTH and treatment. 
For calcium (p = 0.016), and FGF23 (p = 0.0003) there was a difference between 
the high and low PTH (large bar across top), but no effect of treatments (groups 
of 3 bars). For phosphorus, there was a significant effect of both PTH (p < 0.001), 
and a significant effect of treatment (p < 0.001) due to significant effects of 
zoledronic acid to increase phosphorus levels compared to both sclerostin Ab 
treated and control treated animals (both p < 0.001). In contrast, for dkk-1, there 
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was no effect by PTH group, but the treatment effect was significant (p = 0.004), 
with zoledronic acid lowering the dkk-1 compared to both control (p = 0.03) 
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(r = 0.32, p = 0.01) and calcium (r = 0.25, p = 0.047), a modest correlation with 
kidney function (BUN; r = 0.51, p < 0.001), but no significant correlation with 
PTH. The sclerostin levels were inconsistent in the groups treated with the anti-
sclerostin Ab due to probable crossreactivity with the antigen-antibody complex 
and the assay in both the CKD and the NL animals and thus only the other 
groups were evaluated. The sclerostin levels in the high PTH group were 458 ± 
122, high PTH with zol= 563 ± 339, low PTH 249 ± 122, and low PTH with zol = 
260 ± 102 (p = 0.005). There was a strong positive correlation of the log 
sclerostin vs log PTH (r = 0.73, p < 0.001; Figure 22). Given the assay 
limitations, we measured SOST gene expression in the bone by real time PCR to 
determine if anti-sclerostin Ab had any effect on SOST gene expression. The 
results showed an increase in SOST expression with the administration of the 
anti-sclerostin Ab, but only in the calcium treated low PTH animals (Figure 22).  
Cardiovascular outcomes 
As previously reported, the left ventricular mass index was greater in 
untreated CKD animals (3.59 ± 0.12) compared to NL animals (2.99 ± 0.24) (p < 
0.001). Within the CKD groups there was no difference by PTH or by drug 
treatment by two way ANOVA (p = 0.26). Similarly, there was a difference 
between the aorta arch calcification between untreated CKD and NL animals (p = 
0.01) but within the CKD animals no effect on calcification by PTH (p = 0.15) or 
treatments (p = 0.26) by 2 way ANOVA (Figure 23). There was a trend towards 
reduction in calcification by both zoledronic acid and anti-sclerostin Ab in the low  
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Figure 22. Sclerostin levels and SOST expression: Figure 22A shows the 
relationship between the sclerostin and PTH levels (r = 0.73, p < 0.001) for the 
CKD animals. Those animals treated with anti-sclerostin Ab are not included due 
to interference with the assay. Figure 22B shows the expression of total bone 
SOST with and without treatment with anti-sclerostin Ab. There was an increase 
with Ab treatment in only the low PTH animals (* p < 0.001). The expression level 
of SOST in the low PTH animals was significantly greater than in the high PTH 
animals (#, p < 0.001). Data are mean ± SD. 
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Figure 23. Aorta arch calcification: At 35 weeks, the aorta arch was dissected 
free and analyzed for calcium content after HCl extraction, normalizing for tissue 
weight. By 2-way ANOVA there was no significant difference between the 
groups, although there was a trend towards increased calcification in the calcium 
treated control animals; an effect that appeared attenuated by both drug 
treatments. The bar graphs represent the mean ± SD. The box insets in each bar 
indicate the percentage of animals in each group with significant calcification 
(defined as > 5.26 umol/g which is the normal littermate average value of mean + 
2SD). The dashed line represents the mean value from the normal littermate 
animals. 
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PTH group. Eighty percent of animals in the low PTH control group had 
significant calcification (defined as > 5.26 umol/g which is the normal littermate 
average value of mean + 2SD), compared to 20-30% of animals in the other 
groups (boxes in bars in Figure 24). 
Bone outcomes 
As we have previously reported119, the trabecular BV/TV of the untreated 
CKD animals was not different from the normal animals (9.1 ± 4.1 vs. 10.2 ± 
4.2%, respectively) but the cortical porosity was greater (CKD: 2.37 ± 1.74 vs NL: 
0.97 ± 0.39, p = 0.02). In the CKD animals at 35 weeks, there was an effect of 
both PTH (p < 0.0001) and drug treatment (p = 0.03) on trabecular BV/TV 
(Figure 24). The within drug treatment group difference was significant for only 
Anti-sclerostin Ab vs. CTL (p = 0.008). There was also a significant PTH 
group*Drug treatment interaction (p = 0.04) in that the anti-sclerostin Antibody 
treatment increased BV/TV in the low but not high PTH group. Similar results 
were demonstrated for femoral mid-diaphysis cortical bone area and cross-
sectional moment of inertia (Table 11). In contrast, proximal tibia cortical porosity 
as well as all mechanical and geometrical parameters of the femoral mid-
diaphysis showed significant PTH effects (p < 0.001 for all) but only a trend 
towards an effect of drug treatment (p = 0.9) (Figure 24 and Table 11). The 
periosteal perimeter was not different, but the endocortical perimeter was greater 
in the high PTH group compared to the low PTH group (p < 0.001) with no effect 
of treatment due to the wide variability (Figure 24). As a positive control, NL  
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Figure 24. Bone Results: At 35 weeks, bone from the CKD animals was 
assessed by microCT for proximal tibial trabecular bone volume, cortical porosity, 
femur ultimate force and for femur cortical bone endocortical. The animals with 
high PTH (left) were compared to those treated with calcium and with low PTH 
(right) by two way ANOVA examining effect of PTH and treatment. For bone 
volume, porosity, and ultimate force (all p < 0.001) there was a difference 
between the high and low PTH. There was a positive effect of treatment on bone 
volume with the sclerostin Ab increasing the volume more than control (p = 
0.008). There was no effect of treatment for cortical porosity or ultimate force. 
The dashed line represents the mean value from the normal littermate animals.
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 Proximal 
tibia 
Femoral mid-diaphysis 
 BV/T
V 
(%) 
Cortic
al 
Poros
ity 
(%) 
Ultima
te 
Force 
(N) 
 
Stiffnes
s 
(N/mm) 
Energ
y to 
failure 
(mJ) 
Ultima
te 
Stress 
(MPa) 
Modulu
s (MPa) 
Toughn
ess 
(MPa) 
Cortic
al 
thickn
ess 
(mm) 
Corti
cal 
bone 
area 
(mm2) 
Cortic
al 
porosi
ty (%) 
CSMI 
(mm4) 
CKD High PTH 
CTL 10.2 
± 1.9 
2.4 ± 
1.7 
208.9 ± 
27.7 
456.7 ± 
64.6 
93.8 ± 
18.5 
100 ± 
16 
3686 ± 
546 
2.7 ± 0.6 0.58 ± 
0.10 
7.4 ± 
0.4 
2.8 ± 
2.9 
22.4 ± 
1.8 
Scl-
Ab 
11.3 
± 3.7 
7.4 ± 
8.5 
200.5 ± 
48.7 
471.9 ± 
99.0 
83.8 ± 
35.4 
92 ± 28 3527 ± 
916 
2.3 ± 1.1 0.49 ± 
0.19 
8.1 ± 
0.4  
7.2 ± 
5.8 
23.9 ± 
2.2  
Zol 13.0 
± 4.9 
5.9 ± 
6.4 
211.2 ± 
38.3 
428.8 ± 
59.7 
96.6 ± 
30.0 
104 ± 
25 
3570 ± 
683 
2.8 ± 0.9 0.54 ± 
0.18 
7.8 ± 
0.6 
6.2 ± 
7.0 
21.9 ± 
2.7 
CKD Low PTH 
CTL 21.1 
± 3.6 
1.3 ± 
0.5 
256.7 ± 
20.2 
561.6 ± 
47.5 
112.6 
± 15.2 
115 ± 9 4306 ± 
419 
2.9 ± 0.5 0.80 ± 
0.07 
8.8 ± 
0.7 
4.5 ± 
8.3 
23.6 ± 
2.5 
 131 
Scl-
Ab 
25.6 
± 
4.3* 
1.5 ± 
0.7 
295.1 ± 
27.8 
593.9 ± 
31.1 
126.6 
± 29.7 
127 ± 
19 
4224 ± 
555 
3.3 ± 0.9 0.80 ± 
0.05 
9.0 ± 
0.7  
0.77 ± 
0.48 
25.7 ± 
3.1  
Zol 20.9 
± 3.2 
1.4 ± 
0.7 
272.3 ± 
24.3 
567.6 ± 
43.9 
111.9 
± 23.5 
124 ± 
11 
4349 ± 
667 
3.0 ± 0.7 0.82 ± 
0.06 
8.9 ± 
0.8 
0.71 ± 
0.57 
23.9 ± 
3.7 
Normal animals 
CTL 10.2 
± 1.9 
1.0 ± 
0.4 
268.0 + 
21.0 
562.4 ± 
37.5 
131.1 
± 29.1 
116 ± 
16 
3767 ± 
320 
3.6 ± 1.0 0.73 ± 
0.05 
8.6 ± 
0.3 
1.8 ± 
0.6 
26.4 ± 
2.4 
Scl-
Ab 
16.0 
± 
1.9* 
1.2 ± 
0.6 
339.5 ± 
31.3+ 
663.5 ± 
101.9* 
169.7 
± 29.5* 
114 ± 
12 
3254 ± 
443* 
3.9 ± 0.9 0.79 ± 
0.03 * 
10.3 ± 
0.6+ 
1.3 ± 
0.3 
36.8 ± 
3.5+ 
  
Table 11. Bone CT and Biochemical Results 
CTL= control or no treatment; Scl-Ab = treatment with anti-sclerostin Ab; Zol = treatment with zoledronic acid; CSMI = 
cross sectional moment of inertia. Data presented as mean and standard deviation. 
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The CKD animals were compared by two-way ANOVA evaluating the effect of PTH and treatment. There were significant 
differences (p < 0.01) by PTH group for all bone parameters. There was a significant effect of drug treatment in that 
treatment with sclerostin Ab was different than control for trabecular bone volume (p = 0.03), cortical bone area (P = 0.05), 
and CSMI (p = 0.043) with no differences among treatments for the other parameters. Data are mean ± SD. 
The Normal animals with and without treatment with anti-sclerostin Ab were compared by t-test. * = p < 0.05, + = p < 0.01.  
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animals given similar doses of Scl-Ab, demonstrated a robust increase in 
trabecular BV/TV (p < 0.001). There was also an increase in biomechanical 
properties and cortical geometry (Table 11). The anti-sclerostin Ab treatment of 
NL animals had no effect on any of biochemistries. Thus, in the NL rats, there 
was the expected benefit of the anti-sclerostin antibody. 
As we have previously reported, the high PTH group is a high bone 
remodeling model of CKD, with untreated animals having BFRs of nearly three 
times NL controls. There were significantly higher dynamic bone formation 
properties of the proximal tibia trabecular bone in the high PTH animals (Table 
12) compared to the low PTH animals. In both high and low PTH cohorts those 
animals treated with anti-sclerostin antibody had higher remodeling rates 
compared to animals treated with zoledronic acid. 
To understand the differential effects of anti-sclerostin Ab on bone in the 
low and high PTH group, we measured phosphorylated β-catenin by Western 
blot from total bone extracts. In the CKD animals basal expression was 0.39 ± 
0.18. In the CKD animals treated with antisclerostin Ab, the expression was 0.52 
± 0.28 in the high PTH group and 0.19 ± 0.17 in the low PTH group (p = 0.3, with 
differences in the two treated groups of p = 0.008). Phosphorylated β- catenin 
expression represents degradation, and therefore less degradation would 
indicate a positive effect of the anti-sclerostin Ab in the low PTH group, 
consistent with the bone volume findings. 
 
 
134 
 N, # MAR, um/day MS/BS, % BFR/BS, 
um3/um2/year 
CKD High PTH 
CTL 11 2.2 + 1.1 31 + 8 280 + 156 
Scl-Ab 12 2.8 + 1.7 29 + 8 323 + 221 
Zol 9 2.0 + 1.0 21 + 10 166 + 117 
CKD Low PTH 
CTL 10 1.2 + 0.3 11 + 5 49 + 18 
Scl-Ab 12 1.2 + 0.6 28 + 17 154 + 154 
Zol 9 0.4 + 0.2 5 + 4 8 + 7 
Normal animals 
CTL 8 1.2 + 0.3 21 + 7 94 + 42 
Scl-Ab 8 1.4 + 0.3 24 + 9 133 + 66 
 
Table 12. Bone histomorphometry results. 
CTL= control or no treatment; Scl-Ab = treatment with anti-sclerostin Ab; Zol = 
treatment with zoledronic acid; MAR = mineral apposition rate; MS/BS = 
mineralizing surface per bone surface; BFR/BS = bone formation rate per bone 
surface. Data presented as mean and standard deviation. The CKD animals 
were compared by two-way ANOVA evaluating the effect of PTH and drug 
treatment. After log transformation, there were significant PTH (all < 0.001) and 
overall drug treatment (p < 0.02 for all ) effects for MAR, MS/BS and BFR/BS, 
and a significant PTH*drug treatment interaction for MS/BS% (p = 0.006) and 
BFR/BS (p = 0.009) . Between group analyses revealed that Animals with higher 
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PTH had values compared to low PTH (p < 0.002 for all three measurements). 
The MAR and BFR/BS were both different in ZOL compared to anti-sclerostin Ab 
and control (both p < 0.02) but the anti-sclerostin Ab was not different from 
control. All three treatments were different from each other for the MS/BS% (all p 
< 0.03). The Normal animals with and without treatment with anti-sclerostin Ab 
were compared by t-test but there was no significant difference for any 
parameter. 
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Pharmacokinetic results 
Three of 8 CKD rats treated with anti-sclerostin AB developed auto-
antibodies to the drug. The animals that developed auto-antibodies did not have  
appreciably lower BV/TV than those without auto-antibodies and therefore are 
included in all of the analyses. The pharmacokinetic curves are shown in Figure 
25. Thus, auto-antibodies to antihuman sclerostin antibody were formed, similar 
to previously reported in studies using humanized anti-OPG antibody252-253. 
 
Discussion 
 In the present study we demonstrated that treating rats by inhibiting the 
activity of sclerostin in advanced CKD with a relatively normal PTH improved 
tibial trabecular bone volume and cortical bone geometry. In contrast, in animals 
with high PTH no benefit was observed. In the high PTH animals, the magnitude 
of hyperparathyroidism was severe, leading to profound cortical porosity but 
relatively normal tibial trabecular bone volume; neither antisclerostin antibody nor 
zoledronic acid improved the porosity. The phosphorylated β-catenin was not 
changed over baseline in the CKD animals treated with anti-sclerostin Ab with a 
high PTH but were appropriately decreased in the low PTH group, consistent 
with the lack of benefit in the high PTH group. As expected, dynamic 
histomorphometry (Table 12) demonstrated differences between low and high 
PTH for MAR, MS/BS and BFR. There was also a significant interaction between 
PTH group and treatment in the MS/BS and BFR/BS but not MAR. The MS/BS 
was decreased in the ZOL and increased in the anti-sclerostin Ab treated  
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Figure 25. Pharmacokinetic results. Eight animals had blood drawn for 
measurement of the anti-sclerostin antibody 6 and 24 hours after the first and 
fifth dose. The y-axis represents the measured level of the anti-sclerostin 
antibody in the blood of each animal. Each symbol represents a different animal. 
*The presence of autoantibodies in serum at that time point. For the animal 
denoted by the open square (++), levels were undetectable at dose 5 and 
autoantibodies were present. BPS804  =  anti-sclerostin antibody. 
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animals in the Low PTH but not the High PTH groups. The BFR/BS was 
suppressed by ZOL in the Low PTH but not the High PTH groups. Biomechanical 
testing demonstrated that neither anti-sclerostin antibody nor zoledronic acid 
were effective in improving the biomechanical properties of the bone, regardless 
of PTH level. These results demonstrate that cortical bone abnormalities prevail 
in CKD animals with elevated PTH, similar to what is observed in patients with 
CKD57. However, even in the setting of low PTH, the improvement in bone 
volume did not translate to improved biomechanics, suggesting other factors alter 
bone quality in CKD. The efficacy of anti-sclerostin Ab to improve bone volume, 
geometry, and biomechanics in normal rats confirms that the observed lack of 
efficacy in the CKD animals was due to the disease state, and not because of 
auto-antibody development in rats. These results suggest that abnormal Wnt 
signaling, especially in the high PTH group, may negate any effect of blockade of 
the sclerostin-mediated pathway. Alternatively, or additively, other factors in CKD 
may lead to such altered bone quality that anabolic changes due to the anti-
sclerostin antibody are overshadowed. 
Wnt signaling is mediated through the LRP5/6 pathway that is inhibited by 
the circulating factors sclerostin and dkk-1. PTH binds to its receptor PTH1R and 
activates β- catenin signaling via multiple mechanisms: 1) binding to LRP6 to 
activate LRP5/LRP6 signaling even in the absence of Wnt, 2) cAMP signaling to 
directly activate β-catenin, and 3) indirectly via osteoclast activation which then 
increase β-catenin activity in osteoblasts (Reviewed in 241). Thus, PTH can 
activate β-catenin through non Wnt-mediated pathways. Mice expressing a 
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constitutively active PTH1R in osteocytes leads to cAMP signaling which 
increases β-catenin and osteoblast mediated bone modeling in periosteal 
bone254-255. Deletion of LRP6 in osteoblasts blunts the anabolic activity of 
intermittent PTH administration256 whereas deletion of LRP5 does not257. Mice 
expressing a constitutively active PTH1R or animals receiving continuous 
infusion of PTH 1-84 (analogous to the secondary hyperparathyroidism in the 
animals in the present study) also have Wnt-dependent remodeling with 
increased osteoclast bone resorption via RANKL/OPG leading to osteoblast 
activation and β-catenin activation255,258. PTH suppresses expression of dkk-1 in 
osteoblasts, but even if dkk-1 is overexpressed, PTH can still activate the Wnt 
pathway via stabilization of phosphorylation of β-catenin249. In the present study 
we found increased phosphorylated (degraded) β-catenin in the high PTH 
animals compared to the low PTH animals treated with anti-sclerostin Ab 
suggesting that the elevated PTH itself does not increase β-catenin directly but 
more likely interferes with the LRP5/6 receptor. It is important to point out that our 
high PTH animals had very severe hyperparathyroidism and other studies are 
needed to determine if more moderate hyperparathyroidism would show 
beneficial bone effects of anti-sclerostin antibody. 
The importance of Wnt signaling in renal osteodystrophy was first shown 
by Sabbagh and others92 who characterized progressive secondary 
hyperparathyroidism with osteitis fibrosa in the jck mouse model of cystic kidney 
disease. They found an initial increase in immunoexpression of sclerostin and 
phosphorylated β-catenin in earlier CKD, but as the disease progressed and 
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secondary hyperparathyroidism and hyperphosphatemia developed there was a 
relative decline in the number of osteocytes expressing sclerostin. They also 
found no further increase in the phosphorylated β-catenin expression with rising 
PTH consistent with our results of a lower phosphorylated β-catenin in animals 
with high PTH compared to low PTH. They hypothesized this was due to 
progressive rises in PTH or in serum frizzled related protein 4 (sFRP4), another 
inhibitor of sclerostin92. We did not measure sFRP4 in our animals but this 
remains a possibility. In a diabetic/atherosclerotic mouse model of early stage 2 
CKD, serum levels of sclerostin and Dkk1 were increased. The administration of 
Dkk1 monoclonal antibody to these mice led to a decrease in PTH levels, an 
increase in circulating sclerostin levels, and an increase in the low bone 
formation rate, osteoblast and osteoclast number259. The PTH levels, while 
initially increased in these animals were lower at the end of the study and 
equivalent in both the vehicle and anti-dkk treated animals259. Those results with 
the anti-dkk-1 antibody parallel the efficacy observed in our low PTH group with 
anti-sclerostin antibody treatment. Taken together the data suggest that PTH 
plays a major role in β-catenin signaling in renal osteodystrophy. 
Circulating sclerostin levels are increased in patients with progressive 
decline in kidney function, beginning as early as stage 3 CKD260. In contrast to 
other circulating biomarkers, these increases do not appear related to reduced 
renal excretion261. However, in patients with primary hyperparathyroidism, 
sclerostin levels are lower than euparathyroid controls262. In patients on 
hemodialysis, elevated sclerostin levels, but not serum Dkk-1 levels, were 
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associated with increased bone mineral density at both trabecular and cortical 
sites by DXA and improved trabecular architecture by microCT in dialysis 
patients94. By multivariate analyses in a cohort of 60 dialysis patients, elevated 
sclerostin levels were only correlated with osteoblast number on bone biopsy. 
However, sclerostin levels had positive predictive value of 0.93 for high bone 
formation rate compared to only 0.57 for intact PTH; for low bone formation rates, 
PTH was superior91. Dkk-1 levels were not significantly correlated with any 
histomorphometric analyses. We also found elevated Dkk1 levels in our naturally 
occurring CKD animal model. We also saw a slight increase in the dkk-1 levels in 
animals treated with anti-sclerostin Ab in the high PTH group only, perhaps 
another explanation for a lack of efficacy of the anti-sclerostin Ab in the high PTH 
group. 
In the present study, the sclerostin levels were greater in the high PTH 
animals compared to the low PTH animals. In contrast to other studies91, we 
found a positive correlation between PTH and blood sclerostin levels. Given that 
PTH is known to suppress SOST, we then evaluated the levels of SOST 
expression in total bone extracts. There was no difference in basal expression of 
SOST in the CKD compared to normal animals, but there was a trend towards an 
increase in the CKD animals with low PTH (treated with calcium), and a further 
increase in the treatment with anti-sclerostin Ab. We hypothesize that treatment 
with the Ab reduces sclerostin levels leading to upregulation of SOST. 
Unfortunately we could not confirm this as the assay cross reacted with the Ab. 
The increase in SOST with the anti-sclerostin Ab was much greater in the 
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animals with low PTH. This may suggest that PTH inhibits SOST as has been 
shown93, and/or that the elevated calcium or FGF23 in these animals increases 
SOST. Another potential reason why we saw a positive relationship of sclerostin 
with PTH may be due to the elevated phosphorus in these same animals. In a 
study of dialysis patients, elevated sclerostin levels were associated with lower 
GFR, male sex and high phosphorus levels260. In a rat model of CKD induced by 
nephrectomy, parathyroidectomy and a high phosphorus diet vs 
parathyroidectomy and a normal phosphorus diet led to higher circulating 
sclerostin levels, lower bone volume, and increased bone expression of SOST, 
Dkk-1, and Gsk3b suggesting that phosphorus has a PTH independent effect to 
suppress Wnt signaling263. Treating normophosphatemic stage 3 to 4 CKD 
patients with the non-calcium containing phosphate binder sevelamer led to a 
reduction in sclerostin levels, however, calcium binders had no effect on 
sclerostin levels despite effectively lowering phosphorus264. In the present study 
we utilized calcium in the drinking water to suppress PTH, which also acts like a 
phosphate binder to lower phosphorus levels. Thus it is possible that the 
elevated sclerostin levels in the high PTH group are due to hyperphosphatemia, 
and/or that the calcium administration used to lower PTH decreases sclerostin 
levels91. Clearly more work is needed to understand the regulation of SOST, 
especially in the setting of CKD. 
Calcium (or lower PTH) also increases FGF23 levels in our animals as we 
have previously reported119. In the present study, anti-sclerostin Ab had no effect 
on FGF23 levels although there was a trend towards lowering of FGF23 levels in 
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the low PTH group. However, the variability of FGF23 in this naturally occurring 
animal model of CKD was such that this did not reach significance. However, 
treatment with anti-dkk-1 Ab in mice with early stage of CKD did not alter FGF23 
levels259. PTH also stimulates FGF23 via cAMP and Wnt signaling240 and thus 
we would have expected lower, not higher FGF23 levels in our low PTH animals. 
In addition, the low PTH group had elevated FGF23 that was unaffected by anti-
sclerostin Ab. This implies that the calcium treatment used to lower PTH likely 
has a direct effect on FGF23 synthesis. Calcium treatment also led to more 
animals with arterial calcification, an observation that was moderated by both 
zoledronic acid and anti-sclerostin antibody treatment. Similarly, Fang et al found 
that anti-dkk-1 therapy in CKD animals reduced arterial calcification259. Whether 
sclerostin plays a pathogenic role in arterial calcification or the expression is 
simply a marker of osteo-chondrogenic transformation remains to be seen. 
In summary, our study is the first to test the efficacy of anti-sclerostin Ab in 
the setting of renal osteodystrophy. In our rat model of slowly progressive CKD, 
the antibody enhanced trabecular bone volume and mineralization surface, but 
only in the setting of low PTH and this did not translate to improved 
biomechanical properties. In the animals with severe secondary 
hyperparathyroidism, the antibody was not efficacious, most likely due to PTH 
interference of Wnt signaling by alteration of the LRP5/6 receptor, or through 
effects of changes in phosphorus or FGF23. 
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CHAPTER  7 
COMPROMISED VERTEBRAL STRUCTURAL AND MECHANICAL 
PROPERTIES ASSOCIATED WITH PROGRESSIVE KIDNEY DISEASE AND 
THE EFFECTS OF TRADITIONAL PHARMACOLOGICAL INTERVENTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter has been accepted for publication: 
Bone [doi:10.1016/j.bone.2015.04.021] 
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Rationale 
 The previous studies indicated that anti-sclerostin antibody and 
bisphosphonates were incapable of slowing the progression of bone disease in 
the presence of high levels of PTH. These assessments focused on long bones. 
Vertebral bone, a common site of fracture in patients with CKD, was not 
examined. Given the differences between sites composed of predominantly 
cortical bone and those primarily composed of cancellous bone, understanding 
whether there are different factors at play in CKD is an important component for 
addressing fracture risk at different skeletal sites. This study was employed to 
examine the disease effects of CKD on vertebral bone as well as to understand if 
there are differential treatment effects at this site. 
 
Introduction 
 Patients with chronic kidney disease—mineral and bone disorder (CKD-
MBD) have a significantly higher fracture risk than the general population14,141,143. 
This population also displays differences in fracture rates between long bones 
and vertebrae141, suggesting that these two skeletal sites may be differentially 
affected by the disease. A study of Japanese men on dialysis who underwent 
screening lumbar spine imaging studies demonstrated that 20.9% of prevalent 
dialysis patients had evidence of spine fractures265. High resolution CT data have 
revealed significant increases in cortical porosity in the distal limbs with variable 
responses in trabecular bone57. Because vertebral elements are primarily 
composed of trabecular bone, the influence of secondary hyperparathyroidism on 
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these sites could be potentially different than in long bone cortices266. 
Furthermore, the thin cortical shell of the vertebrae bears nearly 50% of the 
load267; thus, cortical bone changes at this site would also have dramatic effects 
on mechanical properties and fracture risk. 
Several animal models of CKD have revealed significant detriments in the 
biomechanical properties of long bones110,150,268. For example, rodent models 
indicate that animals with CKD exhibit lower strength and stiffness compared to 
their normal counterparts108,119,127. 
While much of the decline in mechanical integrity can be attributed to 
structural changes resulting from high parathyroid hormone (PTH) and high 
turnover rates, recent studies indicate that bone quality also plays a role150. 
Unfortunately, vertebral bone in CKD models has yet to be examined at any of 
these levels. The goal of this study was to assess the effects of progressive CKD 
on vertebral bone structure and mechanics and to determine the effects of 
treatment with either anti-remodeling medications (bisphosphonates) or anabolic 
treatments (anti-sclerostin antibody). We hypothesized that a significant 
phenotype would exist in the vertebrae of CKD animals and that treatment would 
restore structural mechanical properties but not the material-level mechanical 
properties.  
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Methods 
Animal model 
Cy/+ rats exhibit the progressive onset of polycystic kidney disease due to 
transmission of an autosomal dominant missense mutation in the geneAnks6, 
which codes for the protein SamCystin53,161-162. Anks6 has been shown to be 
important in childhood recessive cystic kidney disease although heterozygote 
parents have no manifestations56,269-270. The course of kidney disease 
progression in the Cy/+ rats parallels the course of human CKD-Mineral Bone 
Disorder (CKD-MBD)53. A colony of these animals is maintained at the Indiana 
University School of Medicine. All procedures were reviewed and approved by 
the Indiana University School of Medicine Institutional Animal Care and Use 
Committee. 
Experimental design 
The animals described in this work were part of a large experiment that 
included numerous treatment and control groups. Male Cy/+ rats began the study 
at 25 weeks of age at which time animals were fed a casein-based diet (Purina 
AIN-76A, Purina Animal Nutrition, Shreveport, LA, USA; 0.53% Ca and 0.56% 
Pi) in order to accentuate the disease. Subsets of Cy/+ animals were divided into 
the following groups (Figure 26): 
 Controls (CKD):  These animals were left untreated. Based on the 
previously described phenotype these animals have high PTH and high bone 
turnover108,178. 
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Figure 26. Overview of experimental groups, outcome measures, and serum 
PTH levels for the planned comparisons. PTH values from previously published 
manuscript178. 
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 Calcium (CKD-Ca):  These animals were treated with calcium-
supplemented water (3%) starting at 30 weeks of age. Based on the previously 
described phenotype these animals have low PTH and low bone turnover108,178. 
Zoledronic acid (CKD-Z):  These animals were treated with zoledronic acid 
(20 μg/kg/BW as a single subcutaneous injection at 30 weeks of age). Based on 
the previously described phenotype these animals have high PTH and low bone 
turnover108,178. Zoledronic acid was chosen as a representative bisphosphonate 
to study in CKD as it has an infrequent dosing schedule (1x per year in post-
menopausal osteoporosis treatment) and has high affinity for the bone matrix 
making it likely to impart persistent treatment effects. 
Anti-sclerostin antibody (CKD-SCL):  These animals were treated with 
anti-sclerostin antibody (Scl-Ab; 100 mg/kg/week starting at 30 weeks of age). 
Scl-AB was provided by Novartis Institutes for BioMedical Research, Novartis 
Pharma AG. Based on the previously described phenotype these animals have 
high PTH and high bone turnover108,178. Anti-sclerostin antibody was chosen as it 
has emerged as a promising potential anabolic drug treatment. 
Anti-sclerostin antibody plus calcium (CKD-SCL-Ca):  These animals were 
treated with anti-sclerostin antibody and calcium (3% in water). Based on the 
previously described phenotype these animals have low PTH and high bone 
turnover108,178. 
 Normal (NL):  A group of non-diseased male littermates were untreated. 
All animals were sacrificed at 35 weeks of age. For all experiments, serum 
biochemistries and long bone phenotypes have been previously reported in 
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various publications, yet are reported in the results when deemed 
necessary108,119,178. 
Dynamic Histomorphometry 
In order to describe the basal remodeling phenotype of the vertebra in NL 
and CKD animals, the third lumbar vertebra of animals from a separate 
experiment119 was processed for undecalcified histomorphometry. The vertebral 
arch was removed, and the body was embedded in PMMA for sectioning. Thin 
sections (~4 μm) were cut and left unstained for analysis. Briefly, a 2 mm2 region 
of interest in the caudal region of the vertebra cranial to the growth plate was 
used for the analysis. Primary measurements were obtained and used for the 
derived parameters mineralizing surface/bone surface (MS/BS), mineral 
apposition rate (MAR), and bone formation rate/bone surface (BFR) as 
previously described108 using standard nomenclature211. 
Computed tomography 
Morphological parameters of the fourth lumbar vertebrae from all 
experiments were assessed using high-resolution micro-CT (Skyscan 1172). 
Bones were wrapped in parafilm to prevent drying during the scanning. Scans 
were obtained using an x-ray source, set at 60kV with a 12-µm pixel size. Images 
were reconstructed and analyzed using standard Skyscan software (NRecon and 
CTAn, respectively). Trabecular regions of interest were manually drawn to 
isolate it from the cortical bone between the cranial and caudal growth plates. 
Bone volume/tissue volume (BV/TV), trabecular number (Tb.N), and trabecular 
thickness (Tb.Th) were computed according to previously published 
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recommendations186. A single slice at 75% of the total vertebral length (from 
cranial to caudal) was used for the assessment of cortical thickness as this 
represents a region devoid of zygapophyseal attachment. Bone area was 
assessed at 25%, 50%, and 75% of the total height for normalization of 
mechanical properties. 
Mechanics 
Structural mechanical properties and apparent material properties were 
assessed by uniaxial compression testing of the L4 vertebra from all 3 
experiments. At harvest, the vertebrae were wrapped in saline-soaked gauze and 
frozen at -20°. Bone height was assessed from microCT images. Prior to 
mechanical testing, the vertebral arch and the endplates were removed using an 
Isomet saw in order to create parallel surfaces (beneath the growth plates) for 
compression testing. Samples were loaded in displacement control at 0.5 
mm/min. Load and displacement data were collected at 10 Hz and converted to 
stress and strain data from the initial sample height and the average bone area of 
3 slices (25%, 50%, and 75% slices of the initial height of the sample). Load-
displacement data were used to compute ultimate load, stiffness, and energy to 
failure (with failure defined as the initial decrease in load after the ultimate load), 
while apparent material properties were derived from the stress-strain data and 
used to calculate ultimate stress, elastic modulus, and toughness to the point of 
the ultimate stress156.  
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Statistics 
Statistics were carried out on select groups in order to answer a priori 
questions related to 1) basal phenotype of the CKD model, 2) the effects of anti-
remodeling treatment with and without altered PTH levels, and 3) the effects of 
anabolic treatment with and without altered PTH levels (Figure 26). Comparisons 
were made using Student’s t-tests or one-way ANOVA followed by Fisher 
protected least significant difference post hoc tests. P-values were set at ≤ 0.05. 
Data are reported as means and standard deviations. 
 
Results 
CKD with high PTH leads to high remodeling rate, bone loss, and 
compromised structural and material mechanical properties. 
Select biochemistries and animal body weights are presented in Table 13. 
PTH levels in the CKD animals were over 10-fold higher than normal animals 
(Figure 26). Histological assessment of vertebral trabecular bone revealed that 
mineral apposition rate was more than doubled (NL = 1.21.; CKD = 2.98), 
mineralizing surface/bone surface was 2.5x higher (NL = 10.5; CKD = 24.5) and 
bone formation was 6-fold higher in CKD animals compared to normal (Figure 
27a).  
Thus, the untreated CKD model is one of high PTH and high remodeling 
(Figure 27f-g). 
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 Final body 
weight, g 
Serum 
calcium, 
mg/dL 
Serum 
phosphorus, 
mg/dL 
BUN, mg/dL 
NL 554 ± 41 10.3 ± 0.5 4.9 ± 0.9 22 ± 5 
CKD 541 ± 36 9.0 ± 2.0 8.4 ± 1.9 49.2 ± 8.2 
P value NS NS < 0.001 < 0.001 
CKD – 
Calcium 
499 ± 47 ab 11.9 ± 1.5 b 7.0 ± 1.2 ab 61.2 ± 10.5 ab 
CKD – 
Zoledronic 
acid 
531 ± 41 8.7 ± 1.9 7.6 ± 1.9 a 56.2 ± 16.5 ab 
ANOVA P 
value 
0.04 < 0.001 < 0.001 < 0.001 
CKD-Scl AB 505 ± 57 9.9 ± 2.0 a 9.4 ± 3.9 64.4 ± 11.6 ab 
CKD-Scl AB + 
Ca 
515 ± 44 11.1 ± 2.7 a 7.9 ± 2.1 58.4 ± 13.7 ab 
ANOVA P 
value 
NS 0.018 0.002 < 0.001 
Data as mean ± SD. Statistical comparisons were conducted as t-test (between 
NL and CKD), or ANOVA (between NL, CKD, CKD+Calcium, and 
CKD+Zoledronic Acid; and then between NL, CKD, CKD+Calcium, CKD+Scl AB, 
and CKD+Scl AB+Calcium).  Statistically different (p < 0.05) values between 
CKD and NL are given in the t-test p values while differences in the ANOVA are 
noted relative to NL (a) and CKD (b). 
 
Table 13. Descriptive characteristics of animal groups. 
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Figure 27. Vertebral phenotype of animals with high-PTH CKD compared to 
normal littermates (NL). (A) Trabecular bone formation rate, (B) cortical 
thickness, (C) trabecular BV/TV, (D) ultimate load, and (E) energy to failure. 
Representative fluorochrome labeling images (taken from animal with remodeling 
values closest to group mean) from vertebral bone of NL (F) and CKD (G) 
animal. # p < 0.05 versus NL. 
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Vertebral microCT analyses showed that cortical thickness (-17%) and 
trabecular BV/TV (-30%) were both significantly lower in CKD compared to 
normal (Figure 27b-c). Ultimate force (-34%), stiffness (-21%), and energy to 
failure (-42%) were all significantly lower in CKD compared to NL (Figure 27d-e 
and Table 14). Calculation of material properties revealed significant lower 
ultimate stress (-24%) and toughness (-34%), but not modulus, in CKD animals 
(Table 14). 
Low turnover with suppression of PTH normalizes vertebral bone 
morphology and mechanical properties. 
CKD animals treated with calcium (CKD-Ca), which reduced PTH and 
suppressed tibial bone remodeling [20], had similar vertebral cortical thickness 
but significantly higher trabecular BV/TV (+15%), compared to normal, non-
diseased animals (Figure 28a-b). Cortical thickness and BV/TV in CKD-Ca were 
both significantly higher than CKD animals. Ultimate load and energy to failure of 
CKD-Ca vertebrae were equivalent to NL (and higher than CKD) with the 
exception of stiffness, which was not significantly different among groups (Figure 
28c-d). Ultimate stress, modulus, and toughness of CKD-Ca were all equal or 
higher than NL animals (Table 14) and all higher than CKD.  
 In animals treated with zoledronic acid (CKD-Z), which suppresses bone 
remodeling without lowering PTH178, the results were in stark contrast to CKD- 
Ca. Cortical thickness (-16%) and trabecular BV/TV (-18%) were both 
significantly lower than NL and CKD-Ca (Figure 28a-b). Ultimate force 
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 Stiffness, 
N/mm 
Ultimate 
stress, Pa 
Modulus, 
Pa 
Toughness, Pa 
NL 1044  ± 250  30.8 ± 3.9 803 ± 208 0.95 ± 0.41 
CKD 829  ± 332 23.5 ± 4.2 728 ± 290 0.63 ± 0.17 
P value 0.035 0.002 NS 0.04 
CKD – Calcium 804 ± 244 37.8 ± 9.9 ab 724 ± 211 
b 
1.37 ± 0.39 ab 
CKD – Zoledronic 
acid 
646 ± 345 23.4 ± 5.2 a 557 ± 279 
a 
0.86 ± 0.28 
ANOVA P value 0.078 0.001 0.001 0.001 
CKD-Scl AB 477 ± 237 ab 22.9 ± 5.9 ab 426 ± 200 
ab 
1.00 ± 0.54 b 
CKD-Scl AB + 
Calcium 
1072 ± 503 34.1 ± 8.5 b 709 ± 282 1.23 ± 0.30 b 
ANOVA P value 0.002 0.001 0.016 0.006 
Data as mean ± SD. Statistical comparisons were conducted as t-test (between 
NL and CKD), or ANOVA (between NL, CKD, CKD+Calcium, and 
CKD+Zoledronic Acid; and then between NL, CKD, CKD+Calcium, CKD+Scl AB, 
and CKD+Scl AB+Calcium). Statistically different (p < 0.05) values between CKD 
and NL are given in the t-test p values while differences in the ANOVA are noted 
relative to NL (a) and CKD (b). 
 
Table 14. Mechanical phenotype of high PTH, high turnover CKD animals. 
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Figure 28. Influence of reducing remodeling rate, with and without lowering PTH, 
on the vertebral phenotype of animals with CKD. (A) cortical thickness, (B) 
trabecular BV/TV, (C) ultimate load, and (D) energy to failure. Groups with 
different letters are significantly different (p < 0.05). For all parameters, the 
overall ANOVA p value was < 0.05. NL – normal littermates; CKD – animals with 
chronic kidney disease with high PTH levels; CKD-Ca – animals with chronic 
kidney disease treated with calcium to lower remodeling and PTH; CKD-Z – 
animals with chronic kidney disease treated with zoledronic acid to lower 
remodeling. 
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(-28%) was significantly lower in CKD-Z compared to NL, while stiffness and 
energy to failure were not different (Figure 28c-d and Table 14). Ultimate stress 
and modulus were lower than NL, while all three material properties were 
significantly lower than CKD-Ca (Table 14).  
High turnover with suppression of PTH, but not without, enhances 
vertebral morphology and vertebral mechanical properties. 
CKD animals with high PTH treated with anti-sclerostin antibody, 
previously shown to not alter PTH or bone remodeling relative to untreated CKD 
[20], had significantly lower cortical thickness (-11%), trabecular bone volume (-
27%), and ultimate load (-32%), and stiffness (-54%) compared to NL (Figure 
29a-c). Ultimate stress and modulus were both significantly lower than NL (Table 
14). Overall, the vertebral phenotype of the CKD-Scl animals closely resembled 
the CKD animals with the exception of stiffness/modulus (which were lower) and 
energy to failure/toughness (which were higher). 
 When anti-sclerostin antibody was combined with calcium (CKD-SCL-Ca), 
effectively reducing PTH and normalizing remodeling to NL levels [20], the 
results were dramatically different than anti-sclerostin alone. Cortical thickness 
was equivalent to NL animals while BV/TV (+15%) was significantly higher than 
NL, equivalent to CKD-Ca (Figure 29a-b and Table 14). Ultimate load (+25%) 
was significantly higher than all other treatments while energy to failure (+51%) 
was significantly higher than all treatments except CKD-Ca (Figure 29c-d and 
Table 14) while material properties were all comparable to NL animals, higher 
than most other groups (Table 14).  
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Figure 29. Influence of anti-sclerostin antibody treatment, with and without 
lowering PTH, on the vertebral phenotype of animals with CKD. (A) cortical 
thickness, (B) trabecular BV/TV, (C) ultimate load, and (D) energy to failure. 
Groups with different letters are significantly different (p < 0.05). For all 
parameters, the overall ANOVA p value was < 0.05. NL – normal littermates; 
CKD – animals with chronic kidney disease with high PTH levels; CKD-Ca – 
animals with chronic kidney disease treated with calcium to lower remodeling and 
PTH; CKD-SCL – animals with chronic kidney disease treated with anti-sclerostin 
antibody; CKD-SCL-Ca – animals with chronic kidney disease treated with anti-
sclerostin antibody and calcium (to lower PTH).  
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Discussion 
The goal of this study was to assess the vertebral phenotype of CKD 
given the high clinical risk of vertebral fracture in this patient population80,265 and 
the paucity of preclinical data on spine changes with CKD. In this progressive 
CKD animal model we found that 1) elevations in endogenous PTH were 
associated with high turnover bone disease, compromised cortical and trabecular 
bone mass, and reduced mechanical properties (both structural and material) of 
the vertebra and 2) treatment of the vertebral phenotype with either anti-
resorptive or anabolic therapies was only effective, from a mechanical 
standpoint, if serum PTH was reduced. 
CKD patients have a higher risk of fracture compared to non-CKD 
patients17. Changes to long bones have been the central focus of most clinical 
work due to the advances in high-resolution peripheral imaging which has yielded 
rich information regarding changes to cortical/trabecular bone. Most notably 
these studies have shown that changes to the cortical bone are dramatic57 and 
more severe than are typically observed with post-menopausal osteoporosis 
(which affects trabecular bone to a greater degree, at least initially). The risk of 
vertebral fracture is also increased in CKD patients80,265,27-272, yet little information 
exists regarding changes to bone mass/architecture at this site. The distribution 
of cortical and trabecular bone in the vertebra differs significantly from long 
bones and although cortical bone still contributes to the mechanical integrity of 
the spine267, it is possible that the intricacies of bone loss may differ from long 
bones. The paucity of clinical studies focused on the spine is understandable due 
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to imaging limitations. However for reasons that are unclear this extends to 
preclinical studies where few studies have examined vertebral bone268. 
The current study showed dramatic loss of trabecular bone mass and 
thinning of the cortical shell in the vertebra of CKD animals with high PTH, 
irrespective of whether they were untreated, treated with bisphosphonate, or 
treated with anti-sclerostin antibody. These results contrast with the long bone 
phenotype of these same animals where cortical porosity was higher than normal 
but trabecular BV/TV was positively affected in high PTH animals treated with 
these agents178 (Figure 30). In high-PTH CKD animals, both vertebra and 
proximal tibia trabecular bone had high bone formation rate, suggesting that 
simply having high remodeling does not explain the divergent trabecular BV/TV. 
In conditions where PTH is normalized, using calcium supplementation, both 
trabecular and cortical bone area normalized (or enhanced) compared to non-
CKD animals. While additional work will be necessary to elucidate why long 
bones and vertebra differentially respond in the setting of CKD, it raises concern 
about the clinical use of iliac crest bone biopsies as an assessment of trabecular 
bone, especially in assessing bone volume147,273-276. It may be that iliac crest 
biopsy changes are more reflective of long bone trabecular responses than they 
are of the vertebra. This is supported by a previous study in renal transplant 
patients that showed no change in iliac crest biopsy cancellous BV/TV after 6 
months while spine, but not radius, BMD changed significantly during this same 
time frame277.  
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Figure 30. Summary of vertebral and long bone response to disease and 
treatment response. (A) Trabecular bone volume of the vertebra (black bars) and 
proximal tibia (gray bars). (B) Ultimate load of the vertebra (trabecular and 
cortical bone together; black bars) and the femoral diaphysis (purely cortical 
bone; gray bars). Long bone data were pulled from previous publications in this 
same animal model. Data presented as percent of normal animals. 
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The structural mechanical phenotype of the vertebrae closely follows that 
of the long bones in these same animals, where compromised ultimate load, 
stiffness, and energy to fracture existed in animals with high PTH, even if treated 
with the potent anti-remodeling agent zoledronic acid or the potent anabolic anti-
sclerostin antibody178. Treatment with calcium, to lower PTH, normalized vertebra 
ultimate load and energy to failure, both parameters that have functional 
significance for fracture resistance174. In animals where reduced PTH was 
combined with the anabolic intervention of anti-sclerostin antibody, both ultimate 
load and energy to failure exceeded values from normal animals (Figure 29). 
Enhanced vertebral mechanical properties have similarly been observed in 
ovariectomized animals treated with anti-sclerostin antibody278. Yet the response 
in these CKD animals differs from the long bone, where calcium plus anti-
sclerostin antibody normalized, but did not significantly increase, ultimate load 
relative to NL animals178 (Figure 30). These data illustrate the importance of 
normalizing PTH in treating the vertebral mechanical phenotype of CKD and 
highlight that anabolic therapy can be more effective at sites that have large 
proportions of both cortical and trabecular bone (such as the spine and femoral 
neck). 
Structural mechanical properties are determined by bone mass, 
geometry/architecture, and the mechanical properties of the material (sometimes 
referred to as bone quality)46. Compromised bone mass and architecture are 
widely appreciated in CKD while the changes in bone quality have only recently 
begun to be explored48,139. We have shown, using both calculations of material 
164 
properties from whole bone tests108,119,178 as well as by more direct measures150 
that long bones of CKD animals have reduced properties at the material level. 
This is associated with changes to both collagen and matrix hydration179 although 
a cause-effect relationship has not been elucidated. The current work shows that 
high turnover, high PTH CKD disease compromises the mechanical properties of 
the material – as both ultimate stress and toughness, are significantly lower than 
NL. This means that not only does the vertebra have lower bone mass but the 
bone mass that exists has compromised material properties relative to normal. 
Controlling PTH levels normalizes the material properties – contributing to the 
normalization of whole bone mechanical properties while treatments that did not 
affect PTH (zoledronic acid and anti-sclerostin antibody alone) had mixed effects 
on material properties. 
The current experiment utilized zoledronate as a representative 
bisphosphonate to study in the setting of CKD. It is well accepted that each 
bisphosphonate has different biophysical properties of mineral binding strength 
and affinity to hydroxyapatite279. These properties affect many of the physical and 
physiological actions of the drugs including drug localization, speed of onset, 
degree of remodeling suppression, and speed of withdrawal280. It is unclear 
whether a different bisphosphonate would be more beneficial in the setting of 
CKD. Zoledronate has long lasting effects on remodeling suppression, more than 
5 years following a single dose281-282 meaning that it would be difficult to washout 
the effect if needed. Lower affinity bisphosphonates, such as risedronate, have 
been shown to washout more rapidly than alendronate (a high affinity agent)283 
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suggesting that it may be more appropriate in the setting of CKD if concerns exist 
about treatment washout duration. More work with bisphosphonates are 
necessary to understand the details of their effects on bone, as well as the safety 
on the kidney, in the setting of CKD. It is possible that the there is diversity in the 
renal safety among the bisphosphonates but additional work is needed in this 
area284. In addition, despite efficacy of calcium in lowering PTH and improving 
serum calcium, in our previous publications we have observed increased arterial 
calcification suggesting that both efficacy and safety should be considered with 
any interventions. 
In conclusion, the present study provides a clear picture of how 
progressive CKD, with and without interventions, affects vertebral bone 
properties. Since CKD-associated bone disease and fracture risk is significant at 
this site, it is important to recognize that response to treatment differs from long 
bones. Despite these differences, what is clear from this study is that reducing 
PTH is fundamental in normalizing mechanical properties. As such, any anti-
resorptive or anabolic bone therapies utilized in CKD should be examined in 
combination with therapies that suppress PTH (such as calcitriol and 1,25 vitamin 
D analogs and calcimimetics). 
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CHAPTER 8 
RALOXIFENE IMPROVES SKELETAL PROPERTIES IN AN ANIMAL MODEL 
OF CHRONIC KIDNEY DISEASE 
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Rationale 
Prior studies examining anti-sclerostin antibody and bisphosphonates in 
CKD showed incomplete restoration of mechanical properties. Based on the 
previous indications that bone quality is compromised in CKD, the application of 
a treatment that modifies bone quality is particularly appealing in the setting of a 
disease where most other osteoporosis medications are either ineffective or 
avoided over concerns of adverse events. Previous data have shown that 
raloxifene positively affects bone quality, which is why this study tested its 
efficacy in the setting of CKD. 
 
Introduction 
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is 
characterized by hyperphosphatemia, secondary hyperparathyroidism, and an 
increased risk of fractures8-9,60. This metabolic complexity has made treating 
skeletal manifestations difficult. Currently, calcitriol and its analogues are used to 
control elevations in parathyroid hormone (PTH) in patients with advanced 
CKD62. They are known to have positive effects on bone mineral density (BMD) 
in non-CKD patients69, and similar increases have been reported in CKD 
patients285-288. Improvements in histological parameters have also been 
observed196-197,289-291, but studies examining the fracture efficacy of calcitriol in 
patients with CKD have not been conducted64. While low BMD can predict 
fractures in some stages of CKD43, clinical studies have not established a 
consistent relationship between BMD and fracture risk, especially in dialysis 
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patients35-36. Even with recent indications that BMD is a useful surrogate for 
fracture risk in late stage CKD patients45, low BMD only explains about 70% of 
fractures34. One potential reason for this low sensitivity is that bone quality (the 
inherent physical and chemical constitution of bone) is adversely affected in 
CKD50-51,150. 
For patients with early stage CKD (estimated glomerular filtration rate 
greater than 30 mL/min) and normal PTH levels, most guidelines adopt treatment 
recommendations for adults with osteoporosis60-61. The majority of patients with 
osteoporosis are treated with anti-resorptive agents that reduce osteoclast-
mediated bone loss76. Unfortunately, the complex metabolic background of CKD 
and a lack of clinical data in patients with advanced disease have limited the use 
of these agents. For example, bisphosphonates are not recommended due to 
concerns over their renal clearance and their potent suppression of bone 
remodeling to very low levels60. As there are minimal data on other osteoporosis 
treatments in the setting of CKD, there is a significant gap in the current 
understanding of how to treat skeletal disease in these patients61. 
Raloxifene is a selective estrogen receptor modulator with mild anti-
resorptive properties. Clinical trials have shown that it effectively reduces fracture 
risk in patients with osteoporosis despite modest improvements in BMD95-96. 
Preclinical studies indicate that raloxifene improves mechanical properties 
through its effects on bone quality97-99. Specifically, raloxifene positively affects 
bone toughness (the ability of bone to tolerate damage without fracturing). This 
improvement occurs in the absence of significant changes in bone mass97-98 and 
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appears to be partly due to changes in bone matrix hydration101-102. Furthermore, 
secondary analyses of a human clinical trial revealed beneficial renal outcomes 
in patients using raloxifene103. Preclinical experiments104-105 and a small clinical 
study in dialysis patients106 have supported these findings. Taken together, these 
data suggest that raloxifene could have beneficial effects on several 
consequences of CKD. The goal of the current work was to test the hypothesis 
that raloxifene would improve skeletal properties in an animal model of 
progressive CKD. 
 
Methods 
Animal Model 
Cy/+ rats are characterized by autosomal dominant polycystic kidney 
disease (PKD)53. These animals have a mutation (R823W) in Anks6, a gene that 
codes for the protein SamCystin. The function of this protein is unknown54, but 
unlike most other PKD-related proteins, SamCystin does not localize to the 
primary cilia of kidney cells55. This gene has recently been related to 
nephronophthisis in humans56. In this rat model, the mutation leads to a slow and 
gradual onset of CKD53. It parallels the human condition through the gradual 
development of abnormal mineral homeostasis and vascular calcification. Blood 
urea nitrogen (BUN) and creatinine are elevated by 20 weeks of age and indicate 
a 50% reduction in kidney function. At 30 weeks, kidney function is about 20% of 
that observed in normal animals, leading to progressive hyperphoshpatemia, 
hyperparathyroidism, and skeletal abnormalities. 
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Experimental Design 
Male Cy/+ rats were phenotyped for the presence of cystic disease by 
abdominal palpation and serum levels of BUN at 10 and 15 weeks of age. 
Animals with BUN between 30 and 50 mg/dL (with increasing BUN values from 
10 to 15 weeks) were defined as having CKD. Normal littermates (n=8), defined 
by BUN values less than 30 mg/dL with no increase between 10 and 15 weeks 
and an absence of observable cystic kidney disease at sacrifice, served as 
controls161-162. At 24 weeks, animals were placed on a casein diet (Purina AIN-
76A; 0.7% Pi, 0.6% Ca) to increase phosphorus availability. This diet has been 
shown to produce a more consistent kidney disease phenotype53. 
Starting at 25 weeks of age, Cy/+ rats were treated with vehicle (n=9) or 
raloxifene (n=10) (1 mg/kg daily; subcutaneous) for 5 weeks. This treatment 
duration was chosen as it approximates an average bone remodeling cycle in 
skeletally mature rats (roughly six months in humans) and has been shown to be 
sufficient to detect treatment-induced skeletal changes in this 
model108,119. Raloxifene doses were based upon previous studies in 
ovariectomized female rats99. All rats were injected with calcein (10 mg/kg; 
subcutaneous) 14 and 4 days prior to sacrifice to label surfaces with actively 
forming bone. 
At 30 weeks of age, animals were anesthetized with isoflurane and 
underwent cardiac puncture for blood draw followed by exsanguination and 
bilateral pneumothorax to ensure death. The lumbar spine, tibiae, and femora 
were removed and stored at -20OC for analysis. All procedures were approved by 
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and carried out according to the rules and regulations of the Indiana University 
School of Medicine’s Institutional Animal Care and Use Committee. 
Biochemistry 
Blood plasma at 30 weeks was analyzed for BUN, calcium, and 
phosphorus using colorimetric assays (Point Scientific, Canton, MI, or Sigma 
kits). Intact PTH was determined by ELISA (Alpco, Salem, NH). FGF23 was 
assessed with a two-site assay (Immunotopics, San Clemente, CA)38,53,112. 
Micro-Computed Tomography (microCT) 
Using microCT (Skyscan 1172), trabecular bone volume (BV/TV, %) and 
architecture (number, spacing, and thickness) were determined from 
the metaphysis of the proximal tibia and the entire L4 vertebra. Cortical bone 
geometry (area, thickness, bending moments of inertia, and porosity) was 
determined from the femoral midshaft. Cortical thickness was assessed at 75% 
of the height of the vertebra (from cranial to caudal) because this represents a 
region free of zygapophyseal attachment. All bones were wrapped in parafilm to 
prevent drying and scanned at a resolution of 12 µm in accordance with standard 
guidelines186.  
Histomorphometry 
Static and dynamic histomorphometric measures were obtained from the 
proximal metaphysis of the left tibia and the caudal metaphysis of the L3 
vertebra. Histological processing followed previously used protocols187-189. 
Tissues were embedded in methyl methacrylate for undecalcified sections. Mid-
transverse sections (4 µm) of cancellous bone from the proximal tibia and the 
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caudal portion of the L3 vertebra were cut and left unstained for dynamic 
histomorphometry or stained with tartrate-resistant acid phosphatase (TRAP) 
for osteoclast measurements (tibia only). For tibial and vertebral cancellous 
bone, a region of interest (encompassing 7-8 mm2 and 1.5-2.0 mm2, respectively) 
approximately 0.8 mm from the growth plate was analyzed. The unstained 
sections were assessed for total bone surface, single-labeled surface, and 
double-labeled surface to calculate mineral apposition rate (MAR), percent 
mineralizing surface (MS/BS), and bone formation rate (BFR/BS). TRAP-stained 
sections were assessed for bone surface, osteoclast number, and osteoclast 
surface to calculate the number of osteoclasts per unit bone surface (N.Oc/BS) 
and percent osteoclast surface (Oc.S/BS). All histomorphometric nomenclature 
follows standard usage190. 
Whole Bone Mechanics 
Structural mechanical properties of the left femur were determined by four-
point bending. The anterior surface was placed on two lower supports located ±9 
mm from the mid-diaphysis (18 mm span length) with an upper span length of 6 
mm. Specimens were loaded to failure at a rate of 2 mm/min, producing a force-
displacement curve for each sample. Structural mechanical properties (ultimate 
force, stiffness, energy to fracture, total displacement) were obtained directly 
from these curves, while apparent material properties (ultimate stress, elastic 
modulus, toughness) were derived from the force-displacement curves, cross-
sectional moments of inertia (Iml), and the distances from the centroid to the 
tensile surface using standard beam-bending equations for four-point bending47. 
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Structural mechanical properties of the L4 vertebra were determined by 
uniaxial compression. Vertebra height was assessed from microCT images. Prior 
to mechanical testing, the vertebral arch and endplates were removed using an 
Isomet saw to create parallel surfaces (inside the growth plates) for compression 
testing. Specimens were loaded at a rate of 0.5 mm/min, producing a force-
displacement curve for each sample. Structural mechanical properties were 
obtained directly from these curves, while apparent material properties were 
derived from the force-displacement curves, pre-test sample heights, and the 
average bone area of five microCT slices (10%, 30%, 50%, 70%, and 90% slices 
of the pre-test sample height) using standard equations for uniaxial 
compression191-192. 
Tissue Composition 
The anteromedial portion of the right tibial mid-diaphysis was polished with 
a 0.05 µm alumina suspension in order to create a flat region for spectroscopy 
and subsequent indentation testing. Raman spectroscopy was performed using a 
LabRAM HR 800 Raman Spectrometer (HORIBA JobinYvon, Edison, NJ) 
connected to a BX41 microscope (Olympus, Tokyo, Japan). A 660 nm laser was 
focused on the bone surface using a 50X objective to a spot size of ~10 µm. 
Three locations were imaged ~3 mm apart on the polished surface with five 20 
second acquisitions at each location as previously published115. A five-point 
linear baseline correction was applied in LabSpec 5 (HORIBA JobinYvon). Using 
OriginPro 8.6 (OriginLab, Northampton, MA), a single Gaussian peak was fit to 
the PO43-1 peak, and the areas under the PO43-1 (930-980 cm-1), CO32-1 
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(1056-1091 cm-1), and Amide I (1551-1720 cm-1) bands were calculated at each 
location. Type B carbonate substitution was found by the band area ratio of CO32-
1/PO43-1. The degree of matrix mineralization was determined by the band 
area ratio of PO43-1/Amide I. Mineral maturity (crystallinity) was determined by 
the inverse of the full width at half maximum (FWHM) of the PO43-1 peak. 
AFM Indentation 
Using the polished tibial surface described above, indentations were 
performed using a BioScope Catalyst atomic force microscope (Bruker, Santa 
Barbara, CA), operating in peak force tapping mode using previously published 
methods116. Samples were partially submerged in ultrapure water with the 
surface remaining uncovered for optical imaging of the surface in order to 
determine indentation locations but then fully submerged during testing. 
Indentations were performed using a tungsten carbide-coated AFM probe 
(Nanotec; nominal tip radius of 60 nm) with a nominal spring constant of 650 
N/m. Three locations (co-localized with Raman measurements) per sample were 
indented, and at each location (20 µm×20 µm grid), 100 indentations were 
performed. Samples were loaded to 3.25 µN with force-separation curves 
acquired from each indentation. Within each location, indentations were spaced 
about 2 µm apart in order to avoid interactions from neighboring indentations. In 
total, 300 indentations were performed for each sample. The indentation elastic 
modulus was calculated from 20% to 80% of the withdrawal curve using the 
Sneddon model of contact between a rigid cone and an elastic half space 
because the indentation depth is greater than the radius of curvature of the 
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probe116. Only those indentations whose retraction curve produced an r2 value of 
0.90 or higher were included in the analysis (n=6-95 per location). The 
indentation elastic modulus was determined from the following equation: 
𝐹 =
2
𝜋
∙
𝐸𝑠
1 − 𝑣𝑠
∙ tan 𝛼 ∙ 𝛿2 
where F is the indentation force, ES is the indentation elastic modulus of the 
sample, S 
opening angle (assumed to be 20O), and δ is the indentation depth. All of the 
individual indentations were averaged to produce a single value for each 
location, and each of these locations was averaged to produce a single value for 
each sample. 
Nanoindentation 
After AFM indentation, nanoindentation was performed on the same tibial 
samples using a Hysitron TI950 TriboIndenter. As above, samples were partially 
submerged in ultrapure water with the surface remaining uncovered for optical 
imaging of the surface in order to determine indentation locations but then fully 
submerged during testing. Three locations (co-localized with AFM indentations) 
per sample were indented. Pre-saved test locations were imaged using the 
nanoindenter for in situ scanning probe imaging. Within this imaged region, 6 
indentations were performed on a 10 µm x 20 µm grid. Indentations were spaced 
10 µm apart in order to avoid interactions from neighboring indentations. A 
previously calibrated fluid cell Berkovich diamond probe was used for the 
indentations. Machine calibrations were performed at the beginning of each day 
of testing. Tests were conducted in load control, and the loading profile consisted 
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of a 10s loading period, a 10s hold at 3000 µN, and a 10 s unloading period. 
From the resulting load-displacement profiles, the indentation elastic modulus 
and hardness were calculated according to the following equations: 
𝐸𝑟 =  
√𝜋
2√𝐴(ℎ𝑐)
 ∙  𝑆 
𝐻 =  
𝑃𝑚𝑎𝑥
𝐴(ℎ𝑐)
 
where Er is the reduced indentation elastic modulus of the sample, A is contact 
area, hc is the contact displacement, S is the stiffness of the sample determined 
from 40-95% of the unloading slope, H is the hardness of the sample, and Pmax  
is the peak force. All of the individual indentations (n=6 per location) were 
averaged to produce a single value for each location, and each of these locations 
was averaged to produce a single value for each sample. 
Reference Point Indentation 
After nanoindentation, reference point indentation (Biodent Hfc, Active Life 
Scientific, Santa Barbara, CA) was performed on the same tibial samples. Three 
locations (co-localized with nanoindentation) per sample were indented. The 
reference probe, which housed a BP3 test probe, was lowered vertically, normal 
to the surface, until it rested on the surface of the bone. In order to stabilize the 
unit, a reference force of ~13 N was applied before each measurement was 
initiated. Each test included a series of 10 cycles (load, hold, and unload) at 2 Hz 
with a peak force of 10 N. Bones were maintained submerged in ultrapure water 
throughout the duration of the test. Raw data from the RPI analysis software 
(version 2.0) were imported into a customized MATLAB code (Mathworks) 
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designed to provide cycle-by-cycle data for each test114, from which first cycle 
unloading slope, indentation distance increase, first cycle energy dissipation, 
creep indentation distance, first cycle indentation distance, total indentation 
distance, and total energy dissipation were calculated for each test. Each 
location was averaged to produce a single value for each variable. 
Collagen Morphology 
Following indentation testing, the polished tibial surface was partially 
decalcified by soaking the bones in 0.5 M EDTA for 25 minutes followed by five 
minutes of sonication in a water bath. This process was repeated five times for 
each sample. For imaging, RTESPA probes were used (Bruker; nominal radius 
of 8 nm; spring constant = 40 N/m). For measurements of collagen morphology, 
the scan size was set at 3.5 µm with 512×512 pixels and a scan rate of 0.5 
lines/s. Two locations between indentation sites were imaged per sample (one 
location was dropped from a raloxifene sample due to poor image quality), and 
12 fibrils were measured at each location. All 24 fibrils were averaged to produce 
a single value for each animal (one normal sample had only 18 fibrils and two 
CKD samples had14 and 20 fibrils due to poor image quality). Using SPIP 5.1.10 
(Image Metrology, H∅rsholm, Denmark), D-periodic spacing was calculated using 
2D Fast Fourier Transformations as previously described115. 
Collagen Cross-Linking 
After four-point bending, proximal segments of the left femoral cortex (~3 
mm in length) were fully demineralized in 20% EDTA (0.68 M, pH 7.4). 
Approximately 10 mg of demineralized bone were hydrolyzed in 6N HCl (~10 µL 
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per 1 mg) at 110°C for 20-24 hours. After evaporating the acid using a 
SpeedVAC centrifuge with a cold trap, each hydrolysate was resuspended in 
ultrapure water, split into two equal portions, and dried. Half of the residue was 
resuspended in ultrapure water with an internal standard (5×10−6 g/L pyridoxine). 
The solution was filtered and diluted with 0.05% heptafluorobutyric acid in 10% 
acetonitrile, and 50 µL of each hydrolysate were assayed by a high performance 
liquid chromatography (HPLC) system (Beckman-Coulter System Gold 168) with 
a silica-based column (Waters Spherisorb) as previously published150. Standards 
with varying concentrations of pyridinoline (PYD; Quidel), deoxypyridinoline 
(DPD; Quidel), pentosidine (PE; International Maillard Reaction Society), and a 
constant amount of pyridoxine were also assayed. Using a Waters 2475 
fluorescence detector (excitation/emission of 295/400 nm for PYD and DPD and 
328/378 nm for PE), chromatograms were recorded to determine the amount of 
each crosslink. These amounts were then normalized by collagen content, which 
was determined from the other half of each hydrolysate by another HPLC assay. 
With α-amino-butyric acid (α-ABA) included as an internal standard, the amino 
acids were subjected to derivatization with phenyl isothiocyanate (PITC). Along 
with varying concentrations of derivatized hydroxyproline (Sigma) and a constant 
amount of α-ABA as standards, the derivatized samples were resuspended in a 
buffer solution of 5% acetonitrile in 5 mM disodium phosphate. Upon injecting 50 
µL of this sample, chromatograms were generated with a UV detector (Beckman-
Coulter System Gold 168). The calculated mass of hydroxyproline was then 
multiplied by 7.5 (assuming 13–14% of type I collagen by mass) and divided by 
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the molecular weight of collagen (30,000 Da), thereby giving crosslink 
concentration as mol/mol of collagen. 
1H Nuclear Magnetic Resonance Spectroscopy 
A ~5-mm cross-section of the left femoral mid-shaft was placed into a low 
proton, loop-gap-style radio-frequency (RF) coil along with a reference 
microsphere of water (T2  ~  2 s). As previously published102, the nuclear 
magnetic resonance spectroscopy (NMR) analysis was performed in a 4.7-T 
horizontal-bore magnet (Varian Medical Systems, Santa Clara, CA) using 
90°/180° RF pulses of ~9/18-μs duration and collecting Carr-Purcell-Meiboom-
Gill (CPMG) measurements with 10,000 echoes at 100 μs spacing in order to 
separate proton signals within the bone. To generate the spectrum of transverse 
relaxation time constants (T2), the echo magnitudes were fitted with multiple 
exponential decay functions. Upon normalizing the integrated areas of bound 
water (T2  =  1200–800 μs) and pore water (T 2  =  800 μs –600 ms) to the area 
of the reference (T 2  =  600 ms–10 s), the volume of bound water and the 
volume of pore water were divided by the specimen volume (calculated using 
Archimedes’ principle) to give bound water (bw) and pore water (pw) volume 
fractions. 
Statistics 
Comparisons among groups were assessed by one-way ANOVA with 
Fisher’s LSD post-hoc tests. A priori α-levels were set at 0.05 to determine 
significance. Data are presented as mean ± standard deviation. 
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Results 
Mineral Metabolism 
Animals with CKD had higher serum levels of BUN compared to normal 
littermates (+231%), consistent with previous data indicating the presence of late 
stage kidney disease, estimated to be 20-25% of normal kidney function (Table 
15). Serum calcium was normal, while phosphorus (+48%), FGF23 (+266%), and 
PTH levels (+1106%) were all significantly higher than their normal counterparts. 
Raloxifene-treated animals were nearly indistinguishable from their untreated 
CKD counterparts, having BUN, phosphorus, and FGF23 levels that differed from 
normal but not vehicle-treated CKD animals. PTH levels in raloxifene animals 
were significantly lower than untreated CKD animals (-42%) but still higher than 
normal controls (+591%). 
MicroCT 
Vehicle-treated CKD animals had lower trabecular bone volume (with 
lower trabecular number and higher trabecular spacing) relative to normal 
animals at the proximal tibia. Raloxifene normalized proximal tibia trabecular 
bone volume (due to higher trabecular number and lower spacing than CKD 
animals) (Figure 31 and Table 16). A similar pattern of trabecular bone 
morphology was present in the vertebra, with CKD animals having lower 
trabecular bone volume (due to lower trabecular number and higher spacing) that 
was partially restored with raloxifene (Figure 31 and Table 16). 
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Cortical bone of the femoral midshaft was also negatively affected by 
CKD. CKD animals had lower cortical area, cortical thickness, and cross- 
Biochemistry Normal CKD (Vehicle) CKD (Raloxifene) 
BUN (mg/dL) 14.62 ± 1.95 48.32 ± 8.20 * 44.12 ± 5.12 * 
Calcium (mg/dL) 9.979 ± 0.987 11.610 ± 2.323 10.061 ± 2.421 
Phosphorus 
(mg/dL) 
4.527 ± 0.579 6.682 ± 2.408 * 9.700 ± 3.591 * 
PTH (pg/mL) 181.97 ± 105.05 2194.39 ± 
1811.01 * 
1257.46 ± 1456.22 
*# 
FGF23 (pg/mL) 698.36 ± 93.03 2556.83 ± 
1401.96 
6184.88 ± 3403.39 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 15. Biochemistry 
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Figure 31. Cancellous bone structure in the proximal tibia and lumbar vertebra as 
determined by microCT. *, p<0.05 compared to NL; #, p<0.05 compared to CKD-
VEH 
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Proximal Tibia Normal CKD (Vehicle) CKD (Raloxifene) 
BV/TV (%) 17.04 ± 3.34 11.26 ± 1.51 * 14.9 ± 2.70 # 
Tb.Th (mm) 0.106 ± 0.010 0.108 ± 0.004 0.103 ± 0.007 
Tb.N (1/mm) 1.611 ± 0.253 1.052 ± 0.150 * 1.451 ± 0.211 # 
Tb.Sp (mm) 0.369 ± 0.044 0.604 ± 0.114 * 0.420 ± 0.055 # 
Femoral 
Diaphysis 
   
Ct.Th (mm) 0.876 ± 0.037 0.748 ± 0.056 * 0.783 ± 0.039 * 
Ct.Ar (mm2) 8.767 ± 0.631 7.324 ± 0.358 * 7.611 ± 0.397 * 
Iap (mm4) 15.00 ± 2.59 12.40 ± 0.58 * 12.30 ± 1.35 * 
Iml (mm4) 10.23 ± 1.56 7.50 ± 0.59 * 7.86 ± 0.73 * 
Ct.Po (%) 0.690 ± 0.324 0.948 ± 0.401 0.467 ± 0.274 # 
Lumbar Vertebra    
BV/TV (%) 41.88 ± 2.92 30.01 ± 3.98 * 36.27 ± 1.76 *# 
Tb.Th (mm) 0.119 ± 0.004 0.110 ± 0.007 * 0.108 ± 0.005 * 
Tb.N (1/mm) 3.581 ± 0.258 2.726 ± 0.324 * 3.401 ± 0.129 # 
Tb.Sp (mm) 0.213 ± 0.021 0.280 ± 0.031 * 0.235 ± 0.014 * # 
Ct.Th (mm) 0.236 ± 0.033 0.170 ± 0.012 * 0.184 ± 0.025 * 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 16. MicroCT 
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sectional moments of inertia compared to normal controls (Table 16). There was 
no difference in cortical porosity between normal and untreated CKD animals. 
Raloxifene treatment led to less porosity than CKD animals but did not correct 
CKD-induced changes in cortical area, thickness, or moments of inertia. CKD 
animals had thinner vertebral cortices than their normal counterparts, and this 
was not corrected by raloxifene (Table 16). 
Histology 
Vehicle-treated CKD animals had higher trabecular bone formation rates 
in the tibia (+137%) and vertebra (+306%) compared to normal animals (Figure 
32). This was a result of higher mineral apposition rates as well as a higher 
proportion of mineralizing surfaces (Table 17). Animals with CKD also had higher 
osteoclast number and percent osteoclast surface than their normal counterparts 
(Table 17). Raloxifene treatment lowered bone formation rates to normal levels 
at both the tibia and the vertebra (Figure 32) but did not change osteoclast 
parameters (Table 17). 
Whole Bone Mechanics 
Animals with CKD had lower femoral cortical bone ultimate force (-25%), 
stiffness (-22%), and energy to fracture (-23%) compared to normal animals 
(Figure 33 and Table 18). Estimated material properties revealed a significantly 
lower modulus of toughness in CKD animals (-16%) (Figure 33). Ultimate stress 
and elastic modulus were not different (Table 18). Animals treated with raloxifene 
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displayed a higher energy to fracture compared to vehicle-treated CKD animals 
accompanied by higher (though not normal) ultimate force. There was no effect  
 
 
Figure 32. Bone formation rates in the proximal tibia and caudal lumbar vertebra 
as determined by dynamic histomorphometry. *, p<0.05 compared to NL; #, 
p<0.05 compared to CKD-VEH 
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Tibia Normal CKD (Vehicle) CKD (Raloxifene) 
MAR (m/day) 1.305 ± 0.185 2.470 ± 0.569 * 1.890 ± 0.511 * 
MS/BS (%) 26.56 ± 5.14 33.32 ± 4.11 23.89 ± 4.75 # 
BFR 
(m3/m2/year) 
126.65 ± 31.02 299.62 ± 74.35 * 170.40 ± 78.52 # 
Oc.S/BS (%) 7.157 ± 1.250 15.739 ± 3.332 * 15.684 ± 6.857 * 
N.Oc/BS (1/mm) 1.966 ± 0.412 4.125 ± 0.785 * 4.134 ± 1.653 * 
Vertebra    
MAR (m/day) 1.057 ± 0.339 1.983 ± 0.876 * 1.574 ± 0.400 
MS/BS (%) 13.62 ± 3.98 27.81 ± 5.73 * 16.21 ± 3.73 # 
BFR 
(m3/m2/year) 
52.14 ± 21.76 211.94 ± 128.49 * 94.19 ± 39.80 # 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 17. Histomorphometry 
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Figure 33. Whole bone mechanical and apparent material properties of the femur 
as determined by four-point bending: (a) ultimate load, (b) energy to fracture, (c) 
ultimate stress, and (d) modulus of toughness. *, p<0.05 compared to NL; #, 
p<0.05 compared to CKD-VEH 
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Femur Normal CKD (Vehicle) CKD (Raloxifene) 
Ultimate Force (N) 272.08 ± 17.75 204.81 ± 23.20 * 223.44 ± 23.78 * # 
Stiffness (N/mm) 531.67 ± 47.41 412.96 ± 56.28 * 440.66 ± 30.52 * 
Energy to Fracture 
(mJ) 
119.16 ± 15.33 91.65 ± 14.13 * 107.24 ± 20.86 # 
Pre-Yield 
Displacement (m) 
429.36 ± 31.14 381.76 ± 37.59 * 443.46 ± 27.98 # 
Post-Yield 
Displacement (m) 
352.20 ± 76.44 363.39 ± 71.40 381.55 ± 96.43 
Total Displacement 
(mm) 
781.56 ± 53.46 745.15 ± 67.76 825.01 ± 95.15 
Ultimate Stress 
(MPa) 
153.81 ± 15.68 143.94 ± 17.93 146.76 ± 13.28 
Elastic Modulus 
(MPa) 
4.649 ± 0.633 5.144 ± 0.971 4.998 ± 0.466 
Toughness (MPa) 4.336 ± 0.382 3.652 ± 0.545 * 4.096 ± 0.814 # 
Mechanics 
(Vertebra) 
   
Ultimate Force (N) 256.89 ± 60.01 187.06 ± 48.03 * 179.57 ± 38.63 * 
Stiffness (N/mm) 952.09 ± 314.20 866.74 ± 260.33 854.76 ± 277.85 
Energy (mJ) 46.27 ± 10.60 28.05 ± 8.93 * 26.46 ± 7.33 * 
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Pre-Yield 
Displacement (m) 
0.408 ± 0.085 0.337 ± 0.045 0.392 ± 0.093 
Post-Yield 
Displacement (m) 
0.036 ± 0.056 0.019 ± 0.034 0.007 ± 0.006 
Total Displacement 
(mm) 
0.445 ± 0.123 0.355 ± 0.062 0.399 ± 0.97 
Ultimate Stress 
(MPa) 
42.49 ± 10.00 38.74 ± 9.16 34.16 ± 7.89 
Elastic Modulus 
(MPa) 
954.37 ± 334.35 1174.00 ± 447.08 1124.68 ± 372.23 
Toughness (MPa) 1.310 ± 0.470 0.924 ± 0.347 0.714 ± 0.135 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 18. Whole Bone Mechanics 
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of treatment on stiffness. There also was no effect of raloxifene treatment on 
ultimate stress or elastic modulus, but the modulus of toughness was restored to 
normal levels (Figure 33). 
Vertebral compression tests revealed that CKD animals had lower ultimate 
force and energy to ultimate force but no differences in stiffness compared to 
normal animals (Figure 33 and Table 18). There also was no effect on estimated 
material properties of the vertebra. Compared to animals with CKD, raloxifene 
had no impact on any structural or estimated material properties in the vertebra. 
Bone Material Properties 
CKD-vehicle animals were indistinguishable from normal animals for 
indentation properties determined using reference point indentation, 
nanoindentation, and AFM indentation (Table 19). Raloxifene treatment 
significantly increased hardness (assessed by nanoindentation) compared to 
both normal and CKD-vehicle animals (Table 19). Tissue composition (assessed 
by Raman spectroscopy) and collagen crosslinking (assessed by HPLC) 
revealed no differences among the three groups (Table 20). Collagen D-periodic 
spacing was not affected by CKD, but animals treated with raloxifene had higher 
D-periodicity in the collagen fibrils compared to CKD animals (Figure 34). NMR 
spectroscopic measures revealed no differences among groups for bound or free 
water (Table 20). 
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RPI Normal CKD (Vehicle) CKD (Raloxifene) 
First Cycle 
Indentation Distance 
(m) 
71.13 ± 5.47 71.78 ± 5.43 69.28 ± 2.53 
First Cycle Energy 
Dissipation (J) 
225.69 ± 17.71 241.51 ± 27.87 219.15 ± 7.53 
First Cycle 
Unloading Slope 
(N/m) 
0.441 ± 0.069 0.466 ± 0.047 0.446 ± 0.063 
First Cycle Creep 
Indentation Distance 
(m) 
4.921 ± 0.450 5.396 ± 0.749 4.916 ± 0.241 
Indentation Distance 
Increase (m) 
9.813 ± 0.692 11.726 ± 1.968 9.856 ± 0.281 
Total Indentation 
Distance (m) 
77.23 ± 5.50 79.41 ± 4.90 75.51 ± 2.59 
Total Energy 
Dissipation (J) 
561.41 ± 37.24 594.58 ± 34.84 558.21 ± 15.86 
Nanoindentation    
Elastic Modulus 
(GPa) 
11.066 ± 2.766 9.666 ± 1.021 13.200 ± 3.345 
Hardness (MPa) 202.62 ± 22.86 192.68 ± 47.35 422.81 ± 291.97 # 
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AFM Indentation    
Elastic Modulus 
(GPa) 
52.99 ± 25.81 43.21 ± 16.31 49.25 ± 26.20 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 19. Material Properties – Mechanics 
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Raman 
Spectroscopy 
Normal CKD (Vehicle) CKD (Raloxifene) 
Crystallinity 
(1/FWHM PO43-1) 
0.0529 ± 0.0003 0.0534 ± 0.0008 0.0535 ± 0.0005 
Carbonate 
Substitution (CO32-
1/ PO43-1) 
0.247 ± 0.008 0.242 ± 0.013 0.239 ± 0.015 
Relative 
Mineralization (PO43-
1/Amide I) 
2.650 ± 0.332 2.274 ± 0.501 2.384 ± .0422 
Collagen 
Morphology 
   
D-Periodicity (nm) 65.321 ± 0.946 64.466 ± 1.391 65.438 ± 1.289 # 
Collagen Cross-
Linking 
   
Pyridinoline per 
Collagen (mol/mol) 
0.474 ± 0.485 0.223 ± 0.087 0..305 ± 0.079 
Deoxypyridinoline 
per Collagen 
(mol/mol) 
0.372 ± 0.388 0.203 ± 0.095 0.271 ± 0.088 
Pentosidine per 
Collagen 
(mmol/mol) 
815.39 ± 621.34 507.06 ± 288.11 617.48 ± 171.46 
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NMR Spectroscopy    
Bound Water (%) 18.60 ± 3.61 17.88 ± 4.00 17.34 ± 3.43 
Pore Water (%) 3.829 ± 0.988 5.572 ± 3.567 4.158 ± 0.965 
* vs. Normal 
# vs. CKD (Vehicle) 
 
Table 20. Material Properties – Composition and Morphology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
Figure 34. Collagen fibril D-periodic spacing as determined by AFM imaging. #, 
p<0.05 compared to CKD-VEH 
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Discussion 
 These data show that in the setting of progressive CKD with high bone 
turnover, raloxifene can suppress long bone and vertebral trabecular bone 
remodeling and enhance long bone mechanical properties to levels of normal 
controls. Nanoindentation also revealed that raloxifene substantially increased 
the hardness of cortical bone, while AFM imaging of collagen D-periodic spacing 
detected raloxifene-specific effects. These changes demonstrate that raloxifene 
can improve skeletal material properties (those independent of bone mass) as 
well as structural properties and that together these ameliorate CKD-associated 
deficits in whole bone mechanical properties. 
 Raloxifene led to an unexpected lowering of PTH in the CKD animals. 
Although PTH levels remained higher than normal, they were 43% lower than the 
untreated CKD animals. Previous studies have shown that reducing PTH levels 
in this animal model imparts significant skeletal benefits108,119 (although in those 
studies, PTH levels were actually below normal levels). Nonetheless, because of 
this reduction in PTH, we cannot isolate the direct skeletal effects of raloxifene 
from changes associated with this reduction in PTH. Previous data have also 
shown that raloxifene may slow the progression of kidney failure in some 
settings103-106, but few data exist on the relationship between raloxifene and 
PTH292. Based on the BUN assessment in the current study, raloxifene does not 
appear to have any beneficial renal effects in this model, though more extensive 
histopathology assessments would be necessary to make definitive conclusions. 
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 Raloxifene effectively suppressed the high bone formation rates induced 
by CKD to the level of normal animals. This normalization of remodeling is in 
contrast to previous work in the same model using bisphosphonates and calcium, 
both of which suppressed remodeling in trabecular bone to below normal 
levels108,119. Due to concerns of dramatic suppression of bone remodeling in 
patients with CKD, the suppression observed with raloxifene may be 
advantageous. Unexpectedly, osteoclast number and percent osteoclast surface 
remained high in raloxifene-treated animals. Although raloxifene is typically 
associated with suppressed osteoclast formation, reduced osteoclast activity 
without a reduction in number has been shown to occur293-294. In this model of 
hyperparathyroidism, the high levels of PTH may overshadow raloxifene’s effect 
on osteoclast formation with its effect on the activity of mature osteoclasts 
becoming more pronounced. 
 Though raloxifene-induced improvements were observed in trabecular 
bone volume, there was little effect on the CKD-induced changes to cortical bone 
morphology. Untreated CKD animals had compromised mechanical properties of 
the long bones, consistent with previous studies in this model108,119. Raloxifene 
normalized energy to fracture, restoring it to the level of normal animals. 
Estimated material properties indicate that raloxifene specifically improved 
material-level toughness. These effects were absent in the vertebra. Because 
vertebral compression testing ceases at the ultimate load, information regarding 
whole bone and material-level toughness may be limited.  
198 
To make more direct assessments of cortical bone material properties, 
several indentation measurements were conducted at various length scales. Of 
these, raloxifene had positive effects on hardness as measured by 
nanoindentation. Though hardness is generally believed to be a byproduct of 
mineralization, these data indicate that hardness is not determined by 
mineralization alone. In addition, these data are consistent with previous 
observations that raloxifene increased hardness in murine and ovine ovariectomy 
models295-296. While it is not clear how improving material-level hardness leads to 
increases in the modulus of toughness and energy to fracture, all of these 
changes have been previously observed in animals treated with raloxifene97-
98,101,295-296. 
 Previous studies have revealed that raloxifene improvements in material 
properties are associated with higher bound water in the extracellular matrix101-
102. The current NMR data are inconsistent with these previous data because 
they revealed no effect on bound water in raloxifene-treated animals. The reason 
for this discrepancy is unclear. For example, CKD-associated changes in bone 
metabolism may prevent raloxifene from impacting bound water in these animals. 
Differences in animal models (dogs were used in previous studies) may be a 
factor as well101-102. These differences may also reflect variations in the magnetic 
resonance techniques across these studies101-102. 
Rather than changes in hydration, the current work showed that raloxifene 
increased collagen fibril spacing (D-periodicity). This effect is consistent with 
previous work using raloxifene101, though the exact contribution of D-periodicity 
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to whole bone mechanical properties remains unclear. Previous studies have 
shown decreased D-periodic spacing in animals with reduced energy to 
fracture297-298. This work improves the current understanding of D-periodicity by 
showing that increases in D-periodicity are associated with improved bone 
toughness. Because of the failure to clearly understand how changes in D-
periodicity are related to hardness and how these contribute to whole bone 
mechanical properties, subtler differences in material properties may be present. 
After all, several indentation tests failed to detect changes, and the examination 
of tissue composition and collagen cross-linking failed to provide a compelling 
explanation. These data indicate that raloxifene’s impact on D-periodicity may be 
having a more prominent impact on the interaction between collagen fibrils and 
mineral crystals101, an interaction not addressed in the present study. 
 Most clinical data examining raloxifene’s use in CKD are derived from 
trials that inadvertently enrolled patients with mild CKD236. Like their osteoporosis 
counterparts, CKD patients treated with raloxifene had a lower rate of vertebral 
fractures as well as increased BMD at the hip and spine. Far fewer data exist for 
patients with late stage disease due to their exclusion from osteoporosis trials. 
One small study examined BMD in patients on dialysis and showed that 
raloxifene improved BMD in the spine but not in the hip106. Another study 
examined BMD at the distal radius and found that raloxifene improved BMD in 
patients with mild hyperparathyroidism299. Despite these data, there have been 
no assessments of fracture efficacy using raloxifene in CKD. Because the current 
study suggests significant mechanical benefits despite modest changes in bone 
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mass, the positive effects of raloxifene may be overlooked if BMD alone is used 
to determine efficacy. 
The current results support previous recommendations60 that clinical trials 
using raloxifene in patients with late stage CKD should be considered. However, 
they also highlight the fact that measures of bone beyond BMD may be needed 
to truly assess efficacy. Recent techniques assessing bone quality have been 
developed for and examined in humans (ultrashort echo time magnetic 
resonance imaging159 and reference point indentation121,123). These, alongside 
BMD, may provide a better picture of the potential efficacy of raloxifene in 
patients with advanced kidney disease. Because there are concerns about the 
increased risk of thromboembolism (though it was not worse than the general 
population in the post-hoc analyses [34]), late stage predialysis patients might be 
the most logical population to examine first. 
 In summary, these analyses show that raloxifene reduced bone turnover 
and improved whole bone mechanical properties in the setting of CKD. Because 
these changes occurred mostly independently of changes in bone mass, 
traditional methods to evaluate efficacy in CKD bone disease may be insufficient 
for the evaluation of raloxifene in these patients. 
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CHAPTER 9 
DISCUSSION 
Summary 
 The current series of studies was conducted to better understand the 
effects of CKD on skeletal properties and to examine the specific structural and 
mechanical effects of multiple agents currently used or being considered for use 
in patients with CKD. Understanding the multiple factors that lead to fracture in 
CKD, and how these are affected (or not) by treatment, is an important step 
currently missing in much of the CKD literature. 
Animals with progressive kidney disease were examined at two different 
times for the presence of abnormalities in tissue-level mechanical properties and 
tissue composition. Material-level mechanical effects were present by 30 weeks 
(both apparent material properties and directly measured properties), though the 
exact cause of these changes was not definitively identified. At this age, there 
were no disease-driven changes in bone matrix hydration, collagen cross-linking, 
tissue composition, or collagen morphology. Yet, AFM indentation revealed 
substantial heterogeneity in nanoscale mechanical properties (elastic modulus), 
indicative of a change in matrix mechanics. One potential explanation for the 
mechanical changes, despite no change in mineral, collagen, or hydration, could 
be that each technique on its own could not detect subtle change present at this 
point. At 35 weeks, changes in bone matrix hydration and collagen cross-linking 
were present and likely contributed significantly to the whole bone defects in 
mechanical properties detected in those animals. Given the lack of difference in 
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Raman-based mineral assessments, these data suggest negative changes in the 
organic matrix and hydration are driving the mechanical phenotype in CKD. This 
is supported by the fact that these two variables are both specifically linked to 
changes in bone toughness, one of the properties specifically impacted by CKD 
bone disease. 
 Patients with CKD and secondary hyperparathyroidism are currently 
treated with calcitriol and other active vitamin D analogues. Treatment efficacy is 
based primarily upon changes in serum PTH levels. Yet, there are few studies 
that have examined bone outcomes related to PTH suppression in CKD patients 
or even CKD animals. In an effort to better understand how current therapy 
affects CKD bone disease, animals with secondary hyperparathyroidism (PTH 
levels 12-fold higher than normal) were treated with a dose of calcitriol sufficient 
to provide 50% suppression of PTH levels (considered clinically efficacious). 
Though PTH was suppressed, there were no positive skeletal effects observed in 
animals with CKD despite a fairly comprehensive skeletal evaluation (imaging, 
histology, mechanics, material-level assessment of collagen and mineral). 
Because of the paucity of clinical data examining skeletal outcomes of calcitriol 
on CKD bone disease in humans, future studies (both clinical and preclinical) will 
need to examine various levels of PTH suppression and its impact on skeletal 
parameters and fracture risk to assess whether the currently recommended 
levels of PTH suppression actually have the intended effects on skeletal 
outcomes. 
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Suppression of PTH levels with calcium supplementation in drinking water 
had substantial positive skeletal effects, essentially normalizing skeletal 
properties. In contrast to calcitriol treatment, calcium supplementation led to PTH 
values below normal controls. Unfortunately, the skeletal effectiveness occurred 
at the cost of increased vascular calcification. These data are consistent with 
concerns raised about the use of calcium supplementation and calcium-based 
phosphate binders in late stage CKD patients. The level of PTH suppression in 
these studies to levels at or even below normal controls is uncommon clinically, 
meaning that it remains possible that some level of PTH suppression between 
that of calcium (below normal) and calcitriol (about 60% of CKD) could provide 
the optimal balance of bone efficacy without vascular complications. This balance 
is also important as it strikes a skeletal balance between the high bone turnover 
in secondary hyperparathyroidism and the concerns of low bone turnover that 
may result from oversuppressing PTH. In addition, the combination of calcium 
with zoledronic acid and anti-sclerostin antibody, agents that provide no PTH-
lowering effects on their own, provided some additive structural and mechanical 
effects. This clearly highlights the idea that the evaluation of osteoporosis 
treatments in CKD needs to be done in a setting where PTH is controlled to near 
normal levels.  
Zoledronic acid, a high affinity bisphosphonate with significant benefits in 
osteoporosis78, was mostly ineffective in these CKD experiments. While it 
suppressed trabecular bone remodeling, cortical porosity remained high, and 
whole bone structural and mechanical properties were no different than untreated 
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CKD animals. One possible reason for this unexpected result is the dosing 
schedule utilized (one injection every five weeks based upon effective dosing in 
ovariectomized rats293). While this dosing schedule is effective in an osteoporosis 
setting it appears insufficient in the setting of CKD. Normally upon dosing, 
bisphosphonates cover the bone surface and inhibit osteoclasts that come into 
contact with the bone surface. In the setting of drastic hyperparathyroidism 
associated with CKD (Figure 35), there may be enough osteoclast production 
such that once several osteoclasts deplete the surface of bisphosphonates, 
subsequent osteoclasts begin to resorb the bone normally as though the bone 
were in an untreated state. Daily or weekly bisphosphonates may be a means to 
overcome this problem because more frequent administration would continuously 
cover any surfaces depleted by high levels of osteoclast activity. On the other 
hand, though zoledronate did result in efficient suppression of bone resorption in 
cancellous bone, there was no additional detriment observed in CKD animals 
with zoledronate beyond the significant deterioration already present. 
 For anabolic therapy, teriparatide (recombinant human PTH) is currently 
the only approved agent for patients with osteoporosis. However, the existence 
of high PTH in late stage CKD patients often precludes its application. Given the 
early increases in sclerostin that occur in CKD, though, the experimental anti-
sclerostin antibody seemed like a promising approach. Unfortunately, as was the 
case with zoledronate, anti-sclerostin antibody was only effective in the setting of 
calcium-driven PTH suppression. As expected, it led to higher bone formation 
rates and a decline in stiffness, both of which are consistent with the formation of  
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Figure 35. Differences in osteoclast surface coverage in normal animals (top) 
and animals with CKD (bottom). 
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new osteoid. On its own, there was no improvement in cortical bone mass or 
trabecular architecture, and mechanical properties were identical to untreated 
animals. This highlights the importance of bone quality, as even in the presence 
of adding new matrix, the biomechanical properties of the bone remain 
compromised. Simply adding bone in CKD patients is insufficient. 
 Raloxifene, on the other hand, though surrounded by a cloud of questions 
regarding efficacy and safety (e.g., thrombosis) had a substantial impact on bone 
parameters in CKD animals. It corrected cancellous bone loss in both the tibia 
and vertebra secondary to its normalization of bone formation rates in CKD 
animals. Whether these changes in bone remodeling persist to 35 weeks when 
more severe disease is present will need to be examined. Aside from 
remodeling, raloxifene also improved long bone structural and apparent material 
toughness. These changes were associated with microscale changes in 
hardness and higher D-periodicity in collagen fibrils, which may be responsible 
for raloxifene’s positive influence on toughness. More data will need to be 
collected to better understand raloxifene’s mechanism of action and whether or 
not it differs in CKD compared to the other animal models in which it has been 
examined. 
  
Clinical Implications 
 The value of understanding the impact of bone quality on fracture risk is 
ultimately dictated by the ability of current clinical methods to adequately predict 
fracture. This is why recent studies examining BMD in CKD patients have been 
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so important. While BMD only predicts around 70% of fractures in these late 
stage patients, the actual contribution of bone quality to CKD-related fractures is 
still unknown. 
While there have been conflicting data regarding BMD in CKD, studies 
over the last few years appear to indicate that BMD at all stages of CKD does 
indeed have a predictive impact on fracture risk34-36,45. The data in early stage 
CKD patients are hardly surprising and are consistent with recommendations that 
these patients should be treated as though they were osteoporosis patients. The 
later stage data are more intriguing as these most recent studies are the first to 
show a clear predictive relationship between BMD and fracture risk34,45. In fact, 
these studies indicate that the KDIGO guidelines (which do not recommend BMD 
estimates in these patients) may need to be adjusted.  
With this predictive capacity available to clinicians, what value does bone 
quality have in the clinical discussion? Unfortunately, even the best predictors 
have only accounted for 70% of the fractures in this population. Determining the 
value of BMD estimates in individual patients is even more problematic. 
Therefore, future studies will need to examine aspects of bone quality in these 
patients to understand its role in fracture risk. While there are no currently 
approved diagnostics used in CKD, newly developed methods using UTE-MRI 
(to measure bone hydration) and in vivo mechanical testing devices (reference 
point indentation devices such as BioDent and OsteoProbe) may provide a 
means by which to assess bone quality clinically. Because RPI was able to 
detect differences in CKD versus normal animals in the current work (but see 
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Table 5), and bone matrix hydration appears to be altered in later stages of CKD, 
these two aspects of bone quality could provide important data in combination 
with BMD. MRI techniques have already been applied to late stage CKD 
patients159. In addition, recent studies using OsteoProbe in diabetic patients have 
shown that it can detect differences in bone quality when compared to normal 
patients. This is important as this population has a high risk of progressing to late 
stage CKD (17% of the diabetes group in this study had co-existing kidney 
disease). Because of these findings, CKD may be an important conduit by which 
to employ these methods in future clinical studies. 
 Despite calcitriol being the standard of care in CKD patients with 
secondary hyperparathyroidism, the current studies indicate that its suppression 
of PTH may not translate to useful skeletal outcomes in CKD patients. While 
some clinical studies indicate that calcitriol may suppress bone formation (in 
contrast to the current studies), fracture data are unavailable. On the other hand, 
recent studies indicate that cinacalcet not only suppresses PTH effectively66 but 
also lead to a reduction in fractures65. Future studies should examine the level of 
PTH suppression necessary to reduce fractures risk and other adverse metabolic 
outcomes in patients with late stage CKD. 
 Though zoledronate and anti-sclerotin antibody were ineffective on their 
own (and only modestly effective when combined with calcium), significant 
questions about their utility in CKD still remain. Also, their utility in patients with 
hyperparathyroidism may be substantially different than their use in patients with 
controlled PTH levels. First, though, more studies need to be performed to 
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determine dosing regimen for these agents. The assumption that dosage 
approaches (amount and frequency) based on osteoporosis are appropriate has 
been significantly challenged by these animal studies.  
In terms of safety, the current studies indicate that bisphosphonates did 
effectively suppress trabecular bone turnover rates to at or below the levels of 
normal controls. This is consistent with many of the clinical concerns about the 
oversuppression of bone remodeling. Because some remodeling remained intact, 
it is not clear if the fear of adynamic bone disease in the context of 
bisphosphonate therapy is warranted. However, while mechanical properties 
were not improved with zoledronate, no further detrimental effects were observed 
either, which is what might be expected if low bone turnover does have 
detrimental effects in these patients. Fracture studies need to be conducted 
before any definitive connection between low bone remodeling from 
bisphosphonates and fracture risk outweigh the possible benefits from inhibiting 
parathyroid hormone and increasing bone mass (though these changes were not 
observed in the current studies). 
 Raloxifene has had a varied history in treating osteoporosis. While 
patients show mild increases in BMD, the fracture efficacy (predominantly in the 
vertebrae) is much greater than would be predicted from BMD changes alone. In 
fact, this small effect on BMD has likely led to its diminished use in patients with 
osteoporosis. After all, small changes in BMD are difficult to interpret in the 
absence of considerations of bone quality, especially when one considers that 
bisphosphonates increase BMD by ~10%. While the minimal data available in 
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patients with CKD indicate similar outcomes of BMD, there has been great 
hesitation related to its efficacy as well as concerns over thrombosis61. While 
post-hoc analyses of early stage CKD patients receiving raloxifene did not show 
any differences in thrombotic events between patients with and without CKD, the 
introduction of catheters in dialysis patients presents great concerns. Hence, 
pragmatism would indicate that future studies ought to occur in late stage (stages 
3 and 4) predialysis patients, particularly in the setting of hyperparathyroidism. 
Histomorphometry data will be important to determine if there are differences in 
efficacy in patients with high turnover disease and those with low turnover 
disease and may provide helpful information for determining whether there is a 
place for considering combination therapy with agents that suppress PTH. Any 
studies with raloxifene should include the aforementioned tools used to assess 
bone quality since raloxifene’s primary impact appears to be on skeletal material 
properties. 
 
Future Studies 
 The current results answer several important questions about CKD but 
also lead to several more questions. The studies described herein focused on 
CKD-induced bone quality changes of cortical bone. Bone quality in cancellous 
bone is currently understudied. Examining these features would address much of 
the data suggesting a discord between how CKD impacts cortical sites and 
trabecular sites determining if the differences are simply due changes in mass or 
in quality as well. Furthermore, differences in cortical and cancellous bone need 
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to be understood within the contexts of quality changes in existing bone and the 
disease effects that compromise the accumulation of newer bone. After all, most 
cortical bone is formed in these animals prior to the onset of advanced CKD. In 
these rodents, employing a series of dynamic labels would allow for the 
comparison of material properties across multiple tissue ages in cortical bone. 
This would provide important insight into whether CKD is predominantly 
impacting new bone formation or whether it is also significantly compromising 
bone that has already been formed. 
 Secondly, the use of rodent models in a disease that preferentially impacts 
cortical bone is limited. Studies employing larger animal models that normally 
undergo intracortical remodeling would be important. Unfortunately, since there 
are no naturally occurring large animal models of CKD, nephrectomy approaches 
would be necessary. While this would present many of the same difficulties 
discussed regarding rodent nephrectomy models, it would potentially provide a 
better cortical bone assessment than currently available. It would allow for the 
assessment of in vivo microdamage, intracortical remodeling, and provide more 
controlled assessments of bone material properties with a greater availability of 
skeletal tissue. 
 Future studies of calcitriol should focus on dosing in order to determine 
the necessary level of PTH suppression to impart positive skeletal effects. Also, 
given the relationship between serum 1,25[OH]2D3 levels and bone formation294, 
serum vitamin D levels should be assessed. In any such work, bone outcomes 
similar to those examined in the current study should be employed to provide a 
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comprehensive assessment of bone quality and bone quantity. A comparative 
study between calcium and calcitriol would be interesting given the results 
described in these studies. Finally, only one study has employed cinacalcet 
(R568) in the current animal model, and its effect on bone outcomes was 
modest. It too would make for an appropriate comparison in these proposed 
studies. 
 In the area of bisphosphonates, a number of studies should be pursued. 
These could address potential variations in bone binding affinity as well as 
dosing frequency. To further examine zoledronate’s ineffectiveness with the 
single dose regimen used in the current studies, a five-week dosing regimen with 
radiolabeled zoledronate would provide data as to the degree of binding and 
retention on the bone surface. If it is the case that rampant osteoclast activity 
associated with secondary hyperparathyroidism actually depletes the surface of 
bisphosphonates, several alternative approaches could be taken to facilitate 
bisphosphonate use in CKD. First, a higher dosing frequency using zoledronic 
acid could be enacted. For example, in these studies, zoledronate was given 
every five weeks based on its effectiveness in other osteoporosis models. A 
dosing frequency of every two weeks might be a logical next step to examine its 
effectiveness in this model. After all, even raloxifene, which is a very mild anti-
remodeling agent, appeared to have positive effects on remodeling and bone 
structure, potentially due to its daily administration. An alternative to weekly or bi-
weekly zoledronate doses (which is not a standard clinical dosing regimen) would 
be daily or weekly alendronate. These types of studies are essential as the 
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determination of efficacy and safety necessitates an assessment in which the 
drug is binding to the surface and inhibiting osteoclasts as intended. If, even with 
the intended inhibition of osteoclasts, mechanical properties are not preserved, 
then this class of agents may not be sufficient for use in the setting of CKD. 
 Additional work is warranted for raloxifene. As animals with CKD show 
dramatic changes in bone properties from 30 weeks to 35 weeks, the promising 
results for raloxifene at 30 weeks should be further examined at 35 weeks. Such 
studies would be important for examining raloxifene’s efficacy in more severe 
disease. Because of the implications of suppressing PTH, raloxifene should also 
be employed in combination with calcitriol or calcimimetics. More examination will 
also need to be given to the mechanism by raloxifene alone suppresses PTH. 
Because raloxifene has been shown to have positive skeletal outcomes in larger 
mammal models with intracortical remodeling, these studies should also be 
considered in large mammal CKD models. 
 Clinical studies should focus on assessments of raloxifene alone or in 
combination with other agents that suppress PTH activity. Specific outcomes 
should include BMD (including HR-pQCT), RPI (OsteoProbe), and UTE-MRI 
studies, though fracture assessment would be the ideal outcome. In addition, the 
acquisition of biopsy samples for histology may also provide samples for other 
bone quality assessments. Specifically, these studies could employ Raman 
spectroscopy for compositional analysis, nanoindentation, and HPLC. Because 
controls would be difficult to obtain, baseline measures could be used from one 
hip with the contralateral hip serving as the endpoint sample. These analyses 
214 
would provide almost identical outcomes to those examined in these studies, 
providing the strongest link to how well these studies conducted in Cy/+ rats 
would translate to humans with CKD. 
 
Conclusion 
 Using an animal model of progressive CKD, significant defects in bone 
quality were detected. These data may help explain the dramatic fracture risk 
associated with CKD. While calcitriol is the current standard of care in secondary 
hyperparathyroidism, these results raise questions about how well the partial 
suppression of PTH actually impacts fracture risk since there was no benefit to 
mechanical properties. Anti-resorptives and anabolic osteoporosis therapies may 
still have potential, but the administration of these medications in the absence of 
PTH control did not normalize mechanical properties in the setting of CKD. 
Finally, raloxifene was shown to improve whole bone mechanical properties by 
virtue of its impact on the inherent material properties of CKD bone. These 
studies, taken as a whole, call for the assessment of bone quality in CKD 
patients as well as a renewed consideration of the role of raloxifene in treating 
patients with bone abnormalities secondary to late stage CKD. 
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